



**EMORY UNIVERSITY**

Independent Auditors' Reports as Required by Uniform Guidance and  
State of Georgia and Related Information

Year ended August 31, 2018

**EMORY UNIVERSITY**

Independent Auditors' Reports as Required by Uniform Guidance and  
State of Georgia and Related Information

Year ended August 31, 2018

**Table of Contents**

	<b>Page(s)</b>
Independent Auditors' Report	1–2
Consolidated Financial Statements – Years ended August 31, 2018 and 2017	3–44
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	45–46
Supplementary Schedule of Expenditures of Federal Awards – Year ended August 31, 2018	47–72
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards – Year ended August 31, 2018	73
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	74–75
Independent Auditors' Report on Compliance for Major Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	76–78
Schedule of Findings and Questioned Costs	79–83



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

## Independent Auditors' Report

The Board of Trustees  
Emory University  
Atlanta, Georgia

We have audited the accompanying consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statements of financial position as of August 31, 2018 and 2017, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### *Management's Responsibility for the Financial Statements*

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditors' Responsibility*

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Opinion*

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Emory University and its subsidiaries as of August 31, 2018 and 2017, and the changes in their net assets and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



**Other Reporting Required by *Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated January 31, 2019 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia  
January 31, 2019

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
*Years ended August 31, 2018 and 2017*  
*(Dollars in thousands)*

	<u>August 31, 2018</u>	<u>August 31, 2017</u>
<b>ASSETS:</b>		
Cash and cash equivalents	\$ 149,449	\$ 51,113
Patient accounts receivable, net	398,706	364,376
Student accounts receivable, net	109,780	57,713
Loans receivable, net	23,138	24,921
Contributions receivable, net	396,127	80,407
Other receivables, net	336,827	246,286
Prepaid expenses, deferred charges and other assets	341,697	310,799
Investments	8,157,678	8,043,880
Interests in perpetual funds held by others	1,311,406	1,244,906
Property and equipment, net	3,219,005	3,102,848
<b>Total assets</b>	<b><u>\$ 14,443,813</u></b>	<b><u>\$ 13,527,249</u></b>
<b>LIABILITIES AND NET ASSETS:</b>		
Accounts payable and accrued liabilities	558,329	532,244
Deferred tuition and other revenue	521,289	431,735
Interest payable	29,391	29,271
Liability for derivative instruments	128,861	188,612
Bonds and notes payable	1,959,897	1,992,454
Accrued liabilities for benefit obligations and professional liabilities	575,741	565,699
Funds held in trust for others	791,841	747,109
Annuities payable	15,704	14,921
Government advances for federal loan programs	18,659	18,721
Asset retirement obligation	65,996	62,984
<b>Total liabilities</b>	<b><u>4,665,708</u></b>	<b><u>4,583,750</u></b>
Unrestricted net assets:		
Net assets controlled by Emory	4,223,320	3,960,429
Net assets related to noncontrolling interests	113,345	96,633
<b>Total unrestricted net assets</b>	<b><u>4,336,665</u></b>	<b><u>4,057,062</u></b>
Temporarily restricted net assets	3,216,761	2,722,596
Permanently restricted net assets	2,224,679	2,163,841
<b>Total net assets</b>	<b><u>9,778,105</u></b>	<b><u>8,943,499</u></b>
<b>Total liabilities and net assets</b>	<b><u>\$ 14,443,813</u></b>	<b><u>\$ 13,527,249</u></b>

See accompanying notes to consolidated financial statements.

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF ACTIVITIES**  
*Years Ended August 31, 2018 and 2017*  
*(Dollars in thousands)*

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2018	Total August 31, 2017
<b>OPERATING REVENUES AND OTHER SUPPORT:</b>					
Tuition and fees	\$ 710,471	-	-	\$ 710,471	\$ 675,179
Less: scholarship allowances	(276,305)	-	-	(276,305)	(253,897)
Net tuition and fees	434,166	-	-	434,166	421,282
Endowment spending distribution	182,562	-	-	182,562	179,696
Distribution from perpetual funds	35,377	-	-	35,377	34,873
Other investment income designated for current operations	81,257	-	-	81,257	72,622
Gifts and contributions, net	43,656	12,404	-	56,060	44,550
Grants and contracts	470,924	-	-	470,924	470,375
Indirect cost recoveries	144,026	-	-	144,026	131,012
Net patient service revenue	3,404,004	-	-	3,404,004	3,174,419
Medical services	336,141	-	-	336,141	301,404
Sales and services of auxiliary enterprises	74,481	-	-	74,481	74,464
Independent operations	24,348	-	-	24,348	23,097
Other revenue	176,853	-	-	176,853	163,133
Net assets released from restrictions	36,856	(13,149)	-	23,707	29,384
<b>Total operating revenues and other support</b>	<b>5,444,651</b>	<b>(745)</b>	<b>-</b>	<b>5,443,906</b>	<b>5,120,311</b>
<b>OPERATING EXPENSES:</b>					
Salaries	2,703,393	-	-	2,703,393	2,495,653
Fringe benefits	608,246	-	-	608,246	559,474
Student financial aid	19,133	-	-	19,133	13,159
Professional fees and purchased services	526,859	-	-	526,859	503,309
Supplies and pharmaceuticals	827,657	-	-	827,657	757,407
Other operating expenses	353,349	-	-	353,349	341,749
Interest on indebtedness	77,103	-	-	77,103	81,476
Depreciation	260,674	-	-	260,674	247,302
<b>Total operating expenses</b>	<b>5,376,414</b>	<b>-</b>	<b>-</b>	<b>5,376,414</b>	<b>4,999,529</b>
<b>NET OPERATING ACTIVITIES:</b>	<b>68,237</b>	<b>(745)</b>	<b>-</b>	<b>67,492</b>	<b>120,782</b>
<b>NONOPERATING ACTIVITIES, NET:</b>					
Investment return in excess of spending distribution for current operations	127,810	124,188	(3,316)	248,682	360,113
Change in undistributed income from perpetual funds held by others	-	-	26,880	26,880	74,558
Gifts and contributions	2,035	381,473	37,431	420,939	72,764
Loss on disposal of property and equipment	(1,593)	-	-	(1,593)	(11,494)
Loss on defeasance of debt	-	-	-	-	(8,659)
Change in fair value of derivative instruments	59,751	-	-	59,751	80,123
Pension and postretirement benefit plans	28,461	-	-	28,461	23,017
Other nonoperating items, net	(3,100)	10,958	(157)	7,701	(4,885)
Net assets released from restrictions	(1,998)	(21,709)	-	(23,707)	(29,384)
<b>Total nonoperating activities, net</b>	<b>211,366</b>	<b>494,910</b>	<b>60,838</b>	<b>767,114</b>	<b>556,153</b>
<b>CHANGE IN NET ASSETS</b>	<b>279,603</b>	<b>494,165</b>	<b>60,838</b>	<b>834,606</b>	<b>676,935</b>
Less change in net assets related to noncontrolling interests	16,712	-	-	16,712	15,360
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ 262,891</b>	<b>\$ 494,165</b>	<b>\$ 60,838</b>	<b>\$ 817,894</b>	<b>\$ 661,575</b>

See accompanying notes to consolidated financial statements.

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENT OF ACTIVITIES**  
*Year Ended August 31, 2017*  
*(Dollars in thousands)*

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2017
<b>OPERATING REVENUES AND OTHER SUPPORT:</b>				
Tuition and fees	\$ 675,179	-	-	\$ 675,179
Less: scholarship allowances	(253,897)	-	-	(253,897)
Net tuition and fees	421,282	-	-	421,282
Endowment spending distribution	179,696	-	-	179,696
Distribution from perpetual funds	34,873	-	-	34,873
Other investment income designated for current operations	72,622	-	-	72,622
Gifts and contributions	44,550	-	-	44,550
Grants and contracts	470,375	-	-	470,375
Indirect cost recoveries	131,012	-	-	131,012
Net patient service revenue	3,174,419	-	-	3,174,419
Medical services	301,404	-	-	301,404
Sales and services of auxiliary enterprises	74,464	-	-	74,464
Independent operations	23,097	-	-	23,097
Other revenue	163,133	-	-	163,133
Net assets released from restrictions	44,477	(15,093)	-	29,384
<b>Total operating revenues and other support</b>	<b>5,135,404</b>	<b>(15,093)</b>	<b>-</b>	<b>5,120,311</b>
<b>OPERATING EXPENSES:</b>				
Salaries	2,495,653	-	-	2,495,653
Fringe benefits	559,474	-	-	559,474
Student financial aid	13,159	-	-	13,159
Professional fees and purchased services	503,309	-	-	503,309
Supplies and pharmaceuticals	757,407	-	-	757,407
Other operating expenses	341,749	-	-	341,749
Interest on indebtedness	81,476	-	-	81,476
Depreciation	247,302	-	-	247,302
<b>Total operating expenses</b>	<b>4,999,529</b>	<b>-</b>	<b>-</b>	<b>4,999,529</b>
<b>NET OPERATING ACTIVITIES:</b>	<b>135,875</b>	<b>(15,093)</b>	<b>-</b>	<b>120,782</b>
<b>NONOPERATING ACTIVITIES, NET:</b>				
Investment return in excess of spending distribution for current operations	179,573	177,417	3,123	360,113
Change in undistributed income from perpetual funds held by others	-	-	74,558	74,558
Gifts and contributions	5,964	25,465	41,335	72,764
Loss on disposal of property and equipment	(11,494)	-	-	(11,494)
Loss on defeasance of debt	(8,659)	-	-	(8,659)
Change in fair value of derivative instruments	80,123	-	-	80,123
Pension and postretirement benefit plans	23,017	-	-	23,017
Other nonoperating items, net	(7,174)	2,571	(282)	(4,885)
Net assets released from restrictions	41,194	(70,578)	-	(29,384)
<b>Total nonoperating activities, net</b>	<b>302,544</b>	<b>134,875</b>	<b>118,734</b>	<b>556,153</b>
<b>CHANGE IN NET ASSETS</b>	<b>438,419</b>	<b>119,782</b>	<b>118,734</b>	<b>676,935</b>
Less change in net assets related to noncontrolling interests	15,360	-	-	15,360
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ 423,059</b>	<b>\$ 119,782</b>	<b>\$ 118,734</b>	<b>\$ 661,575</b>

See accompanying notes to consolidated financial statements.

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

*Years Ended August 31, 2018 and 2017*

*(Dollars in thousands)*

	<u>2018</u>	<u>2017</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Change in net assets	\$ 834,606	\$ 676,935
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Capital contributions from noncontrolling interests	-	802
Contributions for endowment and capital projects	(420,939)	(17,000)
Net realized gains on sale of investments	(197,789)	(351,422)
Net unrealized gains on investments	(275,657)	(228,118)
Loss on disposal of property and equipment	1,633	11,494
Interests in perpetual funds held by others	(26,880)	(74,558)
Loss on defeasance of debt	-	8,659
Depreciation and amortization	260,674	247,302
Provision for uncollectable accounts	247,732	244,836
Accretion/amortization of bond discounts/premiums and issuance costs	(3,057)	(2,627)
Actuarial adjustments for retiree pension and benefit plans	(28,461)	(23,017)
Change in fair value of derivative instruments	(59,751)	(80,123)
Decrease (increase) in operating assets:		
Accounts and other receivables, net	(424,670)	(249,415)
Contributions receivable for operations	21,167	20,334
Prepaid expenses, deferred charges, and other assets	(38,668)	(29,243)
Increase (decrease) in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	26,205	50,026
Asset retirement obligation	3,012	3,064
Accrued liabilities for benefit obligations and professional liabilities	38,503	(6,750)
Deferred tuition and other revenue	89,554	(37,078)
<b>Net cash provided by operating activities</b>	<u><b>47,214</b></u>	<u><b>164,101</b></u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Disbursements for loans to students	(2,713)	(2,933)
Repayment of loans from students	4,496	4,684
Proceeds from sales and maturities of investments	7,653,840	8,437,212
Purchases of investments	(7,294,192)	(8,984,313)
Purchases of property, plant, and equipment	(378,464)	(347,145)
Increase in funds held in trust for others	44,732	81,894
<b>Net cash provided by (used in) investing activities</b>	<u><b>27,699</b></u>	<u><b>(810,601)</b></u>

(Continued)



**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

*Years Ended August 31, 2018 and 2017*

*(Dollars in thousands)*

	<u>2018</u>	<u>2017</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from contributions for endowment and capital projects	44,432	15,933
Proceeds from bonds payable	-	491,171
Principal repayments of bonds payable	(29,500)	(365,776)
Recovery of posted collateral for debt-related derivatives	7,770	66,502
Increase (decrease) in annuities payable	783	(658)
Decrease in government advances for federal loan programs	(62)	(3)
Bond issuance costs	-	(1,303)
Capital distributions to noncontrolling interests	-	(802)
<b>Net cash provided by financing activities</b>	<u><b>23,423</b></u>	<u><b>205,064</b></u>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>98,336</b>	<b>(441,436)</b>
<b>Cash and cash equivalents at beginning of year</b>	<u><b>51,113</b></u>	<u><b>492,549</b></u>
<b>Cash and cash equivalents at end of year</b>	<u><u><b>\$ 149,449</b></u></u>	<u><u><b>\$ 51,113</b></u></u>
Supplemental disclosures:		
Cash paid for interest	\$ 84,274	\$ 83,455
Accrued liabilities for property, plant and equipment purchases	10,836	10,477

See accompanying notes to consolidated financial statements.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### (1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,100 undergraduate students and 7,400 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare system, Emory Medical Care Foundation (EMCF) and Emory Innovations, LLC.

The Emory Healthcare system (Emory Healthcare) consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUH, EUHM, EJCH, and ESJH are sometimes referred to herein, collectively, as “the Hospitals.”

The consolidated financial statements include the University and all other entities in which Emory has significant financial interest and control. All significant inter-entity accounts and transactions have been eliminated in consolidation.

#### (2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared on the accrual basis in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenues, gains, and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

*Unrestricted Net Assets* – Net assets that are not subject to donor-imposed stipulations; certain unrestricted net assets are designated for specific purposes or uses under various internal operating and administrative arrangements of the University.

*Temporarily Restricted Net Assets* – Net assets that are subject to donor-imposed stipulations; that will be met either by actions of the University and/or the passage of time

*Permanently Restricted Net Assets* – Net assets that are subject to donor-imposed restrictions that the University maintains permanently (note 7); generally, the donors of these assets permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes.

Revenues are reported as increases in unrestricted net assets unless their use is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

Income and realized and unrealized gains on investments of permanently donor-restricted endowment net assets are reported as follows:

- As increases in permanently restricted net assets if the terms of the gift require that they be added to the principal of a permanent endowment fund
- As increases in temporarily restricted net assets until appropriated for expenditure by the University and/or donor restrictions are met

Revenues earned, expenses incurred, and investment returns made available for the University's operating purposes of teaching, research, patient care, and other programs and services are components of the net operating revenues/expenses presented in the consolidated statements of activities. The University considers the following items to be nonoperating: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return in excess of spending distribution for current operations, change in fair value of derivative instruments, pension and postretirement related changes other than net periodic cost, and other, net.

**(a) Cash Equivalents**

Cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities of 90 days or less that are not invested as part of the long-term investment assets. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes.

**(b) Contributions Receivable**

Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift. Contributions to be received after one year, net of an allowance for uncollectible amounts are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is provided based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

**(c) Loans Receivable, Net**

Emory-funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain governmental loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to Federal Direct Loans (which are not reported in the consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

**(d) Other Receivables, Net**

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations, and losses recoverable from reinsurers.

**(e) Investments**

Investments in securities include U.S. and non-U.S. equities and fixed-income instruments, both publicly traded and privately held. Fair value for these investments is measured based on quoted prices in active markets, if available. If the market is inactive, fair value is determined by underlying managers and reviewed by the University after considering various sources of information. Due to variations in trading volumes and the lack of quoted market prices for fixed income, the fair value of fixed income is normally derived through recent reported trades for identical or similar securities, making adjustments through the reporting date based on available market observable data.

Investments in funds primarily include investments in commingled equity and fixed-income funds and other investments in funds (public market investments, private market investments, real estate partnerships, and natural resources) and are reported at fair value, as determined by the University in accordance with the University's valuation policies and procedures. The University has estimated the fair value of the majority of its investments in investment funds on the basis of the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if a) the underlying investment manager's calculation of NAV is fair value based, b) the NAV has been calculated by the fund manager or fund administrator as of the University's fiscal year-end date, and c) the University does not currently have plans to sell the investment for an amount different from NAV. If the reported NAV is not as of the University's fiscal year-end date or is not fair value based, the University will adjust the NAV, if deemed necessary. If the University determines it is not practicable to calculate an adjusted NAV as of the University's fiscal year-end date, the practical expedient will not be utilized and other valuation methodologies will be used. Typically, real estate partnerships and similar funds are valued based on appraisals of underlying properties held and conducted by third-party appraisers retained by the general partner or investment manager. General partners of oil and gas partnerships also use third-party appraisers to value properties. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2018 and 2017.

The University's investments in investment funds are subject to the terms of the respective funds' agreements, private placement memoranda, and other governing agreements of such funds. These terms are typical for hedge fund and private equity arrangements. The University's investments are also subject to management and performance fees as specified in such funds' agreements. Additionally, such funds in which the University invests may restrict both the transferability of the University's interest and the University's ability to withdraw. In light of such restrictions imposed, an investment in these funds is illiquid and subject to liquidity risk.

Investment transactions are accounted for on the trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on the accrual basis. Realized gains and losses are determined by the specific identification method for investments in investment funds and average cost for investments in securities. Additionally, gains and losses from realized and unrealized changes in the fair value of investments are reported in the consolidated statements of activities as increases or

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

decreases in unrestricted net assets, if there are no donor restrictions, or in temporarily restricted net assets, until amounts have been appropriated and the donor-imposed time restrictions have elapsed. Changes in the fair value of these instruments are recognized as nonoperating investment gains or losses in the consolidated statements of activities.

(f) ***Fair Value Measurements***

Fair value measurements reflected in the consolidated financial statements conceptually represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

**Level 1** – Valuations for assets and liabilities traded in active exchange markets as of the reporting date; valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

**Level 2** – Valuations are determined through direct or indirect observations other than quoted market prices. The type of investments in Level 2 also includes certain positions in which the University is a unit of account holder within a fund or account that holds underlying assets that are traded in active exchange markets with readily available pricing.

**Level 3** – Valuations for assets and liabilities that are unobservable and derived from other valuation methodologies, including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions; Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

The majority of the University's investments are held through limited partnerships and commingled funds, for which fair value is estimated using the NAVs reported by the investment managers as a practical expedient. Such investments have not been categorized within the fair value hierarchy. Although a secondary market exists for these investments, the market is not active and individual transactions are typically not observable. When transactions do occur in this limited secondary market, they may occur at discounts to the reported NAV. It is therefore reasonably possible that if the University were to sell these investments in the secondary market, a buyer may require a discount to the reported NAV, and that discount could be significant.

(g) ***Split-Interest Agreements***

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

the trusts are included in investments. Contribution revenues are recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

**(h) *Interests in Perpetual Funds Held by Others***

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such funds are established. The largest fund of this type consists primarily of shares of common stock of The Coca-Cola Company. The carrying value of Emory's interest is adjusted annually for changes in fair value.

**(i) *Property and Equipment, net***

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$107.1 million and \$99.0 million, such as art, museum assets, and rare books, are included in property and equipment on August 31, 2018 and 2017, respectively, but are not depreciated.

**(j) *Net Tuition and Fees***

Tuition and fees revenues are recognized in the period in which the academic services are rendered. Student tuition and fee receipts received in advance of services are reported as deferred revenue. Student financial aid provided by the University for tuition and fees is reflected as a reduction of gross tuition and fees.

**(k) *Gifts and Contributions Revenue***

Contributions, including unconditional promises to give, are recognized as revenues in the period received. Unconditional promises to give, with payments due in future periods, are recorded as increases in temporarily or permanently restricted assets at the estimated present value of future cash flows, net of an allowance for uncollectible pledges.

Donor-restricted contributions are reported as temporarily restricted or permanently restricted revenue that increases those net asset classes. Expirations of temporary restrictions on net assets, such as the donor stipulation being met or the passage of time, are reported as net assets released from restrictions and reflect reclassifications from temporarily restricted net assets to unrestricted net assets. If the donor stipulation for a temporarily restricted contribution is met in the year of the gift, the contribution is reflected in the unrestricted net asset class. Temporary restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

not recognized until they become unconditional; that is, when the conditions on which they depend are met.

**(l) *Grants and Contracts Revenue and Indirect Cost Recoveries***

Funding from a federal agency, corporation, or private foundation (sponsor) is recorded as grants and contracts revenue when it is for a specified activity with a defined budget, period of performance, and scope of work undertaken by the University. The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement and is generally in direct support of the University's mission. Sponsored program revenues and program income are earned when the University has substantially met its obligations and when the contractual performance measures have been completed. Revenue is recognized when services are rendered, or allowable expenditures are incurred as specified in the terms and conditions of the agreements, not necessarily when payments are received. Unearned revenue results when cash is received from sponsors in advance of revenue being earned. Unearned revenue is recorded as a liability (deferred revenue) until it is earned. Amounts recorded in grants and contracts receivable are for services rendered or expenditures incurred in advance of the receipt of funds.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grants and contracts agreements.

**(m) *Net Patient Service Revenue***

Net patient service revenue is reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Emory Healthcare's estimates in this area may differ from actual experience, and those differences may be material.

The Hospitals reserve for third-party payor cost report audits and anticipated settlements, through initial audit and final settlement of the cost reports. The Hospitals' maintain estimates of third-party settlements for the Hospitals' routine exposures in this area in recognition of the complexity of relevant reimbursement regulations and the volatility of related settlement processes.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

**(n) *Sales and Services of Auxiliary Enterprises and Independent Operations***

An auxiliary enterprise, as put forth by the National Association of College and University Business Officers, is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises include residential halls, food services, a bookstore, and parking operations. Fee charges are directly related to the costs of services provided.

Independent operations are activities, which are solely owned and/or controlled by the University but are unrelated or independent of its mission. Independent operations include an externally managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided.

**(o) *Income Taxes***

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code (the Code) and is generally exempt from the federal income taxes on related income pursuant to Section 501(a) of the Code. Accordingly, no provision for income taxes is made in the consolidated financial statements. Unrelated business income of the University is reported on Form 990-T. In December 2017, the Tax Cuts and Job Acts (the Act) was approved by the United States Congress. Emory is currently evaluating the impact of the Act.

**(p) *Derivative Instruments***

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in investments. Changes in fair value of these instruments are recognized as nonoperating investment gains or losses in the consolidated statements of activities. The University will, from time to time, utilize interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements are recognized as nonoperating changes in net assets in the consolidated statements of activities.

**(q) *Pension and Postretirement Benefit Plans***

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in unrestricted net assets.

**(r) *Reclassifications***

Certain amounts included in the accompanying 2017 consolidated statements of financial position have been reclassified to conform with the 2018 presentation.

The University reduced both the purchases and sales of investments, within the investing activities of the consolidated statement of cash flows in 2017, which reflects the netting of high volume cash activities within its investment pools.



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

(s) ***New Accounting Pronouncements***

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers*, which requires entities to recognize revenue to depict the transfer of promised goods or services to customers in amounts that reflect the consideration expected in exchange for those goods or services. Entities should also disclose quantitative and qualitative information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU No. 2014-09 is effective for the University for FY 2019.

In June 2018, the FASB issued ASU No. 2018-08, *Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made*, which clarifies whether grant (or similar transactions) should be accounted for as contributions or exchange transactions. ASU No. 2018-08 is effective in FY 2019 for the University.

In August 2016, the FASB issued ASU No. 2016-14, *Presentation of Financial Statements of Non-for-Profit Entities*. ASU No. 2016-14 (1) reduces the number of net asset classes presented from three to two, (2) requires the presentation of expenses by functional and natural classification in one location, and (3) requires quantitative and qualitative disclosures about liquidity and availability of financial assets. ASU No. 2016-14 is effective in FY 2019 for the University.

In March 2017, the FASB issued ASU No. 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which requires the University to present the service cost component of net benefit cost within operating expenses and all other components of net benefit cost in nonoperating activities. The ASU is effective for the University in FY 2020.

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*. ASU No. 2016-02 requires the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases under the Accounting Standards Codification (ASC) Topic 840 – Leases. The accounting applied by a lessor under ASU No. 2016-02 is largely unchanged from that applied under ASC Topic 840. ASU No. 2016-02 is effective for the University in FY 2020.

(t) ***Use of Estimates***

The preparation of the consolidated financial statements in conformity with GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for uncollectible accounts and contractual adjustments, reserves for employee healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### (u) *Conflict of Interest Policies*

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members. When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

#### (3) **Contributions Receivable**

Contributions receivable as of August 31 consist of the following (in thousands):

	<u>2018</u>	<u>2017</u>
Unconditional promises expected to be collected in:		
Less than one year	\$ 167,912	35,953
One year to five years	275,094	52,171
Over five years	2,983	3,671
	<u>445,989</u>	<u>91,795</u>
Less:		
Allowance for uncollectible amounts	(10,581)	(2,516)
Discount to present value	(39,281)	(8,872)
	<u>\$ 396,127</u>	<u>80,407</u>

At August 31, 2018 and 2017, the five largest outstanding donor pledge balances represented 90% and 42%, respectively, of Emory's gross contributions receivable. Contributions receivable are discounted at rates ranging from 1.83% to 9.24%.

As of August 31, 2018, the University had received bequest intentions and conditional promises of approximately \$27.0 million. These intentions to give are not recognized as assets or revenues and, if received, will generally be restricted for purposes stipulated by the donor.

#### (4) **Business and Credit Concentrations**

Emory Healthcare grants credit to patients, substantially all of whom reside in the service areas. Emory Healthcare generally does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health insurance programs, plans, or policies (e.g., Medicare, Medicaid, Managed Care, capitated, and other

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

preferred provider arrangements and commercial insurance policies). The composition of net receivables from patients and third-party payors follows:

	<b>2018</b>	<b>2017</b>
Managed care and other third-party payors	56%	54%
Medicare	32	38
Patients	5	4
Medicaid	7	4
	100%	100%

#### (5) Net Patient Service Revenue

Emory Healthcare has agreements with governmental and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates. Contractual adjustments under third-party reimbursement programs represent the difference between Emory Healthcare's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

- Medicare – Substantially all acute care and professional services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Revenue from the Medicare program accounted for approximately 40% and 41% of Emory Healthcare's net patient service revenue for the years ended August 31, 2018 and 2017, respectively.
- Medicaid – Inpatient and professional services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Outpatient services are generally paid based on cost reimbursement methodologies. Emory Healthcare's cost reports have been audited and substantially settled for all fiscal years through August 31, 2015. Revenue from the Medicaid program accounted for approximately 4% of Emory Healthcare's net patient service revenue for both years ended August 31, 2018 and 2017.

Emory Healthcare has also entered into other reimbursement arrangements providing for payment methodologies, which include prospectively determined rates per discharge, discounts from established charges, and prospectively determined per diem rates.

The composition of net patient service revenue (excluding charity care) follows (in thousands):

	<b>2018</b>	<b>2017</b>
Gross patient service revenue	\$ 9,893,872	9,106,824
Less provisions for contractual and other adjustments	(6,305,888)	(5,735,501)
Less provisions for uncollectible accounts	(183,980)	(196,904)
Net patient service revenue	\$ 3,404,004	3,174,419

Emory Healthcare recognizes patient service revenue associated with services provided to patients with third-party payor coverage on the basis of contractual rates for the services rendered. For uninsured patients who

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

do not qualify for financial assistance in accordance with Emory Healthcare's established charity/indigent care policy, Emory Healthcare recognizes revenue on the basis of its discounted rates for services provided. On the basis of historical experience, a significant portion of Emory Healthcare's uninsured patients are unable or unwilling to pay for the services provided. Thus, Emory Healthcare records a significant provision for uncollectible accounts related to uninsured patients in the period the services are provided.

Patient service revenue, net of contractual allowances and discounts (but before the provision for uncollectible accounts) recognized during the years ended August 31, 2018 and 2017 from these major payor sources is as follows (in thousands):

	<u>2018</u>	<u>2017</u>
Third-party payors	\$ 3,460,212	3,173,150
Self pay	127,772	198,173
Total	<u>\$ 3,587,984</u>	<u>3,371,323</u>

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### (6) Investments

The following table summarizes investments as of August 31 (in thousands):

	2018	2017
Short-term investments and cash equivalents <sup>(a)</sup>	\$ 248,580	427,137
Investments in securities:		
Global equity securities		
U.S. equity securities	358,632	437,527
Non-U.S. equity securities	200,732	141,152
Fixed-income securities		
U.S government securities <sup>(b)</sup>	653,952	897,719
Domestic bonds and long-term notes <sup>(c)</sup>	590,216	431,770
International bonds and long-term notes <sup>(d)</sup>	208,163	174,647
Investments in private securities <sup>(e)</sup>	15,557	16,287
Commingled funds - equity <sup>(f)</sup>	360,446	762,567
Commingled funds - fixed income <sup>(f)</sup>	450,377	442,598
Investments in funds:		
Public market investments <sup>(g)</sup>	2,775,397	2,251,918
Private market investments <sup>(h)</sup>	1,512,157	1,261,446
Natural resources <sup>(i)</sup>	497,886	518,985
Real estate partnerships <sup>(i)</sup>	279,082	281,497
Derivatives <sup>(k)</sup>	(1,578)	(9,572)
Marketable real estate investments <sup>(l)</sup>	1,902	1,881
Oil and gas properties	1,155	680
Total investments at fair value	8,152,656	8,038,239
Joint ventures (equity method)	5,022	5,641
Total investments	\$ 8,157,678	8,043,880

(a) Includes short-term U.S. and non-U.S Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments; at August 31, 2018 and 2017, \$4.1 million and \$24.2 million, respectively, was posted as collateral (primarily related to derivatives' trading agreements) and was not readily available for use.

(b) Includes \$379.0 million of net pending trade payables related to unsettled forward purchases and sales of such securities as of August 31, 2018.

(c) Includes investments in nongovernment debt securities. Investments consist primarily of credit-oriented securities including U.S investment-graded and below investment-graded debt securities; other investments include mortgage-based securities, asset-backed securities, repurchase agreements, senior loans, and bank loans.

(d) Includes fixed-income investments in non-U.S debt securities, such as government bonds, corporate bonds, bank loans, and asset backed securities.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

- (e) Includes investments in private securities not held through a traditional fund or commingled vehicle.
- (f) Includes professionally managed pooled investment funds registered with the Securities and Exchange Commission or the Comptroller of the Currency (i.e. mutual funds and collective trusts).
- (g) Includes investments in fund structures that pursue multiple strategies to diversify risks and reduce volatility, as well as \$353.0 million in investment subscriptions paid in advance. Fund managers have the ability to shift investments across a wide variety of sectors, geographies, and strategies and from a net long position to a net short position. Certain investments in public market investments may be subject to restrictions that limit the University's ability to withdraw capital until i) a certain "lock-up period" has expired or ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, this class includes investments that may be subject to restrictions that limit the amount that the University is able to withdraw as of a given redemption date.
- (h) Includes illiquid investments in venture capital, growth equity, buyout, mezzanine, distressed debt, and commingled vehicles in which Emory is typically a limited partner or shareholder; the nature of the investment in this category is such that distributions are received through liquidation of the underlying assets of the fund. As of August 31, 2018, it is estimated that underlying assets of the funds will be liquidated over the next 11 years.
- (i) Includes investments in timber, mining, energy, farmland, commodities, and related services businesses held through liquid and illiquid fund structures; the nature of the investments in this category is largely such that distributions are received through liquidation of the underlying assets of the funds. As of August 31, 2018, it is estimated that the underlying assets of the funds will be liquidated over the next nine years.
- (j) Includes illiquid investments in real estate assets, projects, or land held in commingled funds; the fair value of these investments is calculated from the NAV of Emory's ownership interests in these funds. The nature of the investments in this category is such that distributions are received through liquidation of the assets of the funds. As of August 31, 2018, it is estimated that the underlying assets underlying of the funds will be liquidated over the next ten years.
- (k) Includes investments in derivative instruments including both exchange traded and over the counter futures, forwards, swaps, options, rights, and warrants valued at the fair market value of each underlying instrument (note 8).
- (l) Includes miscellaneous investments in real estate such as land gifts.

At August 31, 2018 and 2017, cash equivalents of \$248.6 million and \$427.1 million, respectively, are included in investments and restricted for investment activity within the investment portfolio. The Investment Policy for the long-term asset portfolio contains a target allocation to cash equivalents of 3% with a tolerance band of +/- 10%.

The University's investment policy allows fund managers to use foreign exchange contracts, currency hedges, and other derivative transactions to reduce volatility and manage market risk in investment portfolios. These financial instruments are included in investments at fair value in the accompanying consolidated statements of financial position with the related gain or loss recognized as investment income and gains (losses) in excess of spending distributions for current operations in the accompanying consolidated statements of activities.

The University may hold investments denominated in currencies other than the U.S. dollar. Thus, there is exposure to currency risk because the value of the investments denominated in other currencies may fluctuate due to changes in currency exchange rates, and this can have an effect on the reported value of these investments.

The value of securities held by the University may decline in response to certain economic events, including those events impacting entities whose securities are owned and included in the investment portfolio. Those events impacting valuation may include (but are not limited to) economic changes, market fluctuations,

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

regulatory changes, global and political instability, and currency, interest rate, and commodity price fluctuations. The University attempts to manage this risk through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions.

As of August 31, 2018, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	<u>Unfunded commitments</u>	<u>Redemption frequency (if currently eligible)</u>	<u>Redemption notice period</u>
Public market investments	\$ 20,000	30 days - over 2 years	3 - 306 days
Private market investments	916,428	not eligible	not eligible
Real estate partnerships	296,239	not eligible	not eligible
Natural resources	186,473	30 days or not eligible	45 days or not eligible
	<u>\$ 1,419,140</u>		

Unfunded commitments are expected to be called by funds within five years of fund inception.

Investment return as reflected in the accompanying consolidated statements of activities for the years ended August 31 is as follows (in thousands):

	<u>2018</u>	<u>2017</u>
Investment income, net	\$ 39,055	32,891
Realized and unrealized gains, net	473,446	579,540
Total investment return	<u>512,501</u>	<u>612,431</u>
Operating		
Endowment spending distribution	182,562	179,696
Other investment income designated for current operations	81,257	72,622
Total operating return	263,819	252,318
Nonoperating		
Investment return in excess of spending distribution for current operations	248,682	360,113
Total investment return	<u>\$ 512,501</u>	<u>612,431</u>

The University employs an internal core group of investment professionals dedicated to the management of Emory's investments and external investment managers.

#### (7) Endowment Net Assets

The University's Endowment (Endowment) consists of over 2,032 individual funds established for a variety of purposes, including both donor-restricted endowment funds and funds designated by the board of trustees

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

**(a) Interpretation of Relevant Law**

The board of trustees of the University has approved the University's adoption of the State of Georgia Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources, and the investment policies of the University.

The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, and deposits held in custody and miscellaneous investments. As of August 31, 2018, approximately 64.3% of the investments described in note 6 are classified as endowed net assets. Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2018			2017		
	Donor-restricted	Board-designated	Total	Donor-restricted	Board-designated	Total
Unrestricted	\$ (3,597)	1,556,384	1,552,787	(7,779)	1,498,575	1,490,796
Temporarily restricted	2,765,582	—	2,765,582	2,642,490	—	2,642,490
Permanently restricted	923,950	—	923,950	881,625	—	881,625
Total endowment funds	\$ 3,685,935	1,556,384	5,242,319	3,516,336	1,498,575	5,014,911



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Balance as of August 31, 2016	\$ 1,379,106	2,467,363	837,814	4,684,283
Investment return:				
Investment income	2,807	16,021	—	18,828
Realized and unrealized gains, net	134,226	350,647	—	484,873
Total investment return	137,033	366,668	—	503,701
Cash contributions	1,100	—	41,206	42,306
Additions of funds for endowments	—	—	2,647	2,647
Transfers of institutional funds for quasi-endowments	23,747	(258)	—	23,489
Withdrawal of board-designated funds for strategic initiatives	(5,555)	—	—	(5,555)
Appropriations for expenditure	(51,147)	(162,998)	—	(214,145)
Appropriations for capital purposes	(6,421)	(15,394)	—	(21,815)
Other	12,933	(12,891)	(42)	—
Balance as of August 31, 2017	\$ 1,490,796	2,642,490	881,625	5,014,911
Investment return:				
Investment income	4,183	18,825	—	23,008
Realized and unrealized gains, net	89,993	295,339	—	385,332
Total investment return	94,176	314,164	—	408,340
Cash contributions	168	—	41,209	41,377
Withdrawal of funds for endowments	—	—	(3,348)	(3,348)
Transfers of institutional funds for quasi endowments	28,655	—	—	28,655
Withdrawal of board-designated funds for strategic initiatives	(7,678)	—	—	(7,678)
Appropriations for expenditure	(36,779)	(180,995)	—	(217,774)
Appropriations for capital purposes	(6,110)	(16,054)	—	(22,164)
Other	(10,441)	5,977	4,464	—
Balance as of August 31, 2018	\$ 1,552,787	2,765,582	923,950	5,242,319

**(b) Funds with Deficiencies**

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature that are reported in unrestricted net assets were \$3.6 million and \$7.8 million as of August 31, 2018 and 2017, respectively. Subsequent gains that restore the fair value of the assets of the endowment fund to book value will be classified as an increase in unrestricted net assets.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

**(c) *Return Objectives and Risk Parameters***

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this policy, as approved by the board of trustees, the endowment assets are invested within risk tolerances of the University to provide an expected total return in excess of spending and inflation over the long-term.

**(d) *Strategies Employed for Achieving Objectives***

To satisfy its long-term, rate-of-return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across global equities, fixed income, marketable alternatives, and private investments to achieve its long-term return objectives within prudent risk constraints. The Endowment's long-term target asset allocation is approved by the investment committee of the board of trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

**(e) *Relationship between Investment Objectives and Spending Policy***

The University's board of trustees has established a spending policy that determines how endowment distributions are made. The distribution of endowment income in 2018 and 2017 was based on a hybrid spending policy formula, which is approved by the board of trustees and has both a constant budget growth component and market value based component. The target payout rate was 4.75% for FY 2018 and FY 2017. The University considers the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the board of trustees as part of the budget process.

**(8) *Derivative Instruments and Hedging Activities***

**Investments**

The University has executed derivative financial instruments in the normal course of its business. Investment strategies employed by Emory and investment managers retained by Emory may incorporate futures, options, swaps, and other derivative instruments to adjust elements of investment exposures to various securities, markets, and currencies without actually taking a position in the underlying asset.

These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks. The purchase and sale of exchange-traded derivatives require collateral deposits with a Futures Commission Merchant (FCM). In the event of an FCM's insolvency, recovery may be limited to Emory's pro rata share of segregated customer funds available. It is possible that the recovery amount could be less than the total of cash and other equity deposited. Management does not consider the underlying counterparty risk will have a material impact on the financial position of the University.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Emory's net investment-related derivative exposures, categorized by primary underlying risk, as of and for the years ended August 31 (in thousands):

<b>2018</b>	<b>Gross Notional Amount<sup>(1)</sup></b>	<b>Derivative Assets</b>	<b>Derivative Liabilities</b>	<b>Total Fiscal Year Gains (Losses)<sup>(2)</sup></b>
Interest-rate contracts	\$ 1,083,904	3,772	(2,383)	(9,487)
Foreign exchange contracts	1,112,864	781	(1,959)	(637)
Equity contracts	679,692	17	(2,267)	79,293
Credit contracts	53,900	904	(443)	687
Total	<u>\$ 2,930,360</u>	<u>5,474</u>	<u>(7,052)</u>	<u>69,856</u>

  

<b>2017</b>	<b>Gross Notional Amount<sup>(1)</sup></b>	<b>Derivative Assets</b>	<b>Derivative Liabilities</b>	<b>Total Fiscal Year Gains (Losses)<sup>(2)</sup></b>
Interest-rate contracts	\$ 1,103,290	1,087	(1,017)	6,492
Foreign exchange contracts	511,563	814	(2,260)	(2,637)
Equity contracts	883,547	5,464	(16,513)	31,649
Credit contracts	142,905	2,947	(94)	1,763
Total	<u>\$ 2,641,305</u>	<u>10,312</u>	<u>(19,884)</u>	<u>37,267</u>

(1) The notional amount is representative of the absolute value of the open contracts on August 31, 2018 and 2017.

(2) Gains (losses) on derivatives are included in the consolidated statements of activities in "investment return in excess of (less than) spending distribution for current operations" in "nonoperating activities."

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Emory's investment-related derivative assets and liabilities at August 31, by counterparty, are as follows (in thousands):

<b>2018</b>	<u>Assets</u>	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>
Counterparty A	\$ 4,165	(4,409)	(47,042)
Counterparty B	555	(911)	(30)
Counterparty C	283	(315)	—
Counterparty D	241	(656)	(200)
Counterparty E	159	(41)	—
All other	71	(720)	(350)
Total	<u>\$ 5,474</u>	<u>(7,052)</u>	<u>(47,622)</u>

  

<b>2017</b>	<u>Assets</u>	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>
Counterparty A	\$ 9,403	(17,590)	(71,536)
Counterparty B	310	(138)	246
Counterparty C	221	(339)	(150)
Counterparty D	146	(1,012)	(856)
Counterparty E	72	(69)	—
All other	160	(736)	36
Total	<u>\$ 10,312</u>	<u>(19,884)</u>	<u>(72,260)</u>

### Debt

As a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by factors influencing the spread between the taxable and tax-exempt market interest rates on its basis exchange. Certain university derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivatives in net liability positions. At August 31, 2018, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2018, Emory had nine interest rate swap agreements expiring on various dates ranging from November 15, 2028 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.328% to 4.388% in exchange for variable rate payments from the counterparties based on a percentage of the three-month LIBOR.

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$13.7 million and \$17.4 million during 2018 and 2017, respectively. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2018 and 2017

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that are in a liability position was \$128.9 million and \$188.6 million, collateralized by \$0 and \$7.8 million of cash on August 31, 2018 and 2017, respectively. Collateral postings are reported in prepaid expenses, deferred charges, and other assets in the consolidated statements of financial position.

The following table summarizes the debt-related derivatives as of August 31 (in thousands):

<b>Interest Rate Swaps</b>		<b>2018</b>		<b>2017</b>	
<b>Inception</b>	<b>Maturity</b>	<b>Liability Fair Value</b>	<b>Unrealized Gains</b>	<b>Liability Fair Value</b>	<b>Unrealized Gains</b>
August 4, 2005	September 1, 2035	\$ (20,317)	10,234	(30,551)	13,442
August 25, 2005	September 1, 2035	(6,858)	3,319	(10,177)	4,593
April 19, 2007	November 15, 2028	(991)	578	(1,569)	505
December 1, 2007	September 1, 2035	(15,452)	7,010	(22,462)	9,084
May 1, 2008	September 1, 2038	(19,183)	6,793	(25,976)	10,624
December 1, 2008	December 1, 2042	(22,594)	10,437	(33,031)	15,983
December 1, 2009	September 1, 2035	(16,295)	6,546	(22,841)	9,133
June 23, 2015	September 1, 2035	(20,317)	11,175	(31,492)	12,502
June 23, 2015	September 1, 2035	(6,854)	3,659	(10,513)	4,257
	Total	\$ <u>(128,861)</u>	<u>59,751</u>	<u>(188,612)</u>	<u>80,123</u>

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisors, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed. The swaps are exchanged with primarily six counterparties.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### (9) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2018 (in thousands):

	Total fair value	Investments measured at NAV <sup>(3)</sup>	Level 1	Level 2	Level 3
Financial assets:					
Short-term investments and cash equivalents	\$ 248,580	—	247,493	1,087	—
Investments in securities:					
Global equity securities					
U.S. equity securities	358,632	—	358,420	203	9
Non-U.S. equity securities	200,732	—	199,813	222	697
Fixed-income securities:					
U.S. government securities	653,952	—	217	653,735	—
Domestic bonds and long-term notes	590,216	—	1,550	587,940	726
International bonds and long-term notes	208,163	—	14	208,149	—
Investments in private securities	15,557	—	—	—	15,557
Commingled funds - equity	360,446	63,747	22,859	273,840	—
Commingled funds - fixed income	450,377	—	228,631	221,746	—
Investments in funds:					
Public market investments	2,775,397	2,775,397	—	—	—
Private market investments	1,512,157	1,507,082	—	—	5,075
Natural resources	497,886	493,382	—	—	4,504
Real estate partnerships	279,082	279,082	—	—	—
Derivatives	(1,578)	—	(2,980)	1,402	—
Marketable real estate investments	1,902	—	228	1,674	—
Oil and gas properties	1,155	—	—	—	1,155
Total investments <sup>(1)</sup>	8,152,656	5,118,690	1,056,245	1,949,998	27,723
Interests in perpetual funds held by others <sup>(2)</sup>	1,311,406	—	—	—	1,311,406
<b>Total assets at fair value</b>	<b>\$ 9,464,062</b>	<b>5,118,690</b>	<b>1,056,245</b>	<b>1,949,998</b>	<b>1,339,129</b>
Financial liabilities:					
Derivative instruments - interest rate swaps	(128,861)	—	—	(128,861)	—
Funds held in trust for others	(791,841)	—	—	(791,841)	—
<b>Total liabilities at fair value</b>	<b>\$ (920,702)</b>	<b>—</b>	<b>—</b>	<b>(920,702)</b>	<b>—</b>

(1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (note 6).

(2) Primarily invested in The Coca-Cola Company.

(3) Certain investments that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated statements of financial position.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2017 (in thousands):

	<u>Total fair value</u>	<u>Investments measured at NAV <sup>(3)</sup></u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
<b>Financial assets:</b>					
Short-term investments and cash equivalents	\$ 427,137	—	389,429	37,708	—
<b>Investments in securities:</b>					
Global equity securities					
U.S. equity securities	437,527	—	437,362	137	28
Non-U.S. equity securities	141,152	—	140,831	321	—
Fixed-income securities:					
U.S. government securities	897,719	—	163	897,556	—
Domestic bonds and long-term notes	431,770	—	1,628	429,020	1,122
International bonds and long-term notes	174,647	—	37	174,610	—
Investments in private securities	16,287	—	—	—	16,287
Commingled funds - equity	762,567	366,617	133,757	262,193	—
Commingled funds - fixed income	442,598	—	293,450	149,148	—
<b>Investments in funds:</b>					
Public market investments	2,251,918	2,251,918	—	—	—
Private market investments	1,261,446	1,260,729	—	—	717
Natural resources	518,985	518,985	—	—	—
Real estate partnerships	281,497	281,497	—	—	—
Derivatives	(9,572)	—	4,806	(14,378)	—
Marketable real estate investments	1,881	—	207	1,674	—
Oil and gas properties	680	—	—	—	680
Total investments <sup>(1)</sup>	<u>8,038,239</u>	<u>4,679,746</u>	<u>1,401,670</u>	<u>1,937,989</u>	<u>18,834</u>
Interest in perpetual funds held by others <sup>(2)</sup>	<u>1,244,906</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>1,244,906</u>
Total assets at fair value	<u>\$ 9,283,145</u>	<u>4,679,746</u>	<u>1,401,670</u>	<u>1,937,989</u>	<u>1,263,740</u>
<b>Financial liabilities:</b>					
Derivative instruments - interest rate swaps	(188,612)	—	—	(188,612)	—
Funds held in trust for others	(747,109)	—	—	(747,109)	—
Total liabilities at fair value	<u>\$ (935,721)</u>	<u>—</u>	<u>—</u>	<u>(935,721)</u>	<u>—</u>

- (1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (note 6).
- (2) Primarily invested in The Coca-Cola Company.
- (3) Certain investments that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated statements of financial position.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Investments made directly by the University whose values are based on quoted market prices in active markets, and are therefore classified within Level 1, include actively traded common and preferred stock, U.S. government fixed-income instruments, and non-U.S. government fixed-income instruments. Level 1 investments may also include commingled funds, such as listed mutual funds, futures contracts, and exchange traded funds.

Investments that trade in markets that are considered to be active but are based on dealer quotations or alternative pricing sources supported by observable inputs or investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations, or alternative pricing sources supported by observable inputs, are classified within Level 2. Alternative pricing sources include quotations from market participants and pricing models, which are based on accepted industry modeling techniques. These investments include U.S. investment grade and below investment grade debt securities, international corporate bonds, mortgage-backed securities, asset-backed securities, money market funds, senior loans and bank loans, most derivative contracts other than futures, and commingled structures with quoted market prices.

Investments that do not trade in active markets and for which values are instead derived from significant unobservable inputs are classified within Level 3. When observable prices are not available, these investments are valued using one or more valuation techniques described below.

- **Market approach:** This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- **Income approach:** This approach determines a valuation by discounting future cash flows.
- **Cost approach:** This approach is based on the principle of substitution and the concept that a market participant would not pay more than the amount that would currently be required to replace the asset.

The following tables summarize the University's Level 3 reconciliation for the years ended August 31, 2018 and 2017 (in thousands):

	Balance as of August 31, 2017	Net gains (losses)	Purchases	Sales	Transfer in (out) of Level 3	Balance as of August 31, 2018
Investments in U.S. equity securities	\$ 28	(5)	42	(56)	—	9
Non-U.S. equity securities	—	—	—	—	697	697
Domestic bonds and long-term notes	1,122	(8)	—	(388)	—	726
Investments in private securities	16,287	(497)	—	(233)	—	15,557
Investment in funds:						
Private market investments	717	(345)	85	—	4,618	5,075
Natural resources	—	—	—	—	4,504	4,504
Oil and gas properties	680	475	—	—	—	1,155
Total investments	18,834	(380)	127	(677)	9,819	27,723
Interest in perpetual funds held by others	1,244,906	66,500	—	—	—	1,311,406
Total assets	\$ 1,263,740	66,120	127	(677)	9,819	1,339,129



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

	Balance as of August 31, 2016	Net gains (losses)	Purchases	Sales	Transfer in (out) of Level 3	Balance as of August 31, 2017
Investments in U.S. equity securities	\$ 3	(46)	72	(1)	—	28
Non-U.S. equity securities	507	113	—	(620)	—	—
Domestic bonds and long-term notes	1,112	17	—	(7)	—	1,122
Investments in private securities	14,765	18,574	—	(17,052)	—	16,287
Investment in funds:						
Private market investments	658	15	31	(92)	105	717
Oil and gas properties	680	—	—	—	—	680
Total investments	17,725	18,673	103	(17,772)	105	18,834
Interest in perpetual funds held by others	1,170,348	74,558	—	—	—	1,244,906
Total assets	\$ 1,188,073	93,231	103	(17,772)	105	1,263,740

#### (10) Property and Equipment

Property and equipment at August 31 is summarized as follows (in thousands):

	<u>2018</u>	<u>2017</u>
Land and land improvements	\$ 201,887	201,696
Buildings and improvements	3,668,327	3,376,910
Equipment	2,435,931	2,308,381
Library and museum assets	438,429	414,132
Construction in progress	142,101	214,071
	<u>6,886,675</u>	<u>6,515,190</u>
Less accumulated depreciation	<u>(3,667,670)</u>	<u>(3,412,342)</u>
	<u>\$ 3,219,005</u>	<u>3,102,848</u>

Property and equipment is reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss shall be recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. There were no asset impairments for fiscal year 2018 or 2017.

The University has identified asset retirement obligations primarily from commitments to remove asbestos and lead paint in university facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.00% and discount rate of 4.74%. The liability for asset retirement obligations at August 31, 2018 and 2017 is \$66.0 million and \$63.0 million, respectively.

**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2018 and 2017

**(11) Bonds and Notes Payable**

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following at August 31 (dollars in thousands):

	<u>Average interest rate</u>	<u>Final maturity</u>	<u>Outstanding principal</u>	
			<u>2018</u>	<u>2017</u>
Tax-exempt fixed-rate revenue bonds:				
2016 Series A	4.62%	October 1, 2046	\$ 130,030	130,030
2016 Series B	4.17	October 1, 2043	212,620	221,710
2013 Series A	4.95	October 1, 2043	186,800	191,415
2011 Series A	4.95	September 1, 2041	121,500	121,500
2009 Series B <sup>(1)</sup>	4.79	September 1, 2035	195,470	200,530
2009 Series C	4.93	September 1, 2039	<u>93,555</u>	<u>95,060</u>
Total tax-exempt fixed-rate revenue bonds			<u>939,975</u>	<u>960,245</u>
Tax-exempt variable-rate revenue bonds:				
2013 Series B <sup>(2)</sup>	1.57	October 1, 2039	135,100	135,100
2013 Series C <sup>(2)</sup>	1.83	October 1, 2039	57,865	57,865
2007 Series A	2.00	November 15, 2028	9,740	9,770
2005 Series B	1.17	September 1, 2035	250,000	250,000
2005 Series C	1.16	September 1, 2036	<u>124,150</u>	<u>124,150</u>
Total tax-exempt variable-rate revenue bonds			<u>576,855</u>	<u>576,885</u>
Taxable fixed-rate revenue bonds:				
2009 Series A	5.63	September 1, 2019	250,000	250,000
1994 Series C	8.00	October 1, 2024	4,610	5,080
Series 1991	8.85	April 1, 2022	<u>186</u>	<u>243</u>
Total taxable fixed-rate revenue bonds			<u>254,796</u>	<u>255,323</u>
Taxable variable-rate revenue bonds:				
1999 Series B	1.58	November 1, 2029	8,610	9,085
1995 Series B	1.58	November 1, 2025	1,940	2,115
1994 Series B	1.63	October 1, 2024	<u>7,200</u>	<u>7,970</u>
Total taxable variable-rate revenue bonds			<u>17,750</u>	<u>19,170</u>
Commercial paper:				
2010 Program 1 - Tax-exempt	0.89	August 1, 2050	—	2,834
2008 Program 1 - Taxable	1.73	April 1, 2047	<u>104,344</u>	<u>108,394</u>
Total commercial paper			<u>104,344</u>	<u>111,228</u>
Other long-term debt	Various		<u>10</u>	<u>379</u>
Unamortized bond premiums			<u>76,575</u>	<u>80,642</u>
Unamortized bond discounts			<u>(2,003)</u>	<u>(2,325)</u>
Bond issuance costs			<u>(8,405)</u>	<u>(9,093)</u>
Total bonds and notes payable			<u>\$ 1,959,897</u>	<u>1,992,454</u>

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

- (1) Included in the 2009 Series Bonds is a medium-term maturity of \$43.0 million due on September 1, 2019 at an average interest rate of 4.68%.
- (2) Series 2013B and 2013C bonds are floating rate notes and interest rates are based on a spread to one month LIBOR and The Securities Industry and Financial Markets Association Index (SIFMA), respectively.

The University incurred interest expense of \$77.1 million and \$81.5 million in 2018 and 2017, respectively, net of capitalized interest of \$4.1 million and \$0.8 million in 2018 and 2017, respectively. During 2018 and 2017, the average interest rate on University tax-exempt and taxable variable rate demand bonds was 1.16% and 1.58%, respectively. Related indices for this period were 1.21% for tax-exempt debt (SIFMA) and 1.69% for taxable debt (LIBOR).

During 2017, the University refunded its 2008C and 2005A Series Bonds totaling \$147.2 million with proceeds from the University's issuance of 2016B Series Bonds. The University incurred an accounting loss of \$8.7 million on the refunding of the extinguishment of the 2008C and 2005A Series Bonds, which is included in the nonoperating activities in the accompanying 2017 consolidated statement of activities.

At August 31, 2018, the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

Payable in fiscal year:		
2019	\$	21,873
2020		302,418
2021		18,614
2022		13,461
2023		13,365
Thereafter		<u>1,523,999</u>
		1,893,730
Unamortized net premium		74,572
Unamortized net bond issuance costs		<u>(8,405)</u>
	\$	<u><u>1,959,897</u></u>

In 2010, the University established a \$400.0 million tax-exempt Commercial Paper program. The primary purpose of the program is to meet interim financing needs related to capital projects. As of August 31, 2018 or 2017, the University had no outstanding balances under this program.

The University has a standby credit facility to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has one diversified facility totaling \$150.0 million that is committed for this sole purpose and cannot be used for operating needs of the University. There were no draws against this line of credit in 2018 or 2017.

Emory University's healthcare system, Emory Healthcare, entered into an affiliation agreement with one of its payors effective June 11, 2018. This affiliation agreement includes, among other provisions, a \$100.0 million line of credit to Emory University, which can be utilized for any purpose that advances the charitable mission of Emory Healthcare. There is no outstanding balance on this line of credit as of August 31, 2018.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Emory University has an additional \$75.0 million line of credit unrelated to this Emory Healthcare affiliation agreement for which there is also no outstanding balance as of August 31, 2018.

The University has two letters of credit with a commercial bank totaling \$1.4 million. There were no outstanding balances as of August 31, 2018 or 2017.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

#### (12) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets consist of the following as of August 31 (in thousands):

	<u>2018</u>	<u>2017</u>
Appreciation on endowments restricted until appropriated	\$ 2,640,672	2,517,580
Term endowments	124,910	124,910
Contributions receivable, time, and purpose restricted	372,500	48,447
Restricted for capital projects and other donor purposes	70,013	24,518
Annuity and life income agreements	8,576	7,141
	<u>\$ 3,216,671</u>	<u>2,722,596</u>

Permanently restricted net assets include endowment funds subject to UPMIFA (note 7) as well as perpetual trusts and endowments held by others. Permanently restricted net assets consist of the following as of August 31 (in thousands):

	<u>2018</u>	<u>2017</u>
Donor-restricted endowments	\$ 923,950	881,625
Interests in perpetual funds held by others	1,271,786	1,244,906
Contributions receivable, restricted for endowment	23,627	31,961
Annuity and life income agreements	2,071	2,081
Split-interest trusts	3,245	3,268
	<u>\$ 2,224,679</u>	<u>2,163,841</u>

Generally, the donors of these restricted gifts permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes, such as scholarships, faculty salaries, or other operational and administrative support.

#### (13) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under Internal Revenue Code (IRC) Section 403(b) covering certain employees and teaching staff. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Emory Healthcare sponsors a retirement plan, covering most full time employees, under which annuities are purchased with contributions by Emory Healthcare and its employees. The benefits are vested only to the extent of the annuities purchased. TEC

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

sponsors The Emory Clinic, Inc. Retirement Savings Plan (the Plan), covering all its employees, except those considered leased employees or those covered under collective bargaining agreements, as defined. The Plan provides for employees to make salary reduction contributions and for TEC to make discretionary contributions for employees who have attained the age of 21 and are employees at the date the contribution is made. The Plan provides for contributions at an annual determined percentage of compensation and employees cliff vest in employer contributions after three years of service. Retirement expense totaled \$142.7 million and \$131.6 million during 2018 and 2017, respectively, and is included in operating expense in the accompanying consolidated statements of activities.

The University sponsors an IRC Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the point of termination of employment from the University. As of August 31, 2018 and 2017, respectively, the University held other assets of \$134.7 million and \$115.7 million under the plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$134.7 million and \$115.7 million as of August 31, 2018 and 2017, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

#### (14) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by SJHS (SJHS Pension Plan). The Plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

The changes in the projected benefit obligations as of August 31 follow (in thousands):

	2018		2017	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Projected benefit obligation, beginning of year	\$ 326,875	154,690	324,577	160,393
Interest cost	11,614	6,180	10,605	6,042
Actuarial gains	(10,651)	(6,178)	(1,131)	(6,498)
Benefits paid	(7,804)	(5,574)	(7,176)	(5,247)
Projected benefit obligation, end of year	<u>\$ 320,034</u>	<u>149,118</u>	<u>326,875</u>	<u>154,690</u>

**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2018 and 2017

Given the curtailment of the plans, the accumulated benefit obligations at August 31, 2018 and 2017 are the same as the projected benefit obligations.

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of August 31 follow (in thousands):

	2018		2017	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Fair value of plan assets, beginning of year	\$ 235,118	110,316	213,181	99,096
Actual return on plan assets	12,969	9,406	19,666	10,197
Employer contributions	11,089	7,240	9,447	6,270
Benefits paid	(7,804)	(5,574)	(7,176)	(5,247)
Fair value of plan assets, end of year	\$ 251,372	121,388	235,118	110,316
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$ (68,662)	(27,730)	(91,757)	(44,374)

The components of net periodic pension cost for the years ended August 31 follow (in thousands):

	2018		2017	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Interest cost	\$ 11,614	6,180	10,605	6,042
Expected return on plan assets	(18,827)	(7,777)	(17,156)	(6,971)
Amortization of prior service cost	3,552	(438)	3,061	(438)
Recognized actuarial loss	2,295	1,866	2,576	2,196
Net periodic pension cost	\$ (1,366)	(169)	(914)	829

Net periodic costs are recognized as employees render the services necessary to earn the pension and postretirement benefits.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position for 2018 and 2017 follow:

	2018		2017	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	4.31%	4.28%	4.07%	4.07%
Expected long-term rate of return on plan assets	8.00	6.75	8.00	7.00

Weighted average assumptions used to determine net periodic pension cost for 2018 and 2017 follow:

	2018		2017	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	4.07%	4.07%	3.83%	3.83%
Expected return on plan assets	8.00	7.00	8.00	7.00

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### ***Emory Healthcare Plan Assets***

The Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation.

The following table summarizes the Plan's assets, which are recorded at fair value as of August 31 (in thousands):

	<b>2018</b>				
	<b>Total</b>	<b>Fair value hierarchy</b>		<b>Target</b>	<b>Total asset</b>
	<b>fair value</b>	<b>Level 1</b>	<b>Level 2</b>	<b>allocation</b>	<b>allocation</b>
Investments:					
Short-term investments and cash equivalents	\$ 2,103	(595)	2,698	—%	1%
Commingled funds - equity	174,329	—	174,329	70	69
Commingled funds - fixed income	74,940	—	74,940	30	30
Total investments	<u>\$ 251,372</u>	<u>(595)</u>	<u>251,967</u>	<u>100%</u>	<u>100%</u>
	<b>2017</b>				
	<b>Total</b>	<b>Fair value hierarchy</b>		<b>Target</b>	<b>Total asset</b>
	<b>fair value</b>	<b>Level 1</b>	<b>Level 2</b>	<b>allocation</b>	<b>allocation</b>
Investments:					
Short-term investments and cash equivalents	\$ 354	(332)	686	—%	—%
Commingled funds - equity	163,270	—	163,270	70	70
Commingled funds - fixed income	71,494	—	71,494	30	30
Total investments	<u>\$ 235,118</u>	<u>(332)</u>	<u>235,450</u>	<u>100%</u>	<u>100%</u>

#### ***SJHS Pension Plan Assets***

Under the terms of the agreement forming the JOC, the assets of the SJHS Pension Plan formally remain assets of SJHS and the plan assets remain invested in the CHE Trinity Health Pension Investment Program. Accordingly, neither the JOC nor Emory Healthcare has discretion over the management of the plan assets. However, the plan assets related to the entities contributed to the JOC (and certain other employees leased to the JOC) are contractually required to be clearly separated from the plan assets of the other entities participating in the CHE Trinity Health Employee Pension Program. The SJHS Pension Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the plan's investment objectives.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

The SJHS Pension Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan's target asset allocation.

The following table summarizes the Plan's assets, which are recorded at fair value as of August 31 (in thousands):

	<b>2018</b>				
	<b>Total</b>	<b>Fair value hierarchy</b>		<b>Target</b>	<b>Total asset</b>
	<b>fair value</b>	<b>Level 1</b>	<b>Level 2</b>	<b>allocation</b>	<b>allocation</b>
Investments:					
Short-term investments and cash equivalents	\$ 4,814	2,067	2,747	2%	4%
Commingled funds - equity	66,187	27,008	39,179	52	55
Commingled funds - fixed income	31,751	—	31,751	35	26
Managed funds	18,636	—	18,636	11	15
Total investments	<u>\$ 121,388</u>	<u>29,075</u>	<u>92,313</u>	<u>100%</u>	<u>100%</u>
	<b>2017</b>				
	<b>Total</b>	<b>Fair value hierarchy</b>		<b>Target</b>	<b>Total asset</b>
	<b>fair value</b>	<b>Level 1</b>	<b>Level 2</b>	<b>allocation</b>	<b>allocation</b>
Investments:					
Short-term investments and cash equivalents	\$ 3,990	1,868	2,122	—%	4%
Commingled funds - equity	54,671	23,190	31,481	50	49
Commingled funds - fixed income	35,868	—	35,868	40	33
Managed funds	15,787	—	15,787	10	14
Total investments	<u>\$ 110,316</u>	<u>25,058</u>	<u>85,258</u>	<u>100%</u>	<u>100%</u>

### ***Cash Flows***

Emory Healthcare expects to contribute \$10.5 million to the Emory Healthcare Pension Plan and \$6.4 million to the SJHS Pension Plan in fiscal year 2019.

### ***Expected Future Benefit Payments***

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$8.7 million to \$14.3 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$6.2 million to \$7.6 million for the next five years.

### ***Other Items***

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

## **(15) Postretirement Healthcare and Life Insurance Benefits**

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2018			2017
	Emory University	Emory Healthcare	Total	Total
APBO, beginning of year	\$ 102,631	58,601	161,232	161,116
Service cost	1,680	713	2,393	2,308
Interest cost	3,634	2,039	5,673	5,181
Actuarial gains	(2,201)	(1,121)	(3,322)	(2,602)
Benefits paid	(3,072)	(2,256)	(5,328)	(4,771)
APBO, end of year	<u>\$ 102,672</u>	<u>57,976</u>	<u>160,648</u>	<u>161,232</u>

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of August 31 are as follows (in thousands):

	Emory University	Emory Healthcare	Total	Total
Fair value of plan assets, beginning of year	\$ 68,209	20,452	88,661	80,416
Actual return on plan assets	5,234	1,401	6,635	9,623
Benefits paid by Emory	—	(2,256)	(2,256)	(1,378)
Fair value of plan assets, end of year	<u>\$ 73,443</u>	<u>19,597</u>	<u>93,040</u>	<u>88,661</u>
Funded status - accrued postretirement benefit cost recognized in the consolidated statements of financial position	<u>\$ (29,229)</u>	<u>(38,379)</u>	<u>(67,608)</u>	<u>(72,571)</u>

Actuarial assumptions used to determine the values of the APBO and the benefit costs for years ended August 31, 2018 and 2017 included a discount rate of 4.31% and 4.11%, respectively. Since the plan was amended on April 11, 2002 to limit the University's liability for future medical care cost increases to 4.00%, the per capita cost increase of healthcare benefits is capped at 4.00%. The estimated long-term rate of return on plan assets was 8.00% for the University and Emory Healthcare for both years ended August 31, 2018 and 2017.

**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2018 and 2017

The components of net periodic postretirement benefit cost for years ended August 31 were as follows (in thousands):

	<b>2018</b>			<b>2017</b>
	<b>Emory University</b>	<b>Emory Healthcare</b>	<b>Total</b>	<b>Total</b>
Service cost of benefits earned	\$ 1,680	713	2,393	2,308
Interest cost on APBO	3,634	2,039	5,673	5,181
Expected return on plan assets	(5,334)	(1,559)	(6,893)	(6,218)
Recognized net actuarial loss	2,216	2,350	4,566	6,126
Net periodic postretirement benefit cost	<u>\$ 2,196</u>	<u>3,543</u>	<u>5,739</u>	<u>7,397</u>

The amounts accumulated in unrestricted net assets follow (in thousands):

	<b>2018</b>			<b>2017</b>
	<b>Emory University</b>	<b>Emory Healthcare</b>	<b>Total</b>	<b>Total</b>
Net unrecognized actuarial loss	\$ 39,610	20,749	60,359	68,254
Prior service cost	(146)	120	(26)	46
Total	<u>39,464</u>	<u>20,869</u>	<u>60,333</u>	<u>68,300</u>

In fiscal year 2019, net unrecognized actuarial losses of \$2.0 million for Emory University and \$1.9 million for Emory Healthcare are expected to be amortized from unrestricted net assets into net periodic postretirement benefit cost.

***Plan Assets***

The investment committee of the Emory University board of trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

The following table summarizes the University's VEBA Trust assets as of August 31 (in thousands):

		2018						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	55,891	14,807	13,702	27,382	75%	76%	
Commingled funds - fixed income		17,552	—	8,893	8,659	25	24	
Total investments	\$	<u>73,443</u>	<u>14,807</u>	<u>22,595</u>	<u>36,041</u>	<u>100%</u>	<u>100%</u>	
		2017						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	52,714	15,026	13,656	24,032	75%	77%	
Commingled funds - fixed income		15,495	—	8,968	6,527	25	23	
Total investments	\$	<u>68,209</u>	<u>15,026</u>	<u>22,624</u>	<u>30,559</u>	<u>100%</u>	<u>100%</u>	

The following table summarizes Emory Healthcare's VEBA Trust assets as of August 31 (in thousands):

		2018						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	14,597	—	4,837	9,760	75%	74%	
Commingled funds - fixed income		5,021	—	3,045	1,976	25	26	
Short term investment and cash equivalents		(21)	—	(21)	—	—	—	
Total investments	\$	<u>19,597</u>	<u>—</u>	<u>7,861</u>	<u>11,736</u>	<u>100%</u>	<u>100</u>	
		2017						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	15,377	—	4,563	10,814	75%	75%	
Commingled funds - fixed income		5,075	—	3,067	2,008	25	25	
Total investments	\$	<u>20,452</u>	<u>—</u>	<u>7,630</u>	<u>12,822</u>	<u>100%</u>	<u>100%</u>	

### **Cash Flows**

Emory Healthcare does not expect to contribute to the postretirement benefit plan during fiscal year 2019.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### ***Expected Future Benefit Payments***

Annual future benefit payments are expected to range from \$3.5 million to \$4.7 million for Emory University and from \$2.0 million to \$2.8 million for Emory Healthcare for the next five years.

#### **(16) Charity Care and Community Benefits**

Emory Healthcare provides care to patients who meet certain criteria under their charity care policies without charge or at amounts less than their established rates. Because such operating companies do not pursue collection of amounts determined to qualify as charity care, such amounts are not included in net patient service revenue. Emory Healthcare applies the measurement and disclosure provisions of FASB ASU No. 2010-23, *Health Care Entities (Topic 954): Measuring Charity Care for Disclosure*. ASU No. 2010-23 amends ASC Subtopic 954-605, *Health Care Entities – Revenue Recognition*, and requires that cost be used as the measurement basis for charity care disclosure purposes.

Records are maintained to identify and monitor the level of charity care provided. These records include the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies. The cost of charity care provided totaled approximately \$99.7 million and \$74.7 million for the years ended August 31, 2018 and 2017, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

#### **(17) Functional Expenses**

The consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands):

	<b>2018</b>	<b>2017</b>
Instruction	\$ 458,270	454,276
Research	516,489	490,306
Public service	120,233	102,796
Academic support	174,975	162,308
Student services	102,684	95,017
Institutional support	205,043	199,057
Scholarships and fellowships	23,949	17,668
Medical services	306,932	263,842
Healthcare services	3,398,654	3,145,643
Auxiliary enterprises	46,533	46,554
Independent operations	22,652	22,062
Total operating expenses	\$ 5,376,414	4,999,529

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study and debt financing records. Total amounts allocated in 2018 and 2017 were \$188.7 million and \$192.0 million, respectively. Fundraising costs were approximately \$38.9 million and \$34.1 million in 2018 and 2017, respectively.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

#### **(18) Medical Professional and General Liability Insurance Coverage**

CCIC, Emory Healthcare's wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2018 and 2017, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$144.6 million (discounted at 2%) and \$121.5 million (discounted at 2%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$129.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The University's management believes adequate provision has been made for the related risk.

#### **(19) Related-Party Transactions**

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The board of trustees of CCI comprises 16 to 28 members, including its founders, and others as elected half by the University, including the University's president, and half by the Carter Center class trustees. The University's board of trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws.

Funds held in trust for others include \$758.2 million and \$708.4 million representing CCI's investment in the University's long-term investment portfolio of August 31, 2018 and 2017, respectively.

#### **(20) Commitments and Contingencies**

The University is in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2018 totaled \$68.2 million.

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures, which may be disallowed by the granting agencies cannot be determined at this time, although management expects they will not have a material effect on the University's consolidated financial statements.

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review. In addition, the University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2018 and 2017

resulting liability from these actions will not have a material adverse effect on the consolidated financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance. Management of the University believes any current pending lawsuit subjecting the University to liability would not have a materially adverse effect on the University's consolidated financial position.

#### **(21) Subsequent Events**

Emory has evaluated subsequent events after the consolidated statement of financial position date of August 31, 2018 through January 30, 2019, the date the consolidated financial statements were available to be issued and noted that there are no other items to disclose except as follow:

On September 1, 2018, Emory Healthcare entered into a Definitive Agreement with DeKalb Regional Health System (DRHS) and became the sole and controlling member of DRHS upon acquisition of DRHS's assets and liabilities with the goal of DRHS being integrated operationally, financially, and clinically into Emory Healthcare. DRHS operates a 451-bed general acute care hospital with a freestanding surgery center in Decatur, Georgia; a 100-bed general acute care hospital in Hillandale, Georgia; a 76-bed long-term acute care hospital in Decatur, Georgia; and a physician network of primary care, occupational, and specialty physician practices. The terms of Definitive Agreement addressed, among other matters, the positioning of currently outstanding DRHS indebtedness, commitments of future capital funding, and amendments to the current long-term and transfer agreement between DRHS and the Hospital Authority of DeKalb County, Georgia.

Effective September 1, 2018, Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, have entered into a Master Affiliation Agreement (the affiliation agreement) to establish the Emory and Children's Pediatric Institute (the Institute). The affiliation agreement restructures previous arrangements between the parties for pediatric teaching, research, and related clinical services. Under the terms of the affiliation, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers have transferred to the Institute and became employees thereof. The ownership of the Institute will be 50% Emory University and 50% Children's with equal representation on the governing board.

On September 13, 2018, Emory issued \$164.4 million of its tax-exempt Commercial Paper program to defease DRHS's outstanding debt, DeKalb County Hospital Authority Revenue Anticipation Certificates (DeKalb Medical Center Inc. Project), Series 2010 issued in the original aggregate principal amount of \$183.1 million.



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

## **Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards***

The Board of Trustees  
Emory University  
Atlanta, Georgia

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statement of financial position as of August 31, 2018, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated January 31, 2019.

### **Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia  
January 31, 2019



**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL  
AWARDS**

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture:				
Sustainable Agriculture Research and Education:				
Pass-through University of Georgia	RR337-268/S001428	10.215	\$ —	21,429
Pass-through University of Minnesota	H004403736	10.215	—	305
Total CFDA No. 10.215			—	21,734
U.S. Department of Agriculture:				
Agriculture and Food Research Initiative (AFRI)	2018-67011-28030	10.310	—	15,792
Agriculture and Food Research Initiative (AFRI)	2018-69001-27553/AMN	10.310	—	788
Agriculture and Food Research Initiative (AFRI)	2015-67017-23080	10.310	—	109,610
Pass-through University of Georgia	RC284-661/S001583	10.310	—	99,069
Total CFDA No. 10.310			—	225,259
U.S. Department of Agriculture Total			—	246,993
U.S. Department of Commerce:				
Fisheries Development and Utilization Research and Development Grants and Cooperative Agreements	NA15NMF4270347	11.427	38,663	66,511
Total CFDA No. 11.427			38,663	66,511
Marine Fisheries Initiative	NA17NMF4330319	11.433	—	44,009
Total CFDA No. 11.433			—	44,009
U.S. Department of Commerce Total			38,663	110,520
U.S. Department of Defense:				
Basic and Applied Scientific Research	N00014-16-1-2276	12.300	32,053	206,809
Pass-through Brown University	00000922	12.300	—	26,489
Total CFDA No. 12.300			32,053	233,298
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA1-15-C-0075	12.351	363,781	1,886,672
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA-1-16-1-0029	12.351	—	160,835
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA11810029	12.351	—	4,332
Total CFDA No. 12.351			363,781	2,051,839
Military Medical Research and Development	CA170948	12.420	—	26,630
Military Medical Research and Development	W81XWH-12-0255	12.420	—	15,379
Military Medical Research and Development	W81XWH-14-1-0616	12.420	—	72,128
Military Medical Research and Development	W81XWH-15-1-0132	12.420	—	195,600
Military Medical Research and Development	W81XWH-15-1-0154	12.420	162,904	226,916
Military Medical Research and Development	W81XWH-15-1-0545	12.420	—	429,847
Military Medical Research and Development	W81XWH-15-1-0676	12.420	—	448,463
Military Medical Research and Development	W81XWH-16-1-0535	12.420	—	272,835
Military Medical Research and Development	W81XWH-16-1-0584	12.420	64,108	165,516
Military Medical Research and Development	W81XWH-16-1-0744	12.420	7,465	186,227
Military Medical Research and Development	W81XWH-17-1-0104	12.420	—	145,275
Military Medical Research and Development	W81XWH-17-1-0186	12.420	—	204,343
Military Medical Research and Development	W81XWH1710187	12.420	—	165,614
Military Medical Research and Development	W81XWH-17-1-0271	12.420	—	317,627
Military Medical Research and Development	W81XWH-17-1-0438	12.420	—	173,062
Military Medical Research and Development	W81XWH-17-1-0439	12.420	—	232,958
Military Medical Research and Development	W81XWH-17-1-0459	12.420	—	120,458
Military Medical Research and Development	W81XWH1810526	12.420	—	33,472
Military Medical Research and Development	W81XWH-17-1-0634	12.420	80,527	212,467
Military Medical Research and Development	W81XWH-17-R-0066	12.420	—	328,137
Pass-through Dana Farber Cancer Institute	3078403	12.420	—	(117)
Pass-through Henry M Jackson Foundation	3269 PO# 871905	12.420	—	50,238
Pass-through Natl Trauma Institute	NTI-NTRR15-02	12.420	—	10,742
Pass-through University of California San Francisco	8599sc	12.420	—	21,373
Pass-through University of Miami	SPC-000206	12.420	—	82,035
Pass-through University of Rochester	417122G/URFAO GR5106	12.420	—	98,376
Pass-through University of Texas San Antonio	159424/155536	12.420	—	32,744
Total CFDA No. 12.420			315,004	4,268,345
Basic Scientific Research	W911NF-13-1-0100P007	12.431	—	824
Basic Scientific Research	W911NF-14-1-0208 P00	12.431	—	42,523
Basic Scientific Research	W911NF-17-1-0382	12.431	—	92,828
Basic Scientific Research	W911NF-17-1-0427	12.431	53,238	250,910
Basic Scientific Research	W911NF1810187	12.431	—	46,794
Basic Scientific Research	W911NF1820089	12.431	—	7,033
Pass-through University of California Los Angeles	100GSA786	12.431	—	75,942
Pass-through Virginia Tech	450378-19554-02	12.431	—	128,092
Total CFDA No. 12.431			53,238	644,946
Uniformed Services University Medical Research Projects				
Pass-through Duke University	3834189	12.750	6,946	1,095,415
Pass-through Henry M Jackson Foundation	#2399 PO 794803	12.750	—	2,256
Pass-through Henry M Jackson Foundation	2490 - PO# 825668	12.750	2,664	123,981
Pass-through Henry M Jackson Foundation	3434 PO#882221	12.750	—	18,806
Pass-through Henry M Jackson Foundation	PO 830097/2604	12.750	—	634,780
Total CFDA No. 12.750			9,610	1,875,238

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Air Force Defense Research Sciences Program	FA9550-17-1-0006	12.800	\$ —	163,150
Air Force Defense Research Sciences Program	FA9550-18-1-0189	12.800	—	47,086
Air Force Defense Research Sciences Program	FA9550-18-1-0414	12.800	—	18,590
Air Force Defense Research Sciences Program	FA9550-18-1-0005	12.800	—	100,846
Pass-through Yale University	C17L12686(L00137)	12.800	—	77,129
Total CFDA No. 12.800				<u>406,801</u>
Research and Technology Development	HR0011-16-2-0011	12.910	—	172,801
Research and Technology Development	N66001-16-2-4054	12.910	123,557	978,283
Research and Technology Development	W31P4Q-14-1-0010	12.910	1,951,252	2,370,412
Pass-through Georgia Institute of Technology	RJ728-G1	12.910	—	77,450
Pass-through University of Pennsylvania	569456	12.910	—	203,070
Total CFDA No. 12.910				<u>3,802,016</u>
Contract	W911NF-16-C-0008	12.RD	835,610	1,967,254
Contract	W81XWH-16-0108	12.RD	8,409	209,408
Contract	W81XWH-16-1-0644	12.RD	—	126,458
Contract	W81XWH-16-1-0721	12.RD	—	59,588
Pass-through Georgia Institute of Technology	RH-269G1	12.RD	—	6,741
Pass-through Mclean Hospital	401373	12.RD	—	125,000
Pass-through North Carolina State University	2016-2896-05	12.RD	—	167,365
Pass-through University of Michigan	3004116108 AMD 10	12.RD	—	132,522
Pass-through Weill Cornell Medical College	15060932	12.RD	4,507	45,429
Total CFDA No. 12.RD				<u>2,839,765</u>
U.S. Department of Defense Total				<u>3,697,021</u>
U.S. Department of State:				
Academic Exchange Programs – Humphrey Fellowship Program:				
Pass-through Institute Of International Education	IIE_0138_Emory_7.1.1	19.010	—	45,437
Total CFDA No. 19.010				<u>45,437</u>
U.S. Department of State Total				<u>45,437</u>
U.S. Department of Transportation:				
National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants	DTNH2217D00068	20.614	—	44,378
National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants	DTNH2217F00160	20.614	6,150	577,395
Total CFDA No. 20.614				<u>621,773</u>
U.S. Department of Transportation Total				<u>621,773</u>
National Aeronautics and Space Administration:				
Science	80NSSC18M0053	43.001	—	3,108
Science	NNX14AG01 G	43.001	64,320	106,564
Science	NNX15AH74G-001	43.001	—	13,762
Science	NNX16AE49A	43.001	—	129
Science	NNX16AQ28G 000003	43.001	28,778	193,917
Science	NNX17AE72G	43.001	—	159,816
Pass-through California Institute of Technology	1,588,347	43.001	—	84,853
Pass-through Center for the Advancement of Science In Space	GA-2017-266/MOD. 1	43.001	—	159,399
Pass-through Massachusetts Institute of Technology	5,710,004,161	43.001	—	50,229
Pass-through University of Georgia	RR185-474/S001129	43.001	—	93,038
Pass-through University of Iowa	W000921108/PO 100174	43.001	—	21,861
Total CFDA No. 43.001				<u>886,676</u>
Aeronautics:				
Pass-through California Institute Of Technology	1363692	43.002	—	66,987
Total CFDA No. 43.002				<u>66,987</u>
Exploration	80NSSC188K1116	43.003	—	42,994
Exploration	NNX15AD63G S008	43.003	—	301,385
Pass-through Georgia Institute of Technology	RH412-G2 A1	43.003	—	29,861
Total CFDA No. 43.003				<u>374,240</u>
National Aeronautics and Space Administration Total				<u>93,098</u>
National Endowment for the Humanities:				
Promotion of the Humanities Research	RZ – 230579-15	45.161	—	92,440
Total CFDA No. 45.161				<u>92,440</u>
Promotion of the Humanities Professional Research	FV-256791-17	45.163	—	110,402
Total CFDA No. 45.163				<u>110,402</u>
National Leadership Grants	LG-94-17-0269-17	45.312	—	1,152
Total CFDA No. 45.312				<u>1,152</u>
National Endowment for the Humanities Total				<u>203,994</u>
National Science Foundation:				
Engineering Grants	1609831	47.041	—	146,376
Engineering Grants	1640848	47.041	—	5,485
Engineering Grants	1762211	47.041	—	17,679
Engineering Grants	CBET-1150235	47.041	—	163,903
Engineering Grants	CBET-1512826	47.041	—	116,388
Engineering Grants	CBET1706891	47.041	—	179,504
Engineering Grants	CBET-1818476	47.041	—	132,102
Engineering Grants	ECCS 1503878	47.041	—	125,784

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Engineering Grants	ECCS 1804198	47.041	\$ —	191
Engineering Grants	ECCS 1807568	47.041	—	645
Engineering Grants	EFMA-1741691	47.041	5,983	161,458
Engineering Grants	EFRI-1137229	47.041	5,402	5,402
Engineering Grants	EFRI-1137229	47.041	—	(5,970)
Engineering Grants	PHY1740578	47.041	—	614
Pass-through Georgia Institute of Technology	RJ375-G5	47.041	—	12,543
Total CFDA No. 47.041			11,385	1,062,104
Mathematical and Physical Sciences	1610377	47.049	—	279,740
Mathematical and Physical Sciences	1709132	47.049	—	106,388
Mathematical and Physical Sciences	1751636	47.049	—	32,819
Mathematical and Physical Sciences	1764385	47.049	—	54,923
Mathematical and Physical Sciences	1808771	47.049	—	218
Mathematical and Physical Sciences	1654485 Amendment 00	47.049	25,163	90,797
Mathematical and Physical Sciences	CHE 1808509	47.049	—	68,156
Mathematical and Physical Sciences	CHE-1205646	47.049	499,432	639,126
Mathematical and Physical Sciences	CHE-1309817	47.049	—	2,167
Mathematical and Physical Sciences	CHE-1352040	47.049	—	176,529
Mathematical and Physical Sciences	CHE-1362502	47.049	—	30,722
Mathematical and Physical Sciences	CHE-1412580	47.049	—	74,875
Mathematical and Physical Sciences	CHE-1463552-002	47.049	—	148,989
Mathematical and Physical Sciences	CHE-1465189	47.049	—	95,677
Mathematical and Physical Sciences	CHE-1506405	47.049	—	13,681
Mathematical and Physical Sciences	CHE-1507932	47.049	—	255,990
Mathematical and Physical Sciences	CHE1565912	47.049	—	81,095
Mathematical and Physical Sciences	CHE1611102	47.049	—	94,921
Mathematical and Physical Sciences	CHE1700982	47.049	1,546,251	3,375,176
Mathematical and Physical Sciences	CHE1709182	47.049	—	255,019
Mathematical and Physical Sciences	CHE-1726536	47.049	—	349,469
Mathematical and Physical Sciences	CHE-1755698	47.049	—	177,910
Mathematical and Physical Sciences	CHE-1807865	47.049	—	41,511
Mathematical and Physical Sciences	CHE-1818781	47.049	—	180,863
Mathematical and Physical Sciences	DMR-1808288	47.049	—	11,826
Mathematical and Physical Sciences	DMR-1409851	47.049	—	(32)
Mathematical and Physical Sciences	DMR-1455086	47.049	—	116,079
Mathematical and Physical Sciences	DMR-1504449	47.049	—	76,630
Mathematical and Physical Sciences	DMR-1506446	47.049	—	114,581
Mathematical and Physical Sciences	DMR-1534317	47.049	—	264,612
Mathematical and Physical Sciences	DMR1609763	47.049	—	131,062
Mathematical and Physical Sciences	DMR-1822262	47.049	—	190,167
Mathematical and Physical Sciences	DMS 1522599	47.049	—	53,737
Mathematical and Physical Sciences	DMS-1620406	47.049	—	80,692
Mathematical and Physical Sciences	DMS-1301698	47.049	—	13,767
Mathematical and Physical Sciences	DMS-1401319	47.049	—	3,207
Mathematical and Physical Sciences	DMS-1412973	47.049	—	35,774
Mathematical and Physical Sciences	DMS-1419060	47.049	—	115,919
Mathematical and Physical Sciences	DMS-1463882	47.049	—	104,384
Mathematical and Physical Sciences	DMS-1522760	47.049	—	37,860
Mathematical and Physical Sciences	DMS-1555048	47.049	—	113,552
Mathematical and Physical Sciences	DMS1557960	47.049	—	76,257
Mathematical and Physical Sciences	DMS-1601306	47.049	—	97,263
Mathematical and Physical Sciences	DMS1700355	47.049	—	10,987
Mathematical and Physical Sciences	DMS1719578	47.049	—	110,408
Mathematical and Physical Sciences	DMS1819042	47.049	—	37,756
Mathematical and Physical Sciences	PHY-1410978	47.049	—	46,352
Total CFDA No. 47.049			2,070,846	8,469,601
Geosciences	AGS-1350021	47.050	—	5,394
Pass-through University of California Berkeley	00009258/BB00797482	47.050	—	65,335
Total CFDA No. 47.050			—	70,729
Computer and Information Science and Engineering	1350885	47.070	—	172
Computer and Information Science and Engineering	1618932	47.070	—	42,249
Computer and Information Science and Engineering	1636933	47.070	91,064	251,643
Computer and Information Science and Engineering	1722906	47.070	—	27,306
Computer and Information Science and Engineering	CNS1553579-001	47.070	—	109,225
Computer and Information Science and Engineering	IIS 1822378	47.070	—	32,012
Pass-through Notre Dame University	CNS-1405912	47.070	—	(31)
Total CFDA No. 47.070			91,064	462,576
Biological Sciences	1354829	47.074	—	83,019
Biological Sciences	1359575	47.074	—	77,377
Biological Sciences	1456912	47.074	—	144,252
Biological Sciences	1457291	47.074	40,808	124,312
Biological Sciences	1557724	47.074	34,519	192,517
Biological Sciences	1624104	47.074	—	67,273
Biological Sciences	1655163	47.074	—	82,376
Biological Sciences	66469933	47.074	—	3,249
Biological Sciences	DBI-1344208	47.074	—	52,018
Biological Sciences	DBI-1346549	47.074	—	99,353
Biological Sciences	DBI-1353939	47.074	—	1,660
Biological Sciences	DEB-1601520	47.074	—	4,667
Biological Sciences	DEB-1750553	47.074	—	59,160
Biological Sciences	DEB-1754431	47.074	—	8,605

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Biological Sciences	DEB-1754595	47.074	\$ —	82,764
Biological Sciences	DEB-1834487	47.074	—	38,015
Biological Sciences	IOS-1149829	47.074	—	106,906
Biological Sciences	IOS-1354998	47.074	5,062	109,043
Biological Sciences	IOS1656247	47.074	—	129,132
Biological Sciences	MCB-1413062	47.074	—	73,476
Pass-through University Of California Riverside	S-000585	47.074	—	34,111
Total CFDA No. 47.074			<u>80,389</u>	<u>1,573,285</u>
Social, Behavioral, and Economic Sciences	1,533,260	47.075	29,664	108,513
Social, Behavioral, and Economic Sciences	1,613,577	47.075	—	13,368
Social, Behavioral, and Economic Sciences	1,632,477	47.075	—	157,017
Social, Behavioral, and Economic Sciences	1,632,660	47.075	—	9,713
Social, Behavioral, and Economic Sciences	1,748,293	47.075	—	112,528
Social, Behavioral, and Economic Sciences	1,825,469	47.075	—	542
Social, Behavioral, and Economic Sciences	1634001-001	47.075	—	33,809
Social, Behavioral, and Economic Sciences	BCS-1413395	47.075	—	14,145
Social, Behavioral, and Economic Sciences	BCS-1430403	47.075	—	3,732
Social, Behavioral, and Economic Sciences	BCS-1528091	47.075	—	548
Social, Behavioral, and Economic Sciences	BCS-1560458	47.075	—	16,467
Social, Behavioral, and Economic Sciences	BCS-1658234	47.075	—	22,411
Social, Behavioral, and Economic Sciences	SES-1756853	47.075	—	42,949
Pass-through Auburn University	16-CLA-200580-EU	47.075	—	10,185
Pass-through Columbia University	SES-0951516	47.075	—	11,012
Total CFDA No. 47.075			<u>29,664</u>	<u>556,939</u>
Education and Human Resources	DGE1444932	47.076	—	1,699,357
Pass-through Georgia Institute of Technology	RG083-G1	47.076	—	18,167
Pass-through Georgia State University	SP00012566-01	47.076	—	257,633
Total CFDA No. 47.076			<u>—</u>	<u>1,975,157</u>
National Science Foundation Total			<u>2,283,348</u>	<u>14,170,391</u>
U.S. Department of Veterans Affairs:				
Veterans State Hospital Care	508-17-3-7103-0234	64.016	—	9,585
Total CFDA No. 64.016			<u>—</u>	<u>9,585</u>
U.S. Department of Veterans Affairs Total				
			<u>—</u>	<u>9,585</u>
U.S. Environmental Protection Agency:				
Environmental Protection Consolidated Research: Science to Achieve Results (STAR) Research Program	83586901	66.509	119,270	315,851
Science to Achieve Results (STAR) Research Program	83615301 Mod. 2	66.509	—	366,952
Pass-through Dartmouth College	R904	66.509	—	7,858
Pass-through Harvard University	112514-5080711	66.509	—	84,493
Pass-through Rutgers University	PO519729 8195 Mod 3	66.509	—	53,844
Total CFDA No. 66.509			<u>119,270</u>	<u>828,998</u>
U.S. Environmental Protection Agency Total			<u>119,270</u>	<u>828,998</u>
U.S. Department of Energy:				
Office of Science Financial Assistance Program	DE-FG02-01ER15153-00	81.049	—	147,849
Office of Science Financial Assistance Program	DE-FG02-07ER15906/ 9	81.049	—	414,552
Office of Science Financial Assistance Program	DE-SC0008798-0007	81.049	—	58,342
Office of Science Financial Assistance Program	DE-SC0016004 MOD 000	81.049	—	179,096
Total CFDA No. 81.049			<u>—</u>	<u>799,839</u>
U.S. Department of Energy Total			<u>—</u>	<u>799,839</u>
U.S. Department of Education:				
Overseas Programs – Doctoral Dissertation Research Abroad	PO22A160058	84.022	—	18,092
Total CFDA No. 84.022			<u>—</u>	<u>18,092</u>
Education Research, Development, and Dissemination	R305A160240-18	84.305	—	387,152
Total CFDA No. 84.305			<u>—</u>	<u>387,152</u>
U.S. Department of Education Total			<u>—</u>	<u>405,244</u>
U.S. Department of Health and Human Services:				
Global AIDS	6 NU14GH001237-04-03	93.067	1,468,456	3,013,509
Total CFDA No. 93.067			<u>1,468,456</u>	<u>3,013,509</u>
Chronic Diseases: Research, Control, and Prevention: Pass-through American College of Rheumatology	6NU58DP006138	93.068	—	42,301
Total CFDA No. 93.068			<u>—</u>	<u>42,301</u>
Family Smoking Prevention and Tobacco Control Act Regulatory Research	5R01CA179422-05 REVI	93.077	—	344,824
Total CFDA No. 93.077			<u>—</u>	<u>344,824</u>
Food and Drug Administration_Research	1R01FD005746-01A1	93.103	—	6,845
Food and Drug Administration_Research	5R01FD003527-02 REVI	93.103	41,621	173,145
Food and Drug Administration_Research	5R01FD004814-04	93.103	16,419	401,701
Pass-through Duke University	2,034,640	93.103	—	(687)
Pass-through Duke University	2,036,543	93.103	—	127,879
Pass-through Georgia Institute of Technology	RG219-G2/AMND 5	93.103	—	253,747
Total CFDA No. 93.103			<u>58,040</u>	<u>962,630</u>

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Maternal and Child Health Federal Consolidated Programs	5 T76MC28446-04	93.110	\$ 62,613	396,153
Maternal and Child Health Federal Consolidated Programs	6 T03MC07651--12--03	93.110	—	43,344
Total CFDA No. 93.110			<u>62,613</u>	<u>439,497</u>
Environmental Health	1R01ES028346-01A1	93.113	—	16,479
Environmental Health	1R01ES029212-01	93.113	—	13,146
Environmental Health	1R21ES028903-01A1	93.113	—	5,601
Environmental Health	3P30ES019776-06S1	93.113	73,457	1,593,992
Environmental Health	3R01ES023839-04S1	93.113	—	415,275
Environmental Health	3R21ES025632-02S1	93.113	—	97,410
Environmental Health	4P30RD019776-04	93.113	—	179,233
Environmental Health	4R01ES022223-04	93.113	361,635	698,689
Environmental Health	5 R21 ES022795-02REV	93.113	10,121	10,121
Environmental Health	5K01ES025445-04	93.113	—	190,768
Environmental Health	5K99ES024570-02	93.113	—	(158)
Environmental Health	5K99ES027869-02	93.113	—	72,582
Environmental Health	5P30ES019776-03REVIS	93.113	—	(774)
Environmental Health	5P50ES026071-04S1	93.113	—	953,534
Environmental Health	5R01ES024790-04	93.113	—	451,390
Environmental Health	5R01ES025145-04	93.113	166,649	552,545
Environmental Health	5R01ES025775-03	93.113	69,835	664,041
Environmental Health	5R01ES026082-03	93.113	473,061	666,396
Environmental Health	5R01ES027859-02	93.113	—	275,377
Environmental Health	5R01ES027892-02	93.113	43,451	289,747
Environmental Health	5R21ES028226-02	93.113	—	162,268
Environmental Health	5R24ES028507-02	93.113	40,354	107,642
Environmental Health	5T32ES012160-10	93.113	—	355
Environmental Health	5T32ES012870-15	93.113	—	560,014
Environmental Health	5R01ES023485-05	93.113	—	244,396
Pass-through Dartmouth College	R905	93.113	—	59,090
Pass-through Duke University	203-6059	93.113	—	1,547
Pass-through Oregon State University	PO388A-A Am.3	93.113	—	7,229
Pass-through University of California Los Angeles	1935 G TA389	93.113	—	2,368
Pass-through University of North Carolina Chapel Hill	R01ES021777	93.113	—	(8,596)
Pass-through Wake Forest University	WFUHS 552908	93.113	—	14,101
Total CFDA No. 93.113			<u>1,238,563</u>	<u>8,295,808</u>
Preventive Medicine and Public Health Residency Training Program, Integrative Medicine Program, and National Center for Integrative Primary Healthcare	1 D33HP31663--01--00	93.117	—	49,928
Total CFDA No. 93.117			<u>—</u>	<u>49,928</u>
Oral Diseases and Disorders Research	5R00DE025060-05	93.121	—	144,385
Oral Diseases and Disorders Research	5R01DE025837-03	93.121	6,083	525,481
Oral Diseases and Disorders Research	5R01DE026333-03 REV1	93.121	84,332	1,020,644
Oral Diseases and Disorders Research	5R01DE026941-02	93.121	71,608	406,032
Pass-through University of Pittsburgh	0038322 (125166-5)	93.121	—	27,207
Pass-through University of Pittsburgh	0039171(130983-1)	93.121	—	5,679
Total CFDA No. 93.121			<u>162,023</u>	<u>2,129,428</u>
Grants to Increase Organ Donations	5R39OT269910300	93.134	—	134,272
Total CFDA No. 93.134			<u>—</u>	<u>134,272</u>
Centers for Research and Demonstration for Health Promotion and Disease Prevention:				
Pass-through Morehouse School of Medicine	002-EMORY-260057	93.135	—	137,243
Pass-through New York University	14-AO-00-002153-01	93.135	—	15,391
Pass-through University of Washington	UWSC7246	93.135	—	49,990
Total CFDA No. 93.135			<u>—</u>	<u>202,624</u>
NIEHS Hazardous Waste Worker Health and Safety Training	5UH4ES027093-03	93.142	24,055	231,147
Total CFDA No. 93.142			<u>24,055</u>	<u>231,147</u>
NIEHS Superfund Hazardous Substances_Basic Research and Education				
Pass-through Michigan State University	RC105856Emory	93.143	—	127,637
Total CFDA No. 93.143			<u>—</u>	<u>127,637</u>
Human Genome Research	5R01HG007508-03	93.172	21,205	21,205
Human Genome Research	5R01HG007508-03	93.172	—	(16,488)
Pass-through Brigham and Womens Hospital	115,540	93.172	—	16,626
Pass-through Kaiser Foundation Research Institute	OOS100285-EMORY, HG0	93.172	—	36,440
Pass-through University of Chicago	FP061089B	93.172	—	123,233
Pass-through University of Iowa	PO# 1001531479	93.172	—	90,774
Total CFDA No. 93.172			<u>21,205</u>	<u>271,790</u>
Research Related to Deafness and Communication Disorders	2R1DC008343-11A1	93.173	—	49,336
Research Related to Deafness and Communication Disorders	5F31DC015395-03	93.173	—	56,141
Research Related to Deafness and Communication Disorders	5R01DC008343-10	93.173	—	38,975
Research Related to Deafness and Communication Disorders	5R01DC014496-03 REV1	93.173	—	516,747
Research Related to Deafness and Communication Disorders	5R03DC015302-02	93.173	4,716	64,640
Pass-through University of Memphis	ra5-40456/AMND03 REV	93.173	12,825	47,709
Total CFDA No. 93.173			<u>17,541</u>	<u>773,548</u>
Nursing Workforce Diversity	5D19HP269730303	93.178	—	173,785
Total CFDA No. 93.178			<u>—</u>	<u>173,785</u>
Telehealth Programs:				
Pass-through University of Arizona	G22RH30360	93.211	—	53,633
Total CFDA No. 93.211			<u>—</u>	<u>53,633</u>

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Research and Training in Complementary and Alternative Medicine	4R01AT007052-05	93.213	\$ —	236
Research and Training in Complementary and Alternative Medicine	1K23AT009713-01A1	93.213	—	239
Research and Training in Complementary and Alternative Medicine	5UG3AT008857-02 REVI	93.213	204,681	517,513
Pass-through Georgia State University	SP00013079-02	93.213	—	17,885
Pass-through University of Illinois	16,043	93.213	—	37,510
Total CFDA No. 93.213				573,383
Research on Healthcare Costs, Quality and Outcomes	1R01HS026081-01	93.226	—	11,683
Research on Healthcare Costs, Quality and Outcomes	1R03HS024613-01 REVI	93.226	—	137
Research on Healthcare Costs, Quality and Outcomes	1R03HS024809-01 REVI	93.226	—	15,120
Research on Healthcare Costs, Quality and Outcomes	1R13HS025102-01	93.226	2,062	4,989
Research on Healthcare Costs, Quality and Outcomes	1R13HS025670-01	93.226	25,694	35,356
Research on Healthcare Costs, Quality and Outcomes	1R36HS024845-01 REVI	93.226	—	11,058
Research on Healthcare Costs, Quality and Outcomes	5R00HS022431-05	93.226	—	137,686
Research on Healthcare Costs, Quality and Outcomes	5R01HS024530-03	93.226	—	224,408
Research on Healthcare Costs, Quality and Outcomes	5R01HS024712-02	93.226	—	454,457
Research on Healthcare Costs, Quality and Outcomes	5R03 HS025018-02	93.226	—	51,279
Research on Healthcare Costs, Quality and Outcomes	5R18HS024499-03	93.226	353,515	483,682
Pass-through Cincinnati Childrens Hospital	136514/ AMND 2	93.226	27,462	86,578
Pass-through Vanderbilt University Medical Center	VUMC57339	93.226	—	14,282
Total CFDA No. 93.226				1,530,715
Mental Health Research Grants	1F31MH114624-01A1	93.242	—	3,501
Mental Health Research Grants	1R01MH112788-01A1	93.242	—	82,888
Mental Health Research Grants	1R01MH115174-01	93.242	—	4,286
Mental Health Research Grants	1R01MH117103-01	93.242	—	12,527
Mental Health Research Grants	1R21MH106716-01	93.242	—	511
Mental Health Research Grants	1U01MH116441-01	93.242	—	6,732
Mental Health Research Grants	2P50MH100023-06 REVI	93.242	—	570,038
Mental Health Research Grants	4R01MH095503-05	93.242	—	56,894
Mental Health Research Grants	5R01MH092284-05	93.242	—	11,793
Mental Health Research Grants	5R01MH100318-04 REVI	93.242	—	436,473
Mental Health Research Grants	5R01MH102690-04	93.242	29,061	142,086
Mental Health Research Grants	5R01MH108826-03	93.242	243,652	902,623
Mental Health Research Grants	5R21MH114151-02	93.242	—	138,351
Mental Health Research Grants	1F30MH117873-01	93.242	—	6,619
Mental Health Research Grants	1F32MH115692-01A1 RE	93.242	—	19,686
Mental Health Research Grants	1K23MH114037-01A1	93.242	—	24,386
Mental Health Research Grants	1R01MH112076-02	93.242	—	577,951
Mental Health Research Grants	1R01MH116695-01	93.242	—	276,105
Mental Health Research Grants	1R21MH118092-01	93.242	—	7,423
Mental Health Research Grants	2R56MH071537-11A1	93.242	—	41,811
Mental Health Research Grants	4K01MH095823-05	93.242	—	59,831
Mental Health Research Grants	4P50MH100029-05REVIS	93.242	(1,678)	35,510
Mental Health Research Grants	4R01MH079448-07 REVI	93.242	—	155,946
Mental Health Research Grants	4R01MH094757-05	93.242	—	16,877
Mental Health Research Grants	4R01MH096983-05	93.242	—	81,571
Mental Health Research Grants	4R01MH101477-05	93.242	—	334,638
Mental Health Research Grants	4U01MH101720-04REVIS	93.242	27,907	510,271
Mental Health Research Grants	5F30MH108276-03	93.242	—	68,627
Mental Health Research Grants	5F31MH105237-03	93.242	—	5,981
Mental Health Research Grants	5F31MH106298-03	93.242	—	12,011
Mental Health Research Grants	5F31MH109208-03	93.242	—	44,257
Mental Health Research Grants	5F31MH111224-02 REVI	93.242	—	46,811
Mental Health Research Grants	5F32MH101976-03	93.242	—	61,499
Mental Health Research Grants	5K01MH107320-03	93.242	—	154,378
Mental Health Research Grants	5K01MH108741-03	93.242	29,843	148,139
Mental Health Research Grants	5K23MH095679-05	93.242	—	131,303
Mental Health Research Grants	5K23MH101380-04	93.242	—	123,254
Mental Health Research Grants	5P50MH100023-03S1	93.242	—	12,341
Mental Health Research Grants	5P50MH100023-05	93.242	252,649	1,276,802
Mental Health Research Grants	5P50MH100029-04REVIS	93.242	1,678	1,678
Mental Health Research Grants	5P50MH100029-07	93.242	135,378	1,565,473
Mental Health Research Grants	5R00MH102355-05 REVI	93.242	—	222,625
Mental Health Research Grants	5R01MH069852-13 REVI	93.242	—	427,646
Mental Health Research Grants	5R01MH072908-13 REVI	93.242	13,854	346,468
Mental Health Research Grants	5R01MH073719-09	93.242	—	753,211
Mental Health Research Grants	5R01MH082833-06 REVI	93.242	131,592	326,482
Mental Health Research Grants	5R01MH099021-04/REVI	93.242	90,390	178,954
Mental Health Research Grants	5R01MH099211-05 REVI	93.242	22,266	301,741
Mental Health Research Grants	5R01MH100122-05 REVI	93.242	—	171,765
Mental Health Research Grants	5R01MH100390-05	93.242	289,276	392,780
Mental Health Research Grants	5R01MH100467-05 REVI	93.242	25,292	710,853
Mental Health Research Grants	5R01MH100917-04REVIS	93.242	—	43
Mental Health Research Grants	5R01MH100999-05 REVI	93.242	—	409,180
Mental Health Research Grants	5R01MH104534-04 REVI	93.242	44,066	610,421
Mental Health Research Grants	5R01MH104632-03 REVI	93.242	—	257,841
Mental Health Research Grants	5R01MH105561-04	93.242	99,420	365,425
Mental Health Research Grants	5R01MH107033-03 REVI	93.242	—	682,829
Mental Health Research Grants	5R01MH107305-04 REV	93.242	—	454,503
Mental Health Research Grants	5R01MH108605-03	93.242	—	594,692
Mental Health Research Grants	5R01MH109026-03	93.242	120,729	562,165
Mental Health Research Grants	5R01MH109637-03	93.242	—	624,828
Mental Health Research Grants	5R01MH110364-03 REVI	93.242	29,310	559,803
Mental Health Research Grants	5R01MH110701-02 REVI	93.242	15,761	811,027

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	5R01MH111416-03	93.242	\$ 4,545	289,614
Mental Health Research Grants	5R01MH111682-03	93.242	71,743	822,257
Mental Health Research Grants	5R01MH114692-02	93.242	49,295	381,535
Mental Health Research Grants	5R01MH115831-02	93.242	—	382,211
Mental Health Research Grants	5R21MH102677-02S1	93.242	—	348
Mental Health Research Grants	5R21MH105811-02 REVI	93.242	—	146,198
Mental Health Research Grants	5R21MH105897-02Revis	93.242	—	1,751
Mental Health Research Grants	5R21MH106902-02	93.242	—	71,193
Mental Health Research Grants	5R21MH106904-02	93.242	—	82,141
Mental Health Research Grants	5R21MH108025-02	93.242	—	195,163
Mental Health Research Grants	5R21MH108873-02 REVI	93.242	125,324	149,975
Mental Health Research Grants	5R21MH108928-03 REVI	93.242	—	208,097
Mental Health Research Grants	5R21MH112449-02 REVI	93.242	21,392	150,306
Mental Health Research Grants	5R25MH101079-05	93.242	—	153,252
Mental Health Research Grants	5R34MH106368-03 REVI	93.242	46,202	124,902
Mental Health Research Grants	5R56MH111459-02	93.242	—	410,562
Mental Health Research Grants	5U01MH081988-10	93.242	—	483,012
Mental Health Research Grants	5U01MH101720-03	93.242	—	(277,031)
Mental Health Research Grants	GENFD0001334438	93.242	—	100,630
Pass-through Boston Children'S Hospital	4,500,002.127	93.242	—	36,982
Pass-through Boston University	4,500,002.461	93.242	—	31,162
Pass-through Butler Hospital	9225-5345	93.242	—	35,592
Pass-through Case Western Reserve University	RE5509294	93.242	—	56,410
Pass-through Case Western Reserve University	RE5509490 AM 3	93.242	—	59,499
Pass-through Columbia University	1(GG009422)Amend 3	93.242	—	39,453
Pass-through Columbia University	1(GG012007-01)	93.242	—	19,782
Pass-through Columbia University	4(GG010260)	93.242	—	(8,392)
Pass-through Dartmouth College	R882/AMND 4	93.242	—	(23,205)
Pass-through Duke University	2,035,613	93.242	—	187,275
Pass-through Duke University	2,036,605	93.242	—	66,783
Pass-through Florida State University	R01842	93.242	—	(3,785)
Pass-through Florida State University	R01913	93.242	—	111,477
Pass-through Georgia Institute of Technology	RF655-G1	93.242	—	194,967
Pass-through Georgia State University	SP00011261-02 Am 3	93.242	—	(249)
Pass-through Georgia State University	SP000112851-01	93.242	—	8,976
Pass-through Georgia State University	SP00012441-01	93.242	—	307,135
Pass-through Georgia State University	SP00012851-01	93.242	—	1,056
Pass-through Georgia State University	SP00012851-02	93.242	—	13,556
Pass-through Johns Hopkins University	2,003,557.366	93.242	—	261,262
Pass-through New York University	F8752-02	93.242	—	41,943
Pass-through Public Health Foundation Enterprises	349	93.242	—	211,928
Pass-through State University of New York	1129280-72487	93.242	—	147,719
Pass-through University of Alabama Birmingham	000506211-004	93.242	—	50,477
Pass-through University of California Irvine	2015-3229	93.242	—	17,859
Pass-through University of California Los Angeles	2000 G R J488/AMND 5	93.242	248,911	302,052
Pass-through University of Cape Town	IRMA 28372	93.242	—	60,406
Pass-through University of Iowa	1001469951/AMND 03	93.242	—	60,125
Pass-through University of North Carolina	5,106,111	93.242	—	194,524
Pass-through University of North Carolina	5,106,128	93.242	—	228,672
Pass-through University of Pittsburgh	0032045 (126571-1)	93.242	—	1,408
Pass-through University of Pittsburgh	0052687(129409-2)	93.242	—	64,768
Pass-through University of South Carolina	17-3193	93.242	—	149,929
Pass-through University of South Florida	6144-1113-00-A	93.242	—	24,421
Total CFDA No. 93.242			<u>2,167,858</u>	<u>24,763,247</u>
Public Health Training Centers Grant Program	4 UB6HP27875--04--03	93.249	318,334	961,070
Total CFDA No. 93.249			<u>318,334</u>	<u>961,070</u>
Occupational Safety and Health Program	5R01OH010657-03	93.262	—	429,667
Occupational Safety and Health Program	5R01OH010745-03	93.262	206,050	542,105
Occupational Safety and Health Program	6T03OH008609-12-03	93.262	—	70,427
Pass-through University of Florida	UFDSP00012028	93.262	—	124,056
Total CFDA No. 93.262			<u>206,050</u>	<u>1,166,255</u>
Rapid Expansion of Antiretroviral Therapy Programs for HIV-Infected Persons in Selected Countries in Africa and the Caribbean Under the President's Emergency Plan for AIDS Relief Pass-through Columbia University	5U92HA12772-08-02	93.266	446,876	477,223
Total CFDA No. 93.266			<u>446,876</u>	<u>477,223</u>
Complex Humanitarian Emergency and War-Related Injury Public Health Activities	5NT01GH001185-05-00	93.269	—	93,341
Total CFDA No. 93.269			<u>—</u>	<u>93,341</u>
Alcohol Research Programs	4K08AA021404-05	93.273	—	3,567
Alcohol Research Programs	5U01AA026108-02	93.273	78,049	253,935
Alcohol Research Programs	7K01AA021113-06	93.273	—	47,231
Alcohol Research Programs	1R21AA025723-01A1	93.273	—	23,375
Alcohol Research Programs	4K05AA021143-05	93.273	—	60,089
Alcohol Research Programs	5F31AA024960-03 REVI	93.273	—	61,945
Alcohol Research Programs	5K08AA024512-02	93.273	—	170,744
Alcohol Research Programs	5R00AA021803-05 REVI	93.273	—	259,622
Alcohol Research Programs	5R01AA022601-07	93.273	26,196	360,782
Alcohol Research Programs	5R01AA023826-03 REVI	93.273	—	279,865
Alcohol Research Programs	5R01AA025854-02 REVI	93.273	—	367,182
Alcohol Research Programs	5R01AA025857-03	93.273	—	466,383
Alcohol Research Programs	5R01AA025882-02	93.273	18,729	136,952
Alcohol Research Programs	7R01AA020695-06	93.273	20,965	80,873



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Alcohol Research Programs	7R01AA021390-05 REVI	93.273	\$ —	214,465
Pass-through University of California San Diego	79,573,871	93.273	—	165
Pass-through University of California San Diego	92539292 / S9001718	93.273	—	49,873
Pass-through University of California San Diego	PO# S9000068/AMND#4	93.273	—	(6,637)
Pass-through Wayne State University	WSU17049	93.273	—	1,012
Pass-through Wayne State University	WSU18037	93.273	—	29,671
Total CFDA No. 93.273			143,939	2,861,094
Drug Abuse National Research Service Awards for Research Training	1T32DA015040-01A1	93.278	—	12,908
Total CFDA No. 93.278			—	12,908
Drug Abuse and Addiction Research Programs	5R03CA183016-02	93.279	—	2,372
Drug Abuse and Addiction Research Programs	5K24AI114444-05	93.279	—	197,132
Drug Abuse and Addiction Research Programs	1DP1DA042103-02	93.279	57,908	232,331
Drug Abuse and Addiction Research Programs	1R01DA044297-01A1	93.279	—	113,935
Drug Abuse and Addiction Research Programs	3R01DA038453-04S1	93.279	102,254	284,735
Drug Abuse and Addiction Research Programs	5R01DA035101-05 REVI	93.279	152,335	467,961
Drug Abuse and Addiction Research Programs	1F31DA044726-01A1 RE	93.279	—	23,255
Drug Abuse and Addiction Research Programs	1K99DA039991-01A1	93.279	—	49,962
Drug Abuse and Addiction Research Programs	1R01DA042742-01A1	93.279	—	3,929
Drug Abuse and Addiction Research Programs	1R01DA046197-01	93.279	—	44,301
Drug Abuse and Addiction Research Programs	3R01DA045612-02S1	93.279	85,327	563,746
Drug Abuse and Addiction Research Programs	3R09DA033462-05S1	93.279	—	36,110
Drug Abuse and Addiction Research Programs	5F31DA036316-03	93.279	—	6,059
Drug Abuse and Addiction Research Programs	5R01DA030996-05 REV	93.279	—	(60)
Drug Abuse and Addiction Research Programs	5R01DA037568-05 REVI	93.279	436,242	816,063
Drug Abuse and Addiction Research Programs	5R01DA038196-05	93.279	22,841	699,682
Drug Abuse and Addiction Research Programs	5R01DA038588-04	93.279	—	770,688
Drug Abuse and Addiction Research Programs	5R03DA042358-02	93.279	—	86,275
Drug Abuse and Addiction Research Programs	5R21DA040788-02	93.279	—	134,719
Drug Abuse and Addiction Research Programs	5R21DA042727-02 REVI	93.279	55,553	135,964
Drug Abuse and Addiction Research Programs	5R37DA010344-19	93.279	—	111
Drug Abuse and Addiction Research Programs	5U01DA036233-05 REVI	93.279	93,491	569,698
Pass-through Boston Medical Center	356301	93.279	—	354,361
Pass-through Case Western Reserve University	RESS11460/AMND 2	93.279	—	300,021
Pass-through Case Western Reserve University	RESS11882/AMND 3	93.279	—	190,167
Pass-through Columbia University	1(GG008261-01)	93.279	—	84,860
Pass-through Mount Sinai School of Medicine	0255-0671-4609	93.279	—	20,117
Pass-through Northwestern University	60044002 EU/AMND A02	93.279	—	6,699
Pass-through Northwestern University	60044679 EU	93.279	—	44,838
Pass-through University of Georgia	RR376-428/4945356	93.279	—	28,594
Pass-through University of Kentucky	3200001483-18-065	93.279	—	75,007
Pass-through University of Miami	SPC-000455	93.279	—	253,165
Pass-through University of Michigan	3003998630	93.279	—	12,226
Total CFDA No. 93.279			1,005,951	6,609,013
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	5U01DP005119-05-00	93.283	—	975,786
Pass-through Atlanta Research and Education Fdn	40500-036-17130867	93.283	—	82,422
Pass-through Atlanta Research and Education Fdn	40500-036-18182551	93.283	—	899,892
Pass-through Georgia Dept of Public Health	40500-036-16161891	93.283	—	32,300
Pass-through Georgia Dept of Public Health	40500-051-19161799	93.283	—	658,644
Pass-through Georgia State University	SP00012872-01	93.283	119,524	238,346
Total CFDA No. 93.283			119,524	2,887,390
Discovery and Applied Research for Technological Innovations to Improve Human Health	1R13EB024389-01	93.286	—	10,000
Discovery and Applied Research for Technological Innovations to Improve Human Health	3R21EB025646-01S1	93.286	—	44,213
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB004987-09 REVI	93.286	10,295	166,101
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB020008-04	93.286	89,782	564,619
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB022872-03	93.286	—	489,503
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB016662-02	93.286	17,051	17,051
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB016662-02	93.286	—	(185)
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB019068-02	93.286	—	1,023
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB022828-02	93.286	—	224,291
Discovery and Applied Research for Technological Innovations to Improve Human Health	7R21EB013387-03REVIS	93.286	—	(16,186)
Discovery and Applied Research for Technological Innovations to Improve Human Health	1R13EB026317-01	93.286	—	10,000
Pass-through Georgia Institute of Technology	RB224-G1	93.286	—	(5,215)
Pass-through Georgia Institute of Technology	RB224-S4	93.286	—	6,050
Pass-through Georgia Institute of Technology	RF773-G1	93.286	—	237,963
Pass-through Georgia Institute of Technology	RF990-G1/AMEND1	93.286	—	9,103
Pass-through Georgia Institute of Technology	RG538-G1	93.286	—	32,344
Pass-through Georgia Institute of Technology	RH376-G1/AMND 1	93.286	—	46,402
Pass-through University of California San Francisco	8354sc	93.286	—	127,195
Total CFDA No. 93.286			117,128	1,964,272
Minority Health and Health Disparities Research	1R21MD011590-1A1 REV	93.307	—	27,670
Minority Health and Health Disparities Research	3U01MD010611-03 REVI	93.307	63,298	555,299
Minority Health and Health Disparities Research	5R01MD009064-05 REVI	93.307	—	388,191
Minority Health and Health Disparities Research	5R01MD009746-04 REVI	93.307	—	766,998
Minority Health and Health Disparities Research	5R01MD010241-05	93.307	65,035	389,818
Minority Health and Health Disparities Research	5R01MD010290-04 REVI	93.307	42,111	613,112
Minority Health and Health Disparities Research	5R01MD010455-03 REVI	93.307	—	411,498
Minority Health and Health Disparities Research	5R01MD011682-02 REVI	93.307	51,153	291,503
Minority Health and Health Disparities Research	5R24MD008077-03REVIS	93.307	—	1,109
Minority Health and Health Disparities Research	5R01MD008966-05 REVI	93.307	—	411,064
Pass-through Nova Southeastern University	331500-03 AMD4	93.307	—	193,164
Pass-through Stanford University	61625473-107723	93.307	—	18,145

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through University of Pennsylvania	PO#3830984	93.307	\$ —	628,206
Pass-through University of Southern California	91,779,029	93.307	—	136,412
Pass-through University of Texas Houston	0008663BK	93.307	—	1,197
Pass-through Wake Forest University	WFUHS 551279	93.307	—	23,902
Total CFDA No. 93.307			<u>221,597</u>	<u>4,857,288</u>
Trans-NIH Research Support	5R21CA185932-02	93.310	—	14,277
Trans-NIH Research Support	1DP2AI112242-01 REVI	93.310	—	(367)
Trans-NIH Research Support	5DP5OD019892-05	93.310	—	287,653
Trans-NIH Research Support	5U24DK112341-02 REVI	93.310	13,012	174,802
Trans-NIH Research Support	1U2CES026560-01	93.310	106,874	1,783,801
Trans-NIH Research Support	5R21GM122632-02	93.310	—	318,603
Trans-NIH Research Support	5U01GM116254-03	93.310	109,103	371,639
Trans-NIH Research Support	5DP7OD018424-05	93.310	7,880	400,884
Trans-NIH Research Support	5R01CA163256-05REVIS	93.310	40,165	139,643
Trans-NIH Research Support	1K01OD023034-01	93.310	4,533	98,323
Trans-NIH Research Support	4UH3OD023318-03	93.310	—	1,223,219
Trans-NIH Research Support	5K01OD023039-03	93.310	—	328,958
Pass-through Broad Institute	5230123-5500000603	93.310	—	(1,468)
Pass-through Duke University	203-5654	93.310	—	(7,910)
Pass-through Pennsylvania State University	5114-EU-NIBIB-9785	93.310	—	17
Pass-through Research Foundation for Mental Hygiene	1,013,336	93.310	—	23,506
Pass-through State University of New York Buffalo	R1115612- Amnd 1	93.310	—	37,974
Pass-through University of Miami	SPC-000540	93.310	—	868,879
Pass-through University of Michigan	3,003,774,756	93.310	—	42,962
Pass-through University of North Carolina	5,108,607	93.310	—	17,364
Pass-through University of Utah	10046136-01	93.310	—	53,511
Pass-through Women & Infants Hospital of Rhode Island	9,519	93.310	—	38,559
Pass-through Women & Infants Hospital of Rhode Island	9,525	93.310	—	159,325
Total CFDA No. 93.310			<u>281,567</u>	<u>6,374,154</u>
Rare Disorders: Research, Surveillance, Health Promotion, and Education: Pass-through Research Foundation for Mental Hygiene	PO#127027	93.315	—	17,693
Total CFDA No. 93.315			<u>—</u>	<u>17,693</u>
Research, Monitoring and Outcomes Definitions for Vaccine Safety	6 VSRNV000003-01-01	93.344	—	112,393
Total CFDA No. 93.344			<u>—</u>	<u>112,393</u>
National Center for Advancing Translational Sciences	5UL1TR000454-10	93.350	(490)	(490)
National Center for Advancing Translational Sciences	3UL1TR002378-02S1	93.350	2,471,118	7,708,406
National Center for Advancing Translational Sciences	4KL2TR000455-10 REVI	93.350	34,544	353,953
National Center for Advancing Translational Sciences	4TL1TR000456-10REVIS	93.350	59,448	130,074
National Center for Advancing Translational Sciences	4UL1TR000454-10REVIS	93.350	589,097	1,068,559
National Center for Advancing Translational Sciences	5KL2TR002381-02	93.350	72,738	1,222,032
National Center for Advancing Translational Sciences	5TL1TR002382-02	93.350	—	492,464
National Center for Advancing Translational Sciences	5U54TR001456-08 REVI	93.350	24,514	312,308
National Center for Advancing Translational Sciences	1R21TR001751-01	93.350	—	196,124
Pass-through Lena Biosciences, Inc.	1R43TR001286-01A1	93.350	—	40,065
Pass-through University of Pittsburgh	0055353 (129324-8)	93.350	17,622	35,741
Total CFDA No. 93.350			<u>3,268,591</u>	<u>11,559,238</u>
Research Infrastructure Programs	3P51OD011132-58S1	93.351	—	10,688,577
Research Infrastructure Programs	4R24OD010445-04	93.351	—	341,720
Research Infrastructure Programs	4U24OD011023-14 REVI	93.351	—	947,038
Research Infrastructure Programs	5R21OD020182-02	93.351	3,424	49,548
Research Infrastructure Programs	5R24OD010930-13	93.351	—	1,342,304
Research Infrastructure Programs	5R24OD020174-03 REVI	93.351	362,965	711,049
Research Infrastructure Programs	5R24OD020349-03	93.351	76,925	550,503
Research Infrastructure Programs	5U24OD011023-13	93.351	—	(306)
Research Infrastructure Programs	8R25GM129213-03	93.351	—	168,585
Research Infrastructure Programs	1S10OD021773-01A1	93.351	—	217,877
Research Infrastructure Programs	2U42OD011023-15A1 RE	93.351	—	543,619
Pass-through University of Nebraska	34-5150-2058-001	93.351	—	66,061
Total CFDA No. 93.351			<u>443,314</u>	<u>15,626,575</u>
Construction Support	1C06OD018248-01Revis	93.352	—	888,980
Total CFDA No. 93.352			<u>—</u>	<u>888,980</u>
Nurse Education, Practice and Retention Grants	1 UK1HP31697--01--00	93.359	—	39,748
Total CFDA No. 93.359			<u>—</u>	<u>39,748</u>
Nursing Research	1F31NR017348-01A1 RE	93.361	—	16,534
Nursing Research	5R00NR014587-05	93.361	—	160,248
Nursing Research	5R00NR014675-06 REVI	93.361	—	237,140
Nursing Research	1F31NR015722-02 REVI	93.361	—	44,032
Nursing Research	1F31NR015975-03	93.361	—	46,086
Nursing Research	1F31NR017580-01REVIS	93.361	—	17,496
Nursing Research	1K01NR016984-02	93.361	—	87,325
Nursing Research	1K01NR017664-01	93.361	—	22,961
Nursing Research	1R01NR017018-02 REVI	93.361	359,468	783,802
Nursing Research	3P30NR014134-04S1	93.361	—	(316)
Nursing Research	4P30NR014134-05	93.361	—	91,201
Nursing Research	4R01NR014054-05	93.361	—	63,230
Nursing Research	4R01NR014800-05	93.361	—	329,470
Nursing Research	4T32NR012715-05	93.361	—	92,587

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Nursing Research	5F31NR015180-02REVIS	93.361	\$ —	(9,631)
Nursing Research	5F31NR015400-02 REVI	93.361	—	8,083
Nursing Research	5K01NR015733-03	93.361	—	92,238
Nursing Research	5K01NR016971-02	93.361	—	77,622
Nursing Research	5R01NR012923	93.361	—	24,562
Nursing Research	5R01NR013700-05 REVI	93.361	155,103	423,187
Nursing Research	5R01NR014973-04 Revi	93.361	—	891,700
Nursing Research	5R01NR015783-03REVIS	93.361	—	435,306
Nursing Research	5R21NR014544-02	93.361	27,228	27,228
Nursing Research	5R21NR014544-02	93.361	—	(1,647)
Pass-through Northwestern University	60044948 EU	93.361	—	31,233
Pass-through University of Alabama	UA15-058	93.361	—	27,760
Pass-through Virginia Commonwealth University	FP00001797_SA001	93.361	—	62,976
Pass-through Yale University	M15A11961 (CON-80000	93.361	—	45,516
Total CFDA No. 93.361			<u>541,799</u>	<u>4,127,929</u>
Cancer Cause and Prevention Research	1R01CA215155-01A1	93.393	56,007	329,596
Cancer Cause and Prevention Research	1U01CA220401-01A1	93.393	—	14,910
Cancer Cause and Prevention Research	4R01CA077337-15	93.393	—	22,196
Cancer Cause and Prevention Research	5R01CA095318-14	93.393	—	389,159
Cancer Cause and Prevention Research	5R01CA166825-05 REVI	93.393	14,404	401,448
Cancer Cause and Prevention Research	5R01CA178999-05	93.393	—	182,823
Cancer Cause and Prevention Research	5R01CA179424-04	93.393	—	392,270
Cancer Cause and Prevention Research	5R01CA207467-02	93.393	—	213,547
Cancer Cause and Prevention Research	5R01CA208758-02	93.393	—	226,460
Cancer Cause and Prevention Research	5R21CA182752-02	93.393	—	8,991
Cancer Cause and Prevention Research	5U01CA217875-02	93.393	—	804,005
Cancer Cause and Prevention Research	1R01CA218389-01A1 RE	93.393	—	101,739
Cancer Cause and Prevention Research	3R01CA178999-03S1	93.393	—	(624)
Cancer Cause and Prevention Research	5U01CA154282-05	93.393	4,830	4,830
Pass-through Boston University	4500001596/AMND003	93.393	—	48,072
Pass-through Dartmouth College	R755	93.393	—	109,155
Pass-through Harvard University	114952-5060413/AMND	93.393	—	11,214
Pass-through Mayo Clinic	EMO-202539-05	93.393	—	330,616
Pass-through Ohio State University	60,054,257	93.393	—	105,633
Pass-through State University of New York Stony Brook	81033/1145926/2	93.393	—	14,271
Pass-through University of California San Francisco	9373SC	93.393	—	3,333
Pass-through University of Michigan	3,004,134,624	93.393	—	6,098
Pass-through University of Michigan	3,004,170,880	93.393	—	187,064
Pass-through University of Texas Health Sciences Ctr	0011696A Am 6	93.393	—	2,816
Pass-through Wake Forest University	WFUHS 553087/AMEND #	93.393	—	4,251
Total CFDA No. 93.393			<u>75,241</u>	<u>3,913,873</u>
Cancer Detection and Diagnosis Research	4R01CA156775-06 REVI	93.394	—	140,515
Cancer Detection and Diagnosis Research	4R01CA169188-05	93.394	—	86,476
Cancer Detection and Diagnosis Research	4U01CA168449-05	93.394	—	76,226
Cancer Detection and Diagnosis Research	5R01CA154846-05 REV	93.394	—	114,341
Cancer Detection and Diagnosis Research	5R01CA169937-05 REVI	93.394	—	335,441
Cancer Detection and Diagnosis Research	5R01CA176659-05	93.394	97,803	113,972
Cancer Detection and Diagnosis Research	5R01CA202846-03 REVI	93.394	58,685	426,723
Cancer Detection and Diagnosis Research	5R01CA204254-02 REVI	93.394	81,876	242,051
Cancer Detection and Diagnosis Research	5R21CA176684-02	93.394	—	(1,355)
Cancer Detection and Diagnosis Research	5R21CA182661-02 REVI	93.394	—	10,854
Cancer Detection and Diagnosis Research	5R21CA206508-02 REVI	93.394	—	130,371
Cancer Detection and Diagnosis Research	5U01CA113913-13	93.394	138,833	840,693
Cancer Detection and Diagnosis Research	5U01CA172027-05	93.394	214,092	647,006
Cancer Detection and Diagnosis Research	5U01CA198913-04	93.394	38,872	604,926
Cancer Detection and Diagnosis Research	5U01CA207821-03	93.394	130,384	667,079
Cancer Detection and Diagnosis Research	5U24CA194362-04	93.394	238,004	709,515
Cancer Detection and Diagnosis Research	5R01CA203388-02	93.394	—	250,742
Cancer Detection and Diagnosis Research	5U01CA168449-04	93.394	—	134
Pass-through Beth Israel Deaconess Medical Center	1,028,380	93.394	—	110,899
Pass-through Beth Israel Deaconess Medical Center	01029053-Amend 1	93.394	—	(4,857)
Pass-through Dartmouth College	R890 R219 R891	93.394	—	226,605
Pass-through Ocean Nanotech	1R43CA233382-01	93.394	—	10,206
Pass-through Radboud University	R01CA181171	93.394	—	70,397
Pass-through State University of New York Stony Brook	79284/1142253/2	93.394	—	82,689
Pass-through University of Arkansas for Medical Services	51175, PO #G18012067	93.394	—	242,785
Pass-through University of Arkansas for Medical Services	51599, PO# G18012072	93.394	—	367,848
Pass-through University of California Los Angeles	1900 G TA672/AMND 3	93.394	—	44,727
Pass-through Washington University	WU-15-76 PO#2922479Y	93.394	—	(179)
Total CFDA No. 93.394			<u>998,549</u>	<u>6,546,830</u>
Cancer Treatment Research	1R01CA203928-01A1	93.395	—	303,973
Cancer Treatment Research	1R21CA223300-01A1	93.395	—	23,875
Cancer Treatment Research	3R01CA202763-03S1	93.395	145,712	520,144
Cancer Treatment Research	4R01CA157754-05 REVI	93.395	—	124,120
Cancer Treatment Research	4R01CA160522-05	93.395	—	4,527
Cancer Treatment Research	5 R01 CA176001-05REV	93.395	—	356,896
Cancer Treatment Research	5R01CA118450-10	93.395	—	702
Cancer Treatment Research	5R01CA136534-08	93.395	—	395,128
Cancer Treatment Research	5R01CA180805-03	93.395	—	(283)
Cancer Treatment Research	5R01CA186129-05	93.395	—	452,031
Cancer Treatment Research	5R01CA186918-04	93.395	—	311,936
Cancer Treatment Research	5R01CA188523-05 REVI	93.395	—	499,793
Cancer Treatment Research	5R01CA193828-04	93.395	—	395,624

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cancer Treatment Research	5R01CA194027-03 REVI	93.395	\$ —	531,669
Cancer Treatment Research	5R01CA207768-02	93.395	—	349,671
Cancer Treatment Research	5R01CA208328-02	93.395	43,715	368,109
Cancer Treatment Research	5R01CA214557-05	93.395	102,132	309,651
Cancer Treatment Research	5R21CA185882-02REVIS	93.395	—	14,629
Cancer Treatment Research	5U10CA180864-05	93.395	—	548,211
Cancer Treatment Research	5U10CA180950-05 REVI	93.395	550,554	663,034
Cancer Treatment Research	7R01CA172385-05	93.395	—	337,281
Cancer Treatment Research	7R01CA208253-02	93.395	44,601	210,787
Cancer Treatment Research	1R01CA215718-01A1	93.395	—	211,006
Cancer Treatment Research	1R01CA223220-01A1	93.395	—	39,729
Cancer Treatment Research	1R01CA228414-01	93.395	—	23,437
Cancer Treatment Research	5R01CA154129-05	93.395	—	(409)
Cancer Treatment Research	5R01CA200905-02 REV	93.395	—	459,868
Pass-through Childrens Healthcare of Atlanta	657004-0219-01	93.395	—	8,667
Pass-through Childrens Healthcare of Atlanta	U01CA180886/AMEND #4	93.395	—	94,005
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820-01-EMRY1	93.395	—	22,257
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820-04-EMRY2	93.395	—	27,426
Pass-through Georgia Institute of Technology	RG983-G1	93.395	—	126,924
Pass-through Georgia State University	SP00011812-01 AMND 3	93.395	—	205,152
Pass-through Johns Hopkins University	SUM1CA186691-04 REVI	93.395	—	31,635
Pass-through Medical College of Wisconsin	R01CA181171	93.395	—	19,259
Pass-through Medical College of Wisconsin	PO# 1541088	93.395	—	901
Pass-through Nrg Oncology Foundation, Inc.	009-NRG-16	93.395	—	33,141
Pass-through Nrg Oncology Foundation, Inc.	5U10CA180868-05	93.395	—	96,097
Pass-through Nrg Oncology Foundation, Inc.	Emory- Yr.5	93.395	—	52,333
Pass-through Nrg Oncology Foundation, Inc.	Emory/Bruner-NCOR-05	93.395	—	142,802
Pass-through Nrg Oncology Foundation, Inc.	NCORP01-Xiao-1	93.395	—	8,431
Pass-through Nrg Oncology Foundation, Inc.	NCTN05-Yeager	93.395	—	3,306
Pass-through St Jude Childrens Research Hospital	110068200-7815626/AM	93.395	13,302	57,304
Pass-through Stanford University	61251749-118307	93.395	—	169,989
Pass-through University of Alabama Birmingham	000508488-004/A02	93.395	—	869
Pass-through University of Arizona	225,828	93.395	—	32,633
Pass-through University of California Los Angeles	1568 G TA558	93.395	—	316,743
Pass-through University of Colorado Denver	FY18.803.002	93.395	—	7,751
Pass-through University of Florida	UFDSP00011464/AMND 1	93.395	—	58,121
Pass-through University of Minnesota	P005570002	93.395	—	23,998
Pass-through University of North Carolina Chapel Hill	5,104,715	93.395	10,212	13,091
Pass-through University of Rochester	417076G/GR516650	93.395	—	14,551
Pass-through University of Southern California	78,370,131	93.395	—	80,417
Pass-through University of Tennessee Hlth Science Ctr	18-3923 EMRY	93.395	—	36,581
Pass-through University of Utah	PO#0000175471	93.395	—	387,678
Total CFDA No. 93.395			910,228	9,527,201
Cancer Biology Research	3P30CA138292-10S2	93.396	—	2,604,553
Cancer Biology Research	3R01CA163722-05S1REV	93.396	—	289,528
Cancer Biology Research	5R01CA123490-10 REVI	93.396	—	248,734
Cancer Biology Research	5R01CA140515-09	93.396	11,449	326,536
Cancer Biology Research	5R01CA171189-03	93.396	—	(56)
Cancer Biology Research	5R01CA171189-05	93.396	—	158,557
Cancer Biology Research	5R01CA172392-05 REVI	93.396	—	171,437
Cancer Biology Research	5R01CA174786-05 REVI	93.396	—	237,242
Cancer Biology Research	5R01CA175316-05 REVI	93.396	—	282,312
Cancer Biology Research	5R01CA183594-05 REVI	93.396	1,686	316,515
Cancer Biology Research	5R01CA192844-03 REVI	93.396	99,195	381,875
Cancer Biology Research	5R01CA201340-03S1 RE	93.396	55,049	563,036
Cancer Biology Research	5R21CA201744-02 REV	93.396	—	144,050
Cancer Biology Research	5U01CA160882-05	93.396	150,143	162,752
Cancer Biology Research	7R35CA197603-03	93.396	—	40,599
Cancer Biology Research	4R00CA197804-03	93.396	—	67,786
Pass-through University Of Arizona	293,328	93.396	—	47,484
Total CFDA No. 93.396			317,522	6,042,940
Cancer Centers Support Grants	4P30CA138292-08 REVI	93.397	—	229,334
Cancer Centers Support Grants	5P20CA210298-02 REVI	93.397	12,882	140,085
Pass-through Yale University	C17A12610 (CON-80000	93.397	—	98,580
Total CFDA No. 93.397			12,882	467,999
Cancer Research Manpower	1F31CA225049-01A1 RE	93.398	—	20,948
Cancer Research Manpower	1F31CA225124-01A1	93.398	—	4,694
Cancer Research Manpower	1F31CA232531-01	93.398	—	3,684
Cancer Research Manpower	1K01CA226346-01	93.398	—	37,577
Cancer Research Manpower	4T32CA160040-04	93.398	—	245,102
Cancer Research Manpower	5F30CA206291-03 REVI	93.398	—	49,761
Cancer Research Manpower	5F30CA216939-02	93.398	—	60,141
Cancer Research Manpower	5F31CA180511-03	93.398	—	5,882
Cancer Research Manpower	5F31CA186511-03	93.398	—	167
Cancer Research Manpower	5F31CA186676-03	93.398	—	11,398
Cancer Research Manpower	5F31CA189672-03REVIS	93.398	—	11,392
Cancer Research Manpower	5F31CA189772-03 REVI	93.398	—	12,775
Cancer Research Manpower	5F31CA196181 REVISED	93.398	—	31,127
Cancer Research Manpower	5F31CA200383-02	93.398	—	5,881
Cancer Research Manpower	5F31CA210601-03	93.398	—	55,431
Cancer Research Manpower	5F31CA221002-02	93.398	—	42,626
Cancer Research Manpower	5F99CA223074-02	93.398	—	41,820

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cancer Research Manpower	5K07CA211956-02	93.398	\$ —	146,305
Cancer Research Manpower	5K08CA194162-04	93.398	—	164,117
Cancer Research Manpower	5K24CA201524-04	93.398	—	140,113
Cancer Research Manpower	5K24CA208132-03	93.398	—	176,604
Cancer Research Manpower	5K25CA181503-05	93.398	—	96,642
Cancer Research Manpower	5K99CA197804-02	93.398	—	68,688
Cancer Research Manpower	7K01CA160798-06	93.398	—	87,051
Cancer Research Manpower	1F31CA225119-01 REVI	93.398	—	28,012
Total CFDA No. 93.398				<u>1,547,938</u>
ACL National Institute on Disability, Independent Living, and Rehabilitation Research: Pass-through Georgia Institute Of Technology	RF543-G1	93.433	—	18,164
Total CFDA No. 93.433				<u>18,164</u>
Strengthening Public Health Infrastructure for Improved Health Outcomes	200-2016-91596	93.507	207,000	361,257
Strengthening Public Health Infrastructure for Improved Health Outcomes	200-2016-91600	93.507	—	698
Total CFDA No. 93.507				<u>207,000</u>
Medical Assistance Program Pass-through Ohio State University	ODM201534	93.778	—	21,123
Total CFDA No. 93.778				<u>21,123</u>
Health Careers Opportunity Program	6 D18HP290340301	93.822	—	693,960
Total CFDA No. 93.822				<u>693,960</u>
Ebola Support: Transmission and Prevention Control, Public Health Preparedness, Vaccine Development	1U54CK000453-01-06	93.823	259,852	701,047
Total CFDA No. 93.823				<u>259,852</u>
National Ebola Training and Education Center	5 U3REP150549-04-00	93.825	2,933,788	3,835,843
Total CFDA No. 93.825				<u>2,933,788</u>
Section 223 Demonstration Programs to Improve Community Mental Health Services	1R56HL131059-01	93.829	5,693	129,511
Total CFDA No. 93.829				<u>5,693</u>
Cardiovascular Diseases Research	1F32HL137401-01-A1RE	93.837	—	36,279
Cardiovascular Diseases Research	1K23HL143164-01	93.837	—	11,458
Cardiovascular Diseases Research	1R01HL130915-03 REVI	93.837	90,174	411,167
Cardiovascular Diseases Research	1R01HL135575-02	93.837	—	374,651
Cardiovascular Diseases Research	1R01HL136345-01A1	93.837	—	126,276
Cardiovascular Diseases Research	1R01HL136915-01A1	93.837	—	205,509
Cardiovascular Diseases Research	1R01HL137338-01A1	93.837	—	51,965
Cardiovascular Diseases Research	1R01HL139757-01A1 REV	93.837	—	39,959
Cardiovascular Diseases Research	1R01HL140223-01A1	93.837	—	30,992
Cardiovascular Diseases Research	1R01HL141335-01	93.837	—	28,013
Cardiovascular Diseases Research	1R01HL143348-01	93.837	—	896
Cardiovascular Diseases Research	1U54HL141981-01	93.837	—	315,854
Cardiovascular Diseases Research	3R01HL125761-04S2	93.837	507,282	747,283
Cardiovascular Diseases Research	4R00HL127295-03	93.837	—	94,174
Cardiovascular Diseases Research	4R01HL109413-04	93.837	—	80,259
Cardiovascular Diseases Research	4U54HL112309-05 REVI	93.837	60,773	1,324,210
Cardiovascular Diseases Research	5F30HL118954-03 REVI	93.837	—	11,132
Cardiovascular Diseases Research	5F30HL122065-04	93.837	—	65,083
Cardiovascular Diseases Research	5F31HL136184-02	93.837	—	36,806
Cardiovascular Diseases Research	5F31HL136194-02	93.837	—	45,100
Cardiovascular Diseases Research	5F31HL137367-02	93.837	—	39,844
Cardiovascular Diseases Research	5F32HL124974-03	93.837	—	37,067
Cardiovascular Diseases Research	5F32HL134290-02	93.837	—	57,331
Cardiovascular Diseases Research	5K08HL119592-05	93.837	—	137,485
Cardiovascular Diseases Research	5K08HL124292-04	93.837	—	140,424
Cardiovascular Diseases Research	5K08HL136873-02	93.837	—	152,822
Cardiovascular Diseases Research	5K22HL126922-02	93.837	—	196,290
Cardiovascular Diseases Research	5K23HL105787-04	93.837	—	78,754
Cardiovascular Diseases Research	5K23HL124287-04	93.837	—	209,066
Cardiovascular Diseases Research	5K23HL127251-02 REVI	93.837	5,214	175,338
Cardiovascular Diseases Research	5K23HL128795-03	93.837	—	185,574
Cardiovascular Diseases Research	5P01HL095070-09	93.837	13,126	1,964,486
Cardiovascular Diseases Research	5R00HL119567-05	93.837	—	224,240
Cardiovascular Diseases Research	5R01HL111646-05	93.837	—	(257)
Cardiovascular Diseases Research	5R01HL113167-05	93.837	—	157,654
Cardiovascular Diseases Research	5R01HL119291-05	93.837	56,245	330,561
Cardiovascular Diseases Research	5R01HL119798-05	93.837	205,005	423,522
Cardiovascular Diseases Research	5R01HL122200-02	93.837	68,729	178,928
Cardiovascular Diseases Research	5R01HL122392-05	93.837	83,954	149,949
Cardiovascular Diseases Research	5R01HL125442-04	93.837	319,544	622,835
Cardiovascular Diseases Research	5R01HL127236-03 REVIS	93.837	42,945	422,620
Cardiovascular Diseases Research	5R01HL127726-03 REVI	93.837	—	415,764
Cardiovascular Diseases Research	5R01HL127759-04	93.837	16,224	371,178
Cardiovascular Diseases Research	5R01HL129511-03	93.837	—	422,069
Cardiovascular Diseases Research	5R01HL130471-03 REVI	93.837	35,200	983,310
Cardiovascular Diseases Research	5R01HL133667-02	93.837	—	339,629
Cardiovascular Diseases Research	5R01HL135145-02	93.837	—	160,112
Cardiovascular Diseases Research	5R01HL136205-02 REVI	93.837	34,082	901,314
Cardiovascular Diseases Research	5R25HL131507-03	93.837	—	144,960
Cardiovascular Diseases Research	5R34HL122557-03	93.837	60,059	196,358
Cardiovascular Diseases Research	5T15HL098122-05	93.837	—	7,850
Cardiovascular Diseases Research	5T32HL007745-25	93.837	—	453,863

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	5T32HL130025-02 REVI	93.837	\$ —	485,192
Cardiovascular Diseases Research	5U01HL105561-07REVIS	93.837	331,178	461,762
Cardiovascular Diseases Research	5U01HL128566-04	93.837	324,882	987,012
Cardiovascular Diseases Research	5U10HL110302-07REVIS	93.837	—	370,058
Cardiovascular Diseases Research	5UG1HL135682-02 REVI	93.837	177,165	297,123
Cardiovascular Diseases Research	7R01HL117759-06	93.837	—	224,479
Cardiovascular Diseases Research	2T32HL00774511	93.837	—	(20,486)
Cardiovascular Diseases Research	5P20HL113451-04	93.837	—	63
Cardiovascular Diseases Research	5R01HL125246-04	93.837	10,589	967,860
Cardiovascular Diseases Research	5T32HL007745-20	93.837	—	(76,625)
Cardiovascular Diseases Research	5U10HL109781-05	93.837	33,695	36,572
Cardiovascular Diseases Research	R01HL135182-02 REVIS	93.837	—	309,065
Pass-through Duke University	WBSE2035543/SPS21934	93.837	—	15,635
Pass-through Henry M Jackson Foundation	4127/PO 926290	93.837	—	269
Pass-through Medical College of Wisconsin	5R01HL119747	93.837	—	2,293
Pass-through Medical University of South Carolina	MUSC14-066 Am 2	93.837	3,276	3,987
Pass-through Michigan Technological University	170206321- P0100917	93.837	—	607
Pass-through Morehouse School of Medicine	003-Emory-350086-05	93.837	—	258,167
Pass-through Mount Sinai School of Medicine	0255-1523-4609	93.837	—	19,315
Pass-through Ohio State University	60,059,645	93.837	—	31,589
Pass-through St Jude Childrens Research Hospital	112141020-7770157/AM	93.837	35,695	71,641
Pass-through University of California Davis	201401440-01	93.837	—	199,926
Pass-through University of California San Francisco	8043SC	93.837	—	43,615
Pass-through University of California San Francisco	p10183sc	93.837	—	2,160
Pass-through University of Georgia	RR211-510/S001246/AM	93.837	—	15,597
Pass-through University of Georgia	RR376-352/4945936	93.837	—	7,355
Pass-through University of Minnesota	N004944406	93.837	—	14,251
Pass-through University of Minnesota	N006187412	93.837	—	15,664
Pass-through University of Minnesota	N006522502	93.837	—	4,027
Pass-through University of Minnesota	P004720401	93.837	—	37,436
Pass-through University of Pittsburgh	0046317 (126441-3)/A	93.837	(2,182)	1,921
Pass-through University of Rochester	416,745	93.837	—	50
Pass-through University of Virginia	GB10336 152588	93.837	—	205,157
Pass-through University of Virginia	GB10511.157405	93.837	—	140,850
Pass-through Vanderbilt University	VUMC61877	93.837	—	53,834
Pass-through Wake Forest University	WFUHS 114146/AMND 8	93.837	2,993	5,019
Pass-through Wake Forest University	WFUHS 114870/AMND1	93.837	—	71,023
Pass-through Wake Forest University	WFUHS 552861	93.837	—	37,744
Pass-through Weill Cornell Medical College	170851-03	93.837	—	26,814
Total CFDA No. 93.837			2,515,847	19,646,027
Lung Diseases Research	1R01HL133053-02	93.838	—	299,315
Lung Diseases Research	1R01HL136414-01A1	93.838	73,092	196,031
Lung Diseases Research	2R01HL113548-06A1	93.838	—	36,622
Lung Diseases Research	2T32HL116271-06 REVI	93.838	—	14,230
Lung Diseases Research	4R01HL113548-05	93.838	—	229,844
Lung Diseases Research	4R01HL116958-04	93.838	—	4,084
Lung Diseases Research	5F31HL136101-02REVIS	93.838	—	47,272
Lung Diseases Research	5F31HL139109-02	93.838	—	47,325
Lung Diseases Research	5R01HL102167-08	93.838	—	388,063
Lung Diseases Research	5R01HL125042-04	93.838	—	488,144
Lung Diseases Research	5R01HL126603-04	93.838	276,233	647,942
Lung Diseases Research	5R01HL138508-02	93.838	—	462,797
Lung Diseases Research	5T32HL116271-03	93.838	—	(3,622)
Lung Diseases Research	5T32HL116271-05 REVI	93.838	—	267,410
Lung Diseases Research	5UM1HL134590-03S1	93.838	3,571,316	6,062,430
Lung Diseases Research	5F31HL139134-02 REVI	93.838	—	51,275
Lung Diseases Research	5R01HL122559-04 REVI	93.838	—	187,150
Pass-through Georgia Institute of Technology	RH328-G1	93.838	—	377
Pass-through University of Arizona	328,533	93.838	—	109,043
Total CFDA No. 93.838			3,920,641	9,535,732
Blood Diseases and Resources Research	1R01HL129141-01A1	93.839	—	33,779
Blood Diseases and Resources Research	1R01HL137128-02	93.839	1,886	206,469
Blood Diseases and Resources Research	1R01HL138656-02	93.839	146,012	499,814
Blood Diseases and Resources Research	1R01HL143794-01	93.839	—	20,377
Blood Diseases and Resources Research	5F31HL134241-03	93.839	—	54,522
Blood Diseases and Resources Research	5K01HL131333-03	93.839	—	117,037
Blood Diseases and Resources Research	5K23HL128942-03	93.839	—	155,222
Blood Diseases and Resources Research	5K23HL133446-03	93.839	—	136,490
Blood Diseases and Resources Research	5K23HL133457-02	93.839	12,555	114,026
Blood Diseases and Resources Research	5K23HL136900-02	93.839	—	106,823
Blood Diseases and Resources Research	5P01HL086773-09	93.839	17,326	1,201,821
Blood Diseases and Resources Research	5R01HL082808-13	93.839	65,108	407,840
Blood Diseases and Resources Research	5R01HL095479-08	93.839	531,837	758,530
Blood Diseases and Resources Research	5R01HL117061-06	93.839	—	225,176
Blood Diseases and Resources Research	5R01HL123984-04	93.839	—	397,611
Blood Diseases and Resources Research	5R01HL130995-03	93.839	—	405,091
Blood Diseases and Resources Research	5R01HL131414-03	93.839	—	743,480
Blood Diseases and Resources Research	5R21HL133584-02	93.839	—	152,987
Blood Diseases and Resources Research	5U01HL117721-05	93.839	749,008	1,399,218
Blood Diseases and Resources Research	1F31HL138934-02	93.839	—	43,281
Blood Diseases and Resources Research	1R01HL138423-02	93.839	—	511,347
Blood Diseases and Resources Research	5F31HL131428-02	93.839	—	52,314
Blood Diseases and Resources Research	5R01HL121264-05 REVI	93.839	17,544	453,400
Blood Diseases and Resources Research	5R21HL138062-02	93.839	—	233,898
Blood Diseases and Resources Research	5T32HL069769-15 REVI	93.839	—	115,365

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Bloodworks Northwest Research Institute	839-EMORY-2017	93.839	\$ —	379,751
Pass-through Georgia Institute of Technology	RJ691-G1	93.839	—	23,405
Pass-through Medical University of South Carolina	MUSC17-063-8C868	93.839	—	26,094
Pass-through New England Research Institutes	U01HL072268	93.839	—	(135)
Pass-through Scripps Research Institute	5-53354	93.839	—	53,280
Pass-through University of Florida	UFDSP00011929	93.839	—	48,366
Pass-through University of Florida	UFDSP00012195	93.839	—	5,325
Pass-through University of Iowa	PO#: 1001683003	93.839	—	75,535
Pass-through University of North Carolina Chapel Hill	5,103,509	93.839	—	4,620
Pass-through Washington University	WU-17-115-MOD-3	93.839	—	7,073
Total CFDA No. 93.839			1,541,276	9,169,232
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	4R33HL138657-02	93.840	—	405,859
Total CFDA No. 93.840			—	405,859
Arthritis, Musculoskeletal and Skin Diseases Research	1F32AR068207-01A1	93.846	—	55,754
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR048615-15	93.846	—	(995)
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR054625-10	93.846	—	6,121
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR060268-05	93.846	—	81,259
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR061267-05	93.846	—	71,743
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR062483-05	93.846	—	86,137
Arthritis, Musculoskeletal and Skin Diseases Research	5F31 AR066476-02 REV	93.846	—	20,526
Arthritis, Musculoskeletal and Skin Diseases Research	5F31AR067645-03 REVI	93.846	—	25,271
Arthritis, Musculoskeletal and Skin Diseases Research	5F31AR069994-02 REVI	93.846	—	49,160
Arthritis, Musculoskeletal and Skin Diseases Research	5K01AR065481-04	93.846	—	10,414
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR047901-15	93.846	—	397,964
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048266-15	93.846	7,523	378,773
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048615-17	93.846	—	305,409
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR050501-14	93.846	—	508,297
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR061987-07	93.846	—	321,101
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR062483-04	93.846	—	(616)
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR064307-05	93.846	37,129	266,233
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR067786-04	93.846	—	358,277
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR068157-04	93.846	—	508,156
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR070898-03	93.846	21,529	781,173
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR071397-02	93.846	—	355,682
Arthritis, Musculoskeletal and Skin Diseases Research	5U01AR067169-03 REVI	93.846	10,155	66,736
Arthritis, Musculoskeletal and Skin Diseases Research	7R21AR067903-03	93.846	—	102,820
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR061987-05REVIS	93.846	—	799
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR050501-12	93.846	—	666
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR070091-03	93.846	—	606,602
Pass-through Auburn University	16-HDFS-201305-EU	93.846	—	398,170
Pass-through Duke University	2,037,091	93.846	—	2,473
Pass-through Georgia Institute of Technology	RF880-G1	93.846	—	1,073
Pass-through Georgia Institute of Technology	RG710-G1	93.846	—	34,138
Pass-through Georgia Institute of Technology	RJ335-G1	93.846	—	13,016
Pass-through Georgia Institute of Technology	RJ730-G1	93.846	—	43,290
Pass-through University of Alabama Birmingham	000517922-001	93.846	—	7,734
Pass-through University of Connecticut	UCHC7-95149050	93.846	—	209,699
Pass-through University of North Carolina Chapel Hill	5,103,371	93.846	—	(6,568)
Total CFDA No. 93.846			76,336	6,066,937
Diabetes, Digestive, and Kidney Diseases Extramural Research	1F30DK117570-01A1	93.847	—	3,402
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK110264-01A1 RE	93.847	—	102,285
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK115660-01A1 RE	93.847	—	10,219
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K08DK111998-02	93.847	—	170,037
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R01DK1110409-01A1	93.847	—	663
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R01DK112946-01A1	93.847	—	351,532
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R01DK115937-01	93.847	—	18,082
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK115222-01	93.847	—	754
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R56DK113147-01A1	93.847	59,669	214,227
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK047987-25	93.847	—	25,584
Diabetes, Digestive, and Kidney Diseases Extramural Research	3DP3DK108245-01S1	93.847	54,713	820,354
Diabetes, Digestive, and Kidney Diseases Extramural Research	3R01DK107900-03S1	93.847	67,175	288,477
Diabetes, Digestive, and Kidney Diseases Extramural Research	3T32DK007656-28	93.847	—	190,114
Diabetes, Digestive, and Kidney Diseases Extramural Research	4F30DK100097-04 REVI	93.847	—	22,450
Diabetes, Digestive, and Kidney Diseases Extramural Research	4K24DK096574-10	93.847	—	49,117
Diabetes, Digestive, and Kidney Diseases Extramural Research	4R01DK062092-13 REVI	93.847	—	22,263
Diabetes, Digestive, and Kidney Diseases Extramural Research	4T32DK007734-20	93.847	—	77,668
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F30DK109665-3 REVIS	93.847	—	59,151
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F31DK107229-02REVIS	93.847	—	6,058
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F31DK111171-03	93.847	—	55,478
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F32DK107191-02 REVI	93.847	—	26,266
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK102851-05	93.847	—	155,675
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK109025-02	93.847	—	95,710
Diabetes, Digestive, and Kidney Diseases Extramural Research	5P30DK111024-03	93.847	24,320	491,643
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK041707-22	93.847	—	255,201
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK044234-25 REVI	93.847	—	83,295
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK054514-17 REVI	93.847	—	419,729
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK056239-16	93.847	—	365,204
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059380-15 REVI	93.847	—	201,585
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK061418-13	93.847	—	1,957
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK074731-07	93.847	—	326,795
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK080684-08	93.847	22,631	207,632
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK087694-08	93.847	222,934	943,816

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK092722-07	93.847	\$ —	197,454
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098231-05 REVI	93.847	258,310	905,827
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK100582-04	93.847	—	305,991
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK104125-03	93.847	—	158,985
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK107719-03	93.847	—	310,913
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK108070-03	93.847	97,391	297,779
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK108842-03	93.847	—	340,301
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK111678-02	93.847	—	615,458
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK115213-02	93.847	—	518,022
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK105891-02 REVI	93.847	48,586	103,497
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK112108-02	93.847	—	151,443
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R25DK101390-05	93.847	—	105,745
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK038842-29	93.847	—	406,310
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK057665-19 REVI	93.847	—	469
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32 DK108735-03	93.847	—	210,833
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007771-15	93.847	—	1,295
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK106994-04	93.847	—	307,243
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK116099-02	93.847	—	39,973
Diabetes, Digestive, and Kidney Diseases Extramural Research	4R01DK095750-05	93.847	—	113,341
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK114391-02	93.847	—	118,351
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R03DK117246-01	93.847	—	8,640
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK047987-24	93.847	—	349,602
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098391-04 REVI	93.847	—	92,780
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK114891-02	93.847	1,205	104,499
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK062470-15	93.847	211,224	775,042
Pass-through Childrens Hospital of Los Angeles	TGF010062-T	93.847	—	537
Pass-through Children'S Hospital of Philadelphia	3200370521/PO#963022	93.847	—	52,440
Pass-through Connecticut Childrens Medical Center	17-179296-03	93.847	—	61,481
Pass-through Medical University of South Carolina	MUSC15-032/AMND 3	93.847	—	116,096
Pass-through Medical University of South Carolina	MUSC17-087-8C976	93.847	—	2,500
Pass-through Natl Jewish Health	20,108,201	93.847	—	53,270
Pass-through Northern California Inst of Res and Edu	TIE1980-02	93.847	—	10,022
Pass-through Ohio State University	60,061,837	93.847	—	20,195
Pass-through Research Institute At Nationwide Children's Hospital	700043-0518-00/AMND	93.847	—	48,707
Pass-through University of Alabama Birmingham	000517815-001	93.847	—	5,418
Pass-through University of Florida	UFDSPO0011230	93.847	—	69,939
Pass-through University of Kansas Medical Center	ZAY00020-AMND 3	93.847	—	10,495
Pass-through University of Michigan	3,003,756,238	93.847	—	127,478
Pass-through University of Pennsylvania	565161 / PO 3948207	93.847	—	10,781
Pass-through University of Pittsburgh	0019927 (124826-B)/A	93.847	34,776	52,161
Pass-through University of Pittsburgh	0054687 (129571-S)/A	93.847	—	3,714
Pass-through University of South Florida	6163-1007-00-BI	93.847	—	99,757
Pass-through Virginia Commonwealth University	PD303567-SC105312/AM	93.847	—	156,525
Pass-through Weill Cornell Medical College	183,124	93.847	—	81,228
Pass-through Weill Cornell Medical College	17,091,470	93.847	—	134,005
Total CFDA No. 93.847			1,102,934	13,679,037
Extramural Research Programs in the Neurosciences and Neurological Disorders	1 R03 NS091699-02	93.853	—	565
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS106896-01 REVI	93.853	—	32,008
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS102850-01A1	93.853	—	26,015
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS105971-01REVIS	93.853	—	2,672
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS102652-01A1	93.853	—	91,460
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS102913-01	93.853	—	168,585
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS104801-01A1	93.853	—	33,659
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106120-01 REVI	93.853	—	11,780
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106209-01	93.853	—	54,389
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106323-01	93.853	—	156,079
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106325-01	93.853	—	33,744
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106346-01	93.853	—	11,274
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS108760-01	93.853	—	12,832
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS098092-01A1	93.853	—	223,329
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS102980-01	93.853	—	400,763
Extramural Research Programs in the Neurosciences and Neurological Disorders	1U24NS100673-02	93.853	63,334	185,409
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R01NS078095-06A1	93.853	—	51,558
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R56NS045962-09	93.853	—	70,403
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS092122-03S1 RE	93.853	—	465,380
Extramural Research Programs in the Neurosciences and Neurological Disorders	3U01NS038455-15S1	93.853	1,312,387	1,464,036
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS057190-10	93.853	—	111,377
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS061070-11	93.853	—	(416)
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS078095-05	93.853	—	119,228
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS085006-04	93.853	—	95,281
Extramural Research Programs in the Neurosciences and Neurological Disorders	4U10NS059032-10	93.853	—	48,516
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS086370-03	93.853	—	21,433
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS087713-03	93.853	—	6,058
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS089242-03 REVI	93.853	—	6,037
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS092437-03REVIS	93.853	—	36,288
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS093859-03REVIS	93.853	—	50,469
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS095528-03	93.853	—	44,319
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098648-03	93.853	—	58,018
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098673-03	93.853	—	55,388
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098736-03 REVI	93.853	—	46,777
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098764-02 REVI	93.853	—	47,733
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101786-02	93.853	—	42,167
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101932-02REVIS	93.853	—	49,437
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS103595-02	93.853	—	42,141
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS098615-03 REVI	93.853	—	54,885
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS083626-04	93.853	—	230,827



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS099474-03	93.853	\$ —	184,852
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS083748-05	93.853	—	194,034
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS097576-02 REVI	93.853	—	194,476
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P30NS055077-09	93.853	—	623,008
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P50NS098685-03	93.853	—	1,314,872
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS036232-19	93.853	—	376,525
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS036654-20	93.853	—	333,490
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037112-18	93.853	1,488	300,695
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS047357-13REVIS	93.853	—	240,483
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065371-09	93.853	—	342,082
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065992-07	93.853	—	354,162
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS073994-05	93.853	49,460	68,008
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS073994-05 REVI	93.853	—	23,690
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS077982-04	93.853	—	5,677
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079331-05 REVI	93.853	—	124,011
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079858-05REVIS	93.853	—	129,962
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS083386-05	93.853	—	261,515
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084744-04 REVI	93.853	—	140,030
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084844-05 REVI	93.853	—	206,680
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085568-05	93.853	—	344,369
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS087142-04 REVI	93.853	—	550,462
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088413-05	93.853	—	357,892
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088528-04 REVI	93.853	52,931	307,605
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088748-05	93.853	167,723	614,226
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089694-05	93.853	—	364,039
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089719-04	93.853	—	695,488
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090319-04	93.853	173,835	519,728
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090677-04	93.853	159,223	608,284
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091201-04	93.853	—	182,088
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091585-03 REVI	93.853	—	398,765
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091749-02REVIS	93.853	—	437
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS092343-04	93.853	—	204,491
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS093016-04	93.853	—	151,039
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS093362-04	93.853	—	251,810
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095064-03 REVI	93.853	—	80,056
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095181-03	93.853	—	209,970
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095269-03 REVI	93.853	—	470,494
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095279-04	93.853	—	229,995
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS096236-03	93.853	—	441,662
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS097776-03	93.853	—	393,041
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS100864-02	93.853	—	448,824
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS100908-02	93.853	—	317,192
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS100967-02 REVI	93.853	—	76,095
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS101701-REVIS	93.853	—	450,288
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS102306-02	93.853	85,443	266,788
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS102871-02	93.853	—	370,945
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS092385-02	93.853	—	146,226
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS093446-02 REVI	93.853	—	49,704
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS093550-02	93.853	—	80,644
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS096455-02 REVI	93.853	—	86,488
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS098776-02	93.853	—	69,838
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS100419-02 REVI	93.853	—	28,103
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R24NS092989-03	93.853	—	267,732
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R25NS065739-10	93.853	—	149,467
Extramural Research Programs in the Neurosciences and Neurological Disorders	5T32NS007480-18	93.853	—	309,007
Extramural Research Programs in the Neurosciences and Neurological Disorders	5T32NS096050-23	93.853	—	407,989
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS094302-03S1	93.853	260,650	531,589
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS095932-09	93.853	—	(187)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS077366-07 REVI	93.853	—	249,159
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS086607-05	93.853	—	428,692
Extramural Research Programs in the Neurosciences and Neurological Disorders	5UG3NS100559-02	93.853	—	695,489
Extramural Research Programs in the Neurosciences and Neurological Disorders	7R01NS073768-06REVIS	93.853	—	63,748
Extramural Research Programs in the Neurosciences and Neurological Disorders	7R01NS097549-03	93.853	—	14,149
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS100406-02	93.853	—	43,355
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS103363-01A1REV	93.853	—	26,623
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS106887-01 REVI	93.853	—	15,468
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS100244-01A1	93.853	42,469	182,795
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098663-02	93.853	—	44,960
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101806-02	93.853	—	40,306
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS087775-02	93.853	—	8,127
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS087121-05	93.853	—	147,774
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS051630-13 REVI	93.853	599,757	887,995
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS070526-05 REVI	93.853	—	25,042
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071867-05 REVI	93.853	18,334	81,780
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085387-05	93.853	—	328,440
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS098441-02	93.853	—	523,854
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS099375-02 REVI	93.853	—	279,153
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R03NS103155-02	93.853	—	117,539
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084647-02REV	93.853	—	(147)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS087488-02	93.853	—	68,886
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS104410-02	93.853	—	218,489
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS062778-05REV	93.853	—	(75)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U54NS065701-05 REVI	93.853	—	(38)
Pass-through Case Western Reserve University	RESS10707/AMND#2	93.853	—	55,064

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Cleveland Clinic Foundation	902-SUB	93.853	\$ —	11,252
Pass-through Duke University	16-NIH-1038/AMND#2	93.853	—	12,997
Pass-through George Washington University	15-S27/ MOD #2	93.853	—	166,532
Pass-through Georgia Institute of Technology	RC836-G1	93.853	—	134
Pass-through Georgia Institute of Technology	RG574-G1	93.853	—	125,335
Pass-through Georgia Institute of Technology	2,003,237,738	93.853	—	60,903
Pass-through Georgia Institute of Technology	2003138853 AMEN 4	93.853	—	47,724
Pass-through University of Michigan	420210-EU	93.853	—	162,663
Pass-through University of Michigan	9952sc	93.853	—	(49)
Pass-through University of North Carolina	RC287-436/S001491	93.853	—	15,796
Pass-through University of North Carolina	SPC-000204	93.853	—	67,760
Pass-through University of Southern California	5,102,005	93.853	—	343,052
Pass-through University of Wisconsin-Madison	572647, P01NS097206	93.853	—	373,193
Pass-through University of Wisconsin-Madison	10045274-01 PO#U0000	93.853	—	33,043
Total CFDA No. 93.853			2,987,034	27,479,790
Allergy, Immunology and Transplantation Research	1F31AI122973-01A1	93.855	—	(309)
Allergy, Immunology and Transplantation Research	1K08AI132747-02	93.855	—	178,728
Allergy, Immunology and Transplantation Research	1K22AI130223-01	93.855	—	61,676
Allergy, Immunology and Transplantation Research	1K23AI134182-01A1	93.855	—	46,854
Allergy, Immunology and Transplantation Research	1R01AI128837-02	93.855	—	1,194,061
Allergy, Immunology and Transplantation Research	1R01AI130163-01A1	93.855	—	155,689
Allergy, Immunology and Transplantation Research	1R01AI135806-01A1	93.855	—	21,011
Allergy, Immunology and Transplantation Research	1R01AI136581-01A1	93.855	—	159,657
Allergy, Immunology and Transplantation Research	1R01AI137679-01	93.855	13,276	62,107
Allergy, Immunology and Transplantation Research	1R01AI138646-01	93.855	18,894	216,099
Allergy, Immunology and Transplantation Research	1R01AI139406-01	93.855	—	4,707
Allergy, Immunology and Transplantation Research	1R01AI139675-01	93.855	—	7,280
Allergy, Immunology and Transplantation Research	1R03AI139871-01	93.855	—	942
Allergy, Immunology and Transplantation Research	1R13AI134407-01 REVI	93.855	—	24,747
Allergy, Immunology and Transplantation Research	1R21AI135711-01	93.855	—	82,898
Allergy, Immunology and Transplantation Research	1R21AI135753-01	93.855	9,784	83,282
Allergy, Immunology and Transplantation Research	1R21AI136563-01A1	93.855	—	22,632
Allergy, Immunology and Transplantation Research	1R21AI141094-01	93.855	—	20,202
Allergy, Immunology and Transplantation Research	1R56AI110516-01	93.855	—	(167)
Allergy, Immunology and Transplantation Research	1R56AI117851-01	93.855	—	257
Allergy, Immunology and Transplantation Research	1U01AI132904-02	93.855	45,310	451,969
Allergy, Immunology and Transplantation Research	1U01AI138909-01	93.855	—	14,631
Allergy, Immunology and Transplantation Research	2P30AI050409-19 REVI	93.855	192,522	192,522
Allergy, Immunology and Transplantation Research	2P30AI050409-19 REVI	93.855	—	(54,695)
Allergy, Immunology and Transplantation Research	2R01AI030048-25	93.855	—	192,829
Allergy, Immunology and Transplantation Research	2R01AI051231-17	93.855	47,226	354,463
Allergy, Immunology and Transplantation Research	2R56AI049781-15A1	93.855	—	389,793
Allergy, Immunology and Transplantation Research	2R56AI083366-06A1	93.855	6,542	74,438
Allergy, Immunology and Transplantation Research	3R01AI134244-02S1	93.855	—	545,230
Allergy, Immunology and Transplantation Research	3T32AI074492-09S1REV	93.855	—	280,907
Allergy, Immunology and Transplantation Research	4R01AI028731-26	93.855	—	82,242
Allergy, Immunology and Transplantation Research	4R01AI058057-12	93.855	—	5,358
Allergy, Immunology and Transplantation Research	4R01AI058706-14	93.855	—	441,793
Allergy, Immunology and Transplantation Research	4R01AI064462-10 REVI	93.855	—	77,121
Allergy, Immunology and Transplantation Research	4R01AI070101-10 rev1	93.855	—	70,807
Allergy, Immunology and Transplantation Research	4R01AI072435-11 REVIS	93.855	—	159,326
Allergy, Immunology and Transplantation Research	4R01AI098628-05	93.855	—	335,845
Allergy, Immunology and Transplantation Research	4R01AI099000-05	93.855	—	138,097
Allergy, Immunology and Transplantation Research	4R01AI100110-05	93.855	—	158,463
Allergy, Immunology and Transplantation Research	4R37AI040519-20 REVI	93.855	—	132,178
Allergy, Immunology and Transplantation Research	4T32AI070081-10 REVI	93.855	—	17,591
Allergy, Immunology and Transplantation Research	4U19AI051731-15	93.855	851,745	851,745
Allergy, Immunology and Transplantation Research	4u19AI051731-15	93.855	—	(51,597)
Allergy, Immunology and Transplantation Research	5 R21 AI116200-02	93.855	—	3,146
Allergy, Immunology and Transplantation Research	5011649 / 8470038	93.855	—	62,660
Allergy, Immunology and Transplantation Research	51R21AI129607-02	93.855	—	257,063
Allergy, Immunology and Transplantation Research	5F30AI124568-02	93.855	—	66,446
Allergy, Immunology and Transplantation Research	5F31AI114250-03	93.855	—	53,192
Allergy, Immunology and Transplantation Research	5F31AI122926-03 REVI	93.855	—	58,691
Allergy, Immunology and Transplantation Research	5F31AI124611-03 REVI	93.855	—	60,264
Allergy, Immunology and Transplantation Research	5F31AI131532-02	93.855	—	41,827
Allergy, Immunology and Transplantation Research	5F31AI33950-02	93.855	—	44,140
Allergy, Immunology and Transplantation Research	5K01AI103544-05	93.855	7,133	111,016
Allergy, Immunology and Transplantation Research	5K08AI110528-06	93.855	—	179,106
Allergy, Immunology and Transplantation Research	5K23AI103044-05	93.855	—	130,364
Allergy, Immunology and Transplantation Research	5K23AI108335-05	93.855	—	132,301
Allergy, Immunology and Transplantation Research	5K23AI124913-03	93.855	—	163,893
Allergy, Immunology and Transplantation Research	5K23AI4407-05	93.855	—	147,619
Allergy, Immunology and Transplantation Research	5P01AI125180-03	93.855	545,111	2,317,052
Allergy, Immunology and Transplantation Research	5P30AI050409-20 REVI	93.855	137,425	2,742,369
Allergy, Immunology and Transplantation Research	5R01AI020211-31	93.855	—	378,704
Allergy, Immunology and Transplantation Research	5R01AI030048-24	93.855	—	79,792
Allergy, Immunology and Transplantation Research	5R01AI049781-14	93.855	—	48,360
Allergy, Immunology and Transplantation Research	5R01AI053668-17	93.855	—	240,483
Allergy, Immunology and Transplantation Research	5R01AI064060-14	93.855	317,173	1,132,172
Allergy, Immunology and Transplantation Research	5R01AI065429-14	93.855	—	479,111
Allergy, Immunology and Transplantation Research	5R01AI073707-07	93.855	—	532,910
Allergy, Immunology and Transplantation Research	5R01AI076119-11	93.855	3,873	171,998
Allergy, Immunology and Transplantation Research	5R01AI087465-05	93.855	—	68,847
Allergy, Immunology and Transplantation Research	5R01AI088025-09	93.855	15,925	432,256
Allergy, Immunology and Transplantation Research	5R01AI093406-05	93.855	—	367,891

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology and Transplantation Research	5R01AI104699-05	93.855	\$ —	201,197
Allergy, Immunology and Transplantation Research	5R01AI106715-03	93.855	—	60
Allergy, Immunology and Transplantation Research	5R01AI107960-05	93.855	—	474,883
Allergy, Immunology and Transplantation Research	5R01AI110113-03REVIS	93.855	—	(24,525)
Allergy, Immunology and Transplantation Research	5R01AI110334-03	93.855	—	6,404
Allergy, Immunology and Transplantation Research	5R01AI110334-05	93.855	337,038	643,494
Allergy, Immunology and Transplantation Research	5R01AI110474-03	93.855	—	39,538
Allergy, Immunology and Transplantation Research	5R01AI110482-04	93.855	444,095	817,391
Allergy, Immunology and Transplantation Research	5R01AI110680-04 REVI	93.855	137,541	649,411
Allergy, Immunology and Transplantation Research	5R01AI110701-05	93.855	—	455,686
Allergy, Immunology and Transplantation Research	5R01AI110720-05	93.855	133,510	265,079
Allergy, Immunology and Transplantation Research	5R01AI111557-04	93.855	85,149	622,906
Allergy, Immunology and Transplantation Research	5R01AI111851-04	93.855	272,869	439,125
Allergy, Immunology and Transplantation Research	5R01AI111948-05	93.855	389,282	1,018,814
Allergy, Immunology and Transplantation Research	5R01AI112723-04	93.855	6,896	719,992
Allergy, Immunology and Transplantation Research	5R01AI113021-05	93.855	—	466,131
Allergy, Immunology and Transplantation Research	5R01AI113883-02	93.855	—	8,504
Allergy, Immunology and Transplantation Research	5R01AI116379-04	93.855	—	711,077
Allergy, Immunology and Transplantation Research	5R01AI116933-04	93.855	—	394,415
Allergy, Immunology and Transplantation Research	5R01AI118853-04	93.855	—	465,708
Allergy, Immunology and Transplantation Research	5R01AI121252-03	93.855	—	306,253
Allergy, Immunology and Transplantation Research	5R01AI123126-03	93.855	—	637,684
Allergy, Immunology and Transplantation Research	5R01AI123733-03	93.855	—	349,565
Allergy, Immunology and Transplantation Research	5R01AI124680-03	93.855	29,456	410,646
Allergy, Immunology and Transplantation Research	5R01AI125064-03	93.855	—	1,125,086
Allergy, Immunology and Transplantation Research	5R01AI125268-03 REVI	93.855	—	337,279
Allergy, Immunology and Transplantation Research	5R01AI125405-03	93.855	217,605	540,924
Allergy, Immunology and Transplantation Research	5R01AI126322-03	93.855	337,281	981,404
Allergy, Immunology and Transplantation Research	5R01AI127799-02 REVI	93.855	331,181	553,770
Allergy, Immunology and Transplantation Research	5R01AI128799-02	93.855	11,893	498,351
Allergy, Immunology and Transplantation Research	5R01AI129862-02	93.855	111,864	512,181
Allergy, Immunology and Transplantation Research	5R01AI132833-02	93.855	156,983	492,120
Allergy, Immunology and Transplantation Research	5R21AI103651-02	93.855	—	487
Allergy, Immunology and Transplantation Research	5R21AI112768-02	93.855	—	78,940
Allergy, Immunology and Transplantation Research	5R21AI113385-02 REVI	93.855	11,595	15,122
Allergy, Immunology and Transplantation Research	5R21AI113485-02	93.855	19,798	165,201
Allergy, Immunology and Transplantation Research	5R21AI115183-02	93.855	—	11,300
Allergy, Immunology and Transplantation Research	5R21AI117162-02	93.855	—	21,377
Allergy, Immunology and Transplantation Research	5R21AI117459-02	93.855	54,952	81,413
Allergy, Immunology and Transplantation Research	5R21AI118542-02	93.855	5,057	5,057
Allergy, Immunology and Transplantation Research	5R21AI118542-02	93.855	—	(1,089)
Allergy, Immunology and Transplantation Research	5R21AI121684-02	93.855	20,993	76,222
Allergy, Immunology and Transplantation Research	5R21AI121860-02	93.855	—	175,957
Allergy, Immunology and Transplantation Research	5R21AI122192-02	93.855	—	144,707
Allergy, Immunology and Transplantation Research	5R21AI128313-02	93.855	—	157,678
Allergy, Immunology and Transplantation Research	5R21AI130918-02	93.855	14,542	292,572
Allergy, Immunology and Transplantation Research	5R33AI098800-05	93.855	—	317,985
Allergy, Immunology and Transplantation Research	5R33AI102197-05	93.855	—	44,329
Allergy, Immunology and Transplantation Research	5R33AI104278-05	93.855	—	311,852
Allergy, Immunology and Transplantation Research	5R37AI021150-33	93.855	93,930	391,818
Allergy, Immunology and Transplantation Research	5R37AI048638-17 REVI	93.855	—	(1,759)
Allergy, Immunology and Transplantation Research	5R37AI049660-15	93.855	—	354,834
Allergy, Immunology and Transplantation Research	5R37AI051231-15	93.855	61,307	630,473
Allergy, Immunology and Transplantation Research	5R37AI066998-15	93.855	—	774,048
Allergy, Immunology and Transplantation Research	5R37AI112787-05	93.855	68,773	1,075,660
Allergy, Immunology and Transplantation Research	5T32AI070081-09	93.855	—	27
Allergy, Immunology and Transplantation Research	5T32AI070081-12	93.855	—	158,742
Allergy, Immunology and Transplantation Research	5T32AI106699-05REVIS	93.855	—	237,970
Allergy, Immunology and Transplantation Research	5U01AI084150-05 REVI	93.855	197	122,636
Allergy, Immunology and Transplantation Research	5U01AI103408-03 REV	93.855	—	(15,383)
Allergy, Immunology and Transplantation Research	5U01AI115651-04REVIS	93.855	479,975	1,140,761
Allergy, Immunology and Transplantation Research	5U01AI131566-02 REVI	93.855	—	663,288
Allergy, Immunology and Transplantation Research	5U19AI051731-17	93.855	1,372,890	2,586,167
Allergy, Immunology and Transplantation Research	5U19AI057266-15	93.855	1,266,878	2,653,448
Allergy, Immunology and Transplantation Research	5U19AI090023-05	93.855	—	(2,759)
Allergy, Immunology and Transplantation Research	5U19AI090023-09 REVI	93.855	1,312,027	2,484,295
Allergy, Immunology and Transplantation Research	5U19AI109633-05	93.855	51,330	1,767,892
Allergy, Immunology and Transplantation Research	5U19AI110483-05	93.855	—	432,036
Allergy, Immunology and Transplantation Research	5U19AI111211-05REVIS	93.855	731,013	2,181,096
Allergy, Immunology and Transplantation Research	5U19AI117891-04 REVI	93.855	441,366	1,552,191
Allergy, Immunology and Transplantation Research	5U24AI120134-04	93.855	—	348,034
Allergy, Immunology and Transplantation Research	5UH2AI122320-02	93.855	127,910	132,543
Allergy, Immunology and Transplantation Research	5UH2AI132345-02	93.855	—	282,689
Allergy, Immunology and Transplantation Research	5UH3AI122320-04	93.855	127,584	517,243
Allergy, Immunology and Transplantation Research	5UM1AI069418-12REVIS	93.855	1,058,666	3,138,448
Allergy, Immunology and Transplantation Research	5UM1AI124436-03REVIS	93.855	1,045,525	6,714,952
Allergy, Immunology and Transplantation Research	7R01AI120860-04 REVI	93.855	—	170,502
Allergy, Immunology and Transplantation Research	1F31AI136310-01A1	93.855	—	4,054
Allergy, Immunology and Transplantation Research	1F31AI138391-01	93.855	—	2,027
Allergy, Immunology and Transplantation Research	1R01AI136533-01	93.855	—	194,787
Allergy, Immunology and Transplantation Research	1R01AI137127-01	93.855	—	40,839
Allergy, Immunology and Transplantation Research	1R21AI122001-01	93.855	111,071	139,081
Allergy, Immunology and Transplantation Research	2R01AI064462-11A1	93.855	—	231,313
Allergy, Immunology and Transplantation Research	2R01AI1072435-12A1	93.855	—	59,047
Allergy, Immunology and Transplantation Research	4R01HD067359-05 REVI	93.855	—	185,203
Allergy, Immunology and Transplantation Research	4R33AI121684-03 REVI	93.855	—	281,896
Allergy, Immunology and Transplantation Research	5F31AI115968-02 REVI	93.855	—	5,881
Allergy, Immunology and Transplantation Research	5K01AI106961-03	93.855	—	59,608

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology and Transplantation Research	5R01AI121315-04	93.855	\$ —	239,577
Allergy, Immunology and Transplantation Research	5R01AI133706-02	93.855	—	552,488
Allergy, Immunology and Transplantation Research	5R21AI126816-02	93.855	—	220,237
Allergy, Immunology and Transplantation Research	5U01AI103408-05 REVI	93.855	80,556	2,656,182
Allergy, Immunology and Transplantation Research	5U19AI096187-05 REVI	93.855	—	(30,778)
Pass-through Albert Einstein College of Medicine	310842 Amend #7/PO65	93.855	—	164,916
Pass-through Albert Einstein College of Medicine	PO061337/310429	93.855	—	3,947
Pass-through Benaroya Research Institute At Virginia	FY15ITN166	93.855	—	(7,986)
Pass-through Benaroya Research Institute At Virginia	FY17ITN153	93.855	—	34,768
Pass-through Benaroya Research Institute At Virginia	FY17ITN215	93.855	—	21,965
Pass-through Benaroya Research Institute At Virginia	FY17ITN238 Amen 1	93.855	—	157,170
Pass-through Benaroya Research Institute At Virginia	FY17ITN242	93.855	—	99,844
Pass-through Benaroya Research Institute At Virginia	FY18ITN236/AMND 02	93.855	—	16,803
Pass-through Beth Israel Deaconess Medical Center	1,024,717	93.855	—	3,811
Pass-through Beth Israel Deaconess Medical Center	1,028,933	93.855	—	177,353
Pass-through Boston Children'S Hospital	GENFD0001301584/1306	93.855	1,925	233,931
Pass-through Brigham and Womens Hospital	110,009	93.855	—	11,864
Pass-through Brigham and Womens Hospital	110,229	93.855	—	9,084
Pass-through Brigham and Womens Hospital	110,758	93.855	—	66,341
Pass-through Brigham and Womens Hospital	114,727	93.855	—	51,356
Pass-through Brigham and Womens Hospital	5UM1AI068636-12	93.855	—	191,457
Pass-through Case Western Reserve University	RES509044	93.855	—	67,983
Pass-through Case Western Reserve University	RES511329	93.855	—	184,976
Pass-through Case Western Reserve University	RES511346-02	93.855	—	417,118
Pass-through Childrens Hospital Oakland	12.7845_Emory_5	93.855	—	48,637
Pass-through Duke University	2,036,511	93.855	—	337,674
Pass-through Duke University	2,036,513	93.855	—	33,748
Pass-through Duke University	2,036,514	93.855	—	78,154
Pass-through Duke University	2,037,075	93.855	—	34,422
Pass-through Duke University	2,037,707	93.855	—	78,557
Pass-through Duke University	2,037,818	93.855	—	13,574
Pass-through Duke University	2,037,819	93.855	—	30,595
Pass-through Duke University	2,037,823	93.855	—	45,760
Pass-through Duke University	2,038,471	93.855	—	39,241
Pass-through Family Health International	PO15004277	93.855	617,582	1,118,940
Pass-through Fred Hutchinson Cancer Research Center	852,867	93.855	—	1,146
Pass-through Fred Hutchinson Cancer Research Center	888,347	93.855	—	10,623
Pass-through Fred Hutchinson Cancer Research Center	888,692	93.855	—	191,044
Pass-through Fred Hutchinson Cancer Research Center	893,339	93.855	—	166,365
Pass-through Fred Hutchinson Cancer Research Center	893,628	93.855	—	126,481
Pass-through Fred Hutchinson Cancer Research Center	906,010	93.855	—	94,598
Pass-through Fred Hutchinson Cancer Research Center	924,077	93.855	—	34,308
Pass-through Fred Hutchinson Cancer Research Center	925,441	93.855	—	20,886
Pass-through Fred Hutchinson Cancer Research Center	925,564	93.855	—	40,959
Pass-through Fred Hutchinson Cancer Research Center	926,099	93.855	—	481,949
Pass-through Fred Hutchinson Cancer Research Center	928,214	93.855	—	146,187
Pass-through Fred Hutchinson Cancer Research Center	937,630	93.855	—	161,906
Pass-through Georgia Institute of Technology	RE606-G2	93.855	—	43,007
Pass-through Georgia Institute of Technology	RG532-G3	93.855	—	23,755
Pass-through Georgia Institute of Technology	RG673-G1/AMEND #2	93.855	—	144,955
Pass-through Georgia State University	SP00011671-03	93.855	—	47,181
Pass-through Georgia State University	SP00012249-01/AMND1	93.855	—	7,460
Pass-through Georgia State University	SP00012355-02	93.855	—	29,787
Pass-through Georgia State University	SP00013279-01	93.855	—	2,447
Pass-through Harvard University	152382.5087277.1106	93.855	—	334,545
Pass-through Henry M Jackson Foundation	307419-3,01-64461/PO	93.855	—	126,354
Pass-through Johns Hopkins University	2,002,658,448	93.855	—	70,608
Pass-through Johns Hopkins University	2003605819/AMND 1	93.855	—	197,091
Pass-through Johns Hopkins University	5U19AI113127-05	93.855	—	37,856
Pass-through Johns Hopkins University	LDR 01 MOD 01	93.855	—	4,828
Pass-through La Jolla Institute for Allergy	22496-60-382	93.855	—	185,100
Pass-through Massachusetts General Hospital	228,429	93.855	—	10,278
Pass-through Mayo Clinic Rochester	PO85200032	93.855	—	277,233
Pass-through Md Anderson	PO: 3001155590	93.855	—	38,499
Pass-through Medical University of South Carolina	MUSC17-121-8D052	93.855	—	64,519
Pass-through Medical University of South Carolina	MUSC18-045-8D291	93.855	—	66,115
Pass-through Mount Sinai School of Medicine	25,580,714,609	93.855	—	51
Pass-through Mount Sinai School of Medicine	25,586,564,609	93.855	—	156,000
Pass-through Mount Sinai School of Medicine	0254-3193-4609	93.855	—	(10,467)
Pass-through Mount Sinai School of Medicine	0255-B001-4609	93.855	—	171,112
Pass-through Ohio State University	60,051,430	93.855	—	(4,989)
Pass-through Ohio State University	60,063,308	93.855	—	90,272
Pass-through Philadelphia College of Osteopathic Medicine	461,092	93.855	—	18,264
Pass-through Regents of The University of California	00009477/BB00944024	93.855	—	171,696
Pass-through Regents of The University of California	10350sc	93.855	—	12,733
Pass-through Regents of The University of California	9862SC Amendment #1	93.855	—	3,144
Pass-through Research Institute At Nationwide Children's Hospital	82,154,216	93.855	—	312,867
Pass-through Scripps Research Institute	5-53726	93.855	—	78,210
Pass-through Seattle Childrens Hospital	11578SUB/MOD #3	93.855	—	38,632
Pass-through Stanford University	61019079-117727	93.855	—	28,041
Pass-through Stanford University	61537964-28291	93.855	—	176,804
Pass-through Tulane University	TUL-HSC-553582-16/17	93.855	—	304,107
Pass-through Tulane University	TUL-HSC-555661-17/18	93.855	—	203,082
Pass-through University of Alabama Birmingham	000338217-SP021-010	93.855	—	(4,402)
Pass-through University of Alabama Birmingham	000502889-SP007-001	93.855	—	278,456
Pass-through University of Alabama Birmingham	000505362-001	93.855	—	67,591
Pass-through University of California Davis	201303042-01	93.855	—	318,940

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through University of California San Diego	86,085,916	93.855	\$ —	555
Pass-through University of California San Diego	82056849(PO# S900157	93.855	—	15,900
Pass-through University of California San Francisco	8820sc/AMEND #3	93.855	—	36,117
Pass-through University of California San Francisco	9255sc AM. 1	93.855	—	68,197
Pass-through University of California San Francisco	9434sc	93.855	—	544,036
Pass-through University of Georgia	RR374-101/4708622	93.855	—	(2,492)
Pass-through University of Georgia	RR374-126/S001205	93.855	—	147,722
Pass-through University of Houston	R-16-0075/AMND 2	93.855	—	124,768
Pass-through University of Louisiana At Lafayette	87100-02	93.855	—	29,773
Pass-through University of Louisiana At Lafayette	8799-01	93.855	—	771
Pass-through University of Maryland, Baltimore	10018314-742	93.855	—	1,269,230
Pass-through University of Miami	SPC-000203	93.855	—	14
Pass-through University of Nebraska	34-5160-2084-001	93.855	—	31,564
Pass-through University of Nebraska	34-5160-2108-001 AMD	93.855	—	619,329
Pass-through University of Nebraska	Subaward 34-5160-208	93.855	—	15,404
Pass-through University of Nevada	UNR-16-45	93.855	—	46,942
Pass-through University of North Carolina	5,105,563	93.855	—	942,611
Pass-through University of North Carolina Chapel Hill	511,015	93.855	—	45,153
Pass-through University of North Carolina Chapel Hill	5,103,944	93.855	—	71,583
Pass-through University of North Carolina Chapel Hill	5,107,082	93.855	—	173,872
Pass-through University of North Carolina Chapel Hill	5,108,091	93.855	—	36,563
Pass-through University of North Carolina Chapel Hill	5,108,670	93.855	—	27,437
Pass-through University of Pennsylvania	566,489	93.855	—	34,724
Pass-through University of Pennsylvania	572,632	93.855	—	672,073
Pass-through University of Pennsylvania	573,804	93.855	—	222,478
Pass-through University of Texas Southwestern	GMO150402/PO#RGC0000	93.855	—	94,836
Pass-through University of Utah	10045323-01_PO#U0000	93.855	—	161,456
Pass-through University of Washington Seattle	UWSC6143	93.855	—	227,450
Pass-through Vanderbilt University	VUMC 38503	93.855	—	682
Pass-through Vanderbilt University	VUMC57217	93.855	—	(459)
Pass-through Vanderbilt University	VUMC59385/AMND 3	93.855	—	341,822
Pass-through Vanderbilt University	VUMC62527	93.855	—	78,500
Pass-through Vanderbilt University Medical Center	VUMC40875/AMND 1	93.855	—	1,952
Pass-through Vanderbilt University Medical Center	VUMC59252	93.855	—	9,891
Pass-through Washington University	2934532E/WU-18-91	93.855	—	31,200
Pass-through Wistar Institute	25131-04-374	93.855	—	462,478
Pass-through Yale University	GK000080 (CON-800005	93.855	—	83,889
Total CFDA No. 93.855			14,392,024	86,092,497
Microbiology and Infectious Diseases Research				
Pass-through Baylor College of Medicine	7,000,000,342	93.856	—	428,200
Pass-through University of Florida	39733_2018_0UFDSP000	93.856	—	606,868
Total CFDA No. 93.856				1,035,068
Biomedical Research and Research Training	1F32GM126734-01	93.859	—	26,407
Biomedical Research and Research Training	1R01GM123136-01A1	93.859	1,667	30,064
Biomedical Research and Research Training	1R01GM124280-01A1	93.859	—	45,549
Biomedical Research and Research Training	1R01GM129495-01	93.859	—	29,703
Biomedical Research and Research Training	1R25GM125598-01	93.859	—	3,870
Biomedical Research and Research Training	2R01GM083889-19	93.859	—	85,860
Biomedical Research and Research Training	2R01GM084070-10	93.859	—	4,525
Biomedical Research and Research Training	2R01GM100151-05	93.859	—	10,913
Biomedical Research and Research Training	2T32GM008490-26	93.859	—	38,656
Biomedical Research and Research Training	3F31GM116556-02S1	93.859	—	55,195
Biomedical Research and Research Training	3R01GM054787-25S1	93.859	69,247	471,746
Biomedical Research and Research Training	3R01GM104198-08S1	93.859	—	266,621
Biomedical Research and Research Training	3R01GM118012-04S1	93.859	23,547	69,690
Biomedical Research and Research Training	3R25GM099644-03S1REV	93.859	—	123,971
Biomedical Research and Research Training	3T32GM008169-30S1	93.859	—	30,875
Biomedical Research and Research Training	4R01GM051173-31REV	93.859	—	(14,039)
Biomedical Research and Research Training	4R01GM058728-16	93.859	—	73
Biomedical Research and Research Training	4R01GM077569-08	93.859	—	112
Biomedical Research and Research Training	4R01GM101040-04	93.859	—	1,223
Biomedical Research and Research Training	4R01GM103613-04	93.859	—	248,272
Biomedical Research and Research Training	4R01GM104323-04	93.859	—	49,191
Biomedical Research and Research Training	4R01GM105813-04REVIS	93.859	5,571	113,466
Biomedical Research and Research Training	4T32GM008602-20	93.859	—	98,389
Biomedical Research and Research Training	52T32GM008169-32	93.859	—	1,167,288
Biomedical Research and Research Training	5F31GM111047-03 REVI	93.859	—	11,940
Biomedical Research and Research Training	5F31GM112418-03	93.859	—	12,641
Biomedical Research and Research Training	5F31GM113397-03 REVI	93.859	—	11,392
Biomedical Research and Research Training	5F31GM113631-02	93.859	—	6,058
Biomedical Research and Research Training	5F31GM115178-03REVIS	93.859	—	53,695
Biomedical Research and Research Training	5F31GM123750-02 REVI	93.859	—	49,276
Biomedical Research and Research Training	5F32GM113570-03	93.859	—	35,373
Biomedical Research and Research Training	5K12GM000680-19	93.859	70,652	1,003,126
Biomedical Research and Research Training	5R01GM049245-23REVIS	93.859	—	(32,506)
Biomedical Research and Research Training	5R01GM051173-33 REVI	93.859	75,715	462,143
Biomedical Research and Research Training	5R01GM072808-13	93.859	—	301,660
Biomedical Research and Research Training	5R01GM083889-18	93.859	—	788
Biomedical Research and Research Training	5R01GM084070-09	93.859	—	190,024
Biomedical Research and Research Training	5R01GM090158-07REVIS	93.859	31,598	183,627
Biomedical Research and Research Training	5R01GM093278-09S1	93.859	57,664	400,264
Biomedical Research and Research Training	5R01GM099142-08	93.859	—	392,040
Biomedical Research and Research Training	5R01GM104540-05 REVI	93.859	31,144	140,883
Biomedical Research and Research Training	5R01GM106565-04 REVI	93.859	—	206,765
Biomedical Research and Research Training	5R01GM108838-03 REVI	93.859	—	114

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	5R01GM109501-05	93.859	\$ 187,395	380,873
Biomedical Research and Research Training	5R01GM109779-04 REVI	93.859	—	330,617
Biomedical Research and Research Training	5R01GM110000-04REVIS	93.859	—	236,707
Biomedical Research and Research Training	5R01GM110663-04	93.859	—	534,861
Biomedical Research and Research Training	5R01GM113228-04	93.859	—	302,277
Biomedical Research and Research Training	5R01GM114306-03REVIS	93.859	—	(42)
Biomedical Research and Research Training	5R01GM114561-03 REVI	93.859	188,061	269,847
Biomedical Research and Research Training	5R01GM114612-03 REVI	93.859	147,891	317,932
Biomedical Research and Research Training	5R01GM116065-04	93.859	37,481	271,174
Biomedical Research and Research Training	5R01GM116991-03	93.859	—	444,126
Biomedical Research and Research Training	5R01GM117946-03 REVI	93.859	188,734	438,328
Biomedical Research and Research Training	5R01GM120271-03	93.859	—	323,700
Biomedical Research and Research Training	5R01GM121967-02	93.859	—	196,512
Biomedical Research and Research Training	5R01GM122083-03	93.859	150,825	345,659
Biomedical Research and Research Training	5R01GM124061-02	93.859	63,231	195,684
Biomedical Research and Research Training	5R25GM099644-03REVIS	93.859	—	43,880
Biomedical Research and Research Training	5R25GM102789-05 REVI	93.859	70,362	187,193
Biomedical Research and Research Training	5R35GM122549-02	93.859	—	154,784
Biomedical Research and Research Training	5R35GM122568-02	93.859	—	166,180
Biomedical Research and Research Training	5T32GM008367-29	93.859	—	408,312
Biomedical Research and Research Training	5T32GM008490-25REVIS	93.859	—	485,670
Biomedical Research and Research Training	5T32GM095442-08	93.859	—	277,188
Biomedical Research and Research Training	1K99GM127671-01	93.859	—	34,371
Biomedical Research and Research Training	1R21GM127971-01	93.859	—	47,821
Biomedical Research and Research Training	3R35GM122591-02S1	93.859	—	637,306
Biomedical Research and Research Training	5F32GM125350-02	93.859	—	51,610
Biomedical Research and Research Training	5R01GM035463-31 REVI	93.859	—	415,407
Biomedical Research and Research Training	5R01GM053640-21	93.859	—	271,540
Biomedical Research and Research Training	5R01GM069971-12 REVI	93.859	—	332,702
Biomedical Research and Research Training	5R01GM091875-17	93.859	—	280,679
Biomedical Research and Research Training	5R01GM124472-02 REVI	93.859	—	325,064
Biomedical Research and Research Training	5R35GM119426-03	93.859	—	349,305
Biomedical Research and Research Training	5T32GM008602-22	93.859	—	276,796
Pass-through Albert Einstein College of Medicine	311119/AMND 2	93.859	—	37,942
Pass-through Albert Einstein College of Medicine	31133K	93.859	—	373,182
Pass-through Duke University	13-NIH-1020	93.859	—	6,111
Pass-through Fred Hutchinson Cancer Research Center	215,918	93.859	—	211,275
Pass-through Fred Hutchinson Cancer Research Center	//0000905064	93.859	—	20,102
Pass-through Georgetown University	AWD7772899-GR205575	93.859	—	14,499
Pass-through Georgia Institute of Technology	RH644-G1	93.859	—	26,146
Pass-through Ohio State University	60,062,196	93.859	—	55,672
Pass-through Pennsylvania State University	5683-EU-DHHS-1650	93.859	—	136,905
Pass-through Scripps Research Institute	5-53479	93.859	—	81,887
Pass-through Scripps Research Institute	5-53854/AMND 1	93.859	—	325,114
Pass-through University of California San Diego	83805795/PO#S9001596	93.859	—	89,460
Pass-through University of Georgia	RR166-500/S001097	93.859	—	697
Pass-through University of Georgia	RR166-501/4708616	93.859	—	270,876
Pass-through University of Georgia	RR166-501/4708617	93.859	—	151,987
Pass-through University of Minnesota	P003397401/AMND4	93.859	—	(382)
Pass-through University of Texas Health Sciences Ctr	0013729A	93.859	—	1,587
Pass-through University of Texas Medical Branch	16-052 PO#UOOPC-1418	93.859	—	96,221
Pass-through University of Washington	UWSC10194 / BPO28142	93.859	—	13,066
<b>Total CFDA No. 93.859</b>			<b>1,400,785</b>	<b>17,622,973</b>
Child Health and Human Development Extramural Research	1F31HD092025-01A REV	93.865	—	35,333
Child Health and Human Development Extramural Research	1R21HD089160-02	93.865	—	165,076
Child Health and Human Development Extramural Research	2R01HD046922-12	93.865	—	321,275
Child Health and Human Development Extramural Research	2T32HD071845-06 REVI	93.865	—	69,589
Child Health and Human Development Extramural Research	3K12HD072245-05S1	93.865	—	40,410
Child Health and Human Development Extramural Research	3R21HD092785-02S1	93.865	—	200,488
Child Health and Human Development Extramural Research	5F31HD080404-02	93.865	—	5,881
Child Health and Human Development Extramural Research	5F31HD086964-02	93.865	—	51,680
Child Health and Human Development Extramural Research	5F31HD088043-03	93.865	—	54,330
Child Health and Human Development Extramural Research	5K01HD074726-05	93.865	—	103,555
Child Health and Human Development Extramural Research	5K01HD079584-05	93.865	—	117,940
Child Health and Human Development Extramural Research	5K01HD080722-04	93.865	—	130,323
Child Health and Human Development Extramural Research	5K12HD085850-04	93.865	—	411,462
Child Health and Human Development Extramural Research	5K23HD078153-05	93.865	—	175,827
Child Health and Human Development Extramural Research	5K23HD080837-04	93.865	—	169,650
Child Health and Human Development Extramural Research	5K25HD086276-03	93.865	—	138,657
Child Health and Human Development Extramural Research	5R01HD071982-05	93.865	17,679	168,917
Child Health and Human Development Extramural Research	5R01HD074486-05	93.865	—	268,437
Child Health and Human Development Extramural Research	5R01HD077623-05	93.865	—	223,173
Child Health and Human Development Extramural Research	5R01HD082373-04REVIS	93.865	—	290,315
Child Health and Human Development Extramural Research	5R01HD085877-03 REVI	93.865	—	175,383
Child Health and Human Development Extramural Research	5R01HD090642-03	93.865	134,059	279,063
Child Health and Human Development Extramural Research	5R01HD092033-02	93.865	—	441,894
Child Health and Human Development Extramural Research	5R01HD092595-02	93.865	182,573	466,597
Child Health and Human Development Extramural Research	5R03HD081438-02	93.865	3,737	17,311
Child Health and Human Development Extramural Research	5R03HD083727-02 REVI	93.865	—	77,220
Child Health and Human Development Extramural Research	5R03HD087606-02	93.865	—	41,602
Child Health and Human Development Extramural Research	5R21HD078121-02	93.865	—	7,483
Child Health and Human Development Extramural Research	5R21HD079699-02 REVI	93.865	—	30,068
Child Health and Human Development Extramural Research	5R21HD080107-02 REVI	93.865	107,784	107,784
Child Health and Human Development Extramural Research	5R21HD080107-02 REVI	93.855	—	(5,106)
Child Health and Human Development Extramural Research	5R21HD084114-02	93.865	10,396	44,153
Child Health and Human Development Extramural Research	5R21HD086491-02	93.865	192,486	211,741
Child Health and Human Development Extramural Research	5R21HD087760-02 REVI	93.865	—	191,081

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Child Health and Human Development Extramural Research	5R21HD089056-02	93.865	\$ 5,048	172,366
Child Health and Human Development Extramural Research	5R21HD093027-02	93.865	—	76,213
Child Health and Human Development Extramural Research	5R25HD079102-05 REVI	93.865	—	84,568
Child Health and Human Development Extramural Research	5T32HD071845-05 REVI	93.865	—	146,462
Child Health and Human Development Extramural Research	5U01HD066439-04	93.865	—	2,508
Child Health and Human Development Extramural Research	5UG1HD027851-28REVIS	93.865	—	268,295
Child Health and Human Development Extramural Research	5U54NS091859-04	93.865	—	2,700,948
Child Health and Human Development Extramural Research	1R01HD095741-01A1	93.865	—	1,726
Child Health and Human Development Extramural Research	2K12HD072245-06	93.865	—	247,048
Child Health and Human Development Extramural Research	4P01HD032571-20	93.865	208,541	403,111
Child Health and Human Development Extramural Research	5K12HD072245-04REVIS	93.865	—	(121)
Child Health and Human Development Extramural Research	5R01HD075784-05	93.865	173,973	563,002
Child Health and Human Development Extramural Research	5R01HD090925-02	93.865	—	546,189
Child Health and Human Development Extramural Research	5R03HD083729-02 REVI	93.865	26,806	50,497
Child Health and Human Development Extramural Research	5R21HD086762-02 REVI	93.865	36,510	144,372
Child Health and Human Development Extramural Research	5T32HD052460-10	93.865	—	26,134
Pass-through Georgia State University	R01HD079327	93.865	—	(25,245)
Pass-through Georgia State University	SP00011537-1 AMD 4	93.865	—	76,299
Pass-through Mclean Hospital	401,286	93.865	—	57,553
Pass-through Medical University of South Carolina	MUSC17-025-8B465	93.865	—	18,757
Pass-through Seattle Children'S Research Institute	11536SUB/MOD1	93.865	—	17,888
Pass-through Tulane University	TUL-HSC-554721-16/17	93.865	—	20,030
Pass-through Universit of California, Santa Barbara	KK1601 Amend 1	93.865	—	19,404
Pass-through University of California Davis	201224693-01/AMND5	93.865	—	85,822
Pass-through University of California San Francisco	9547sc	93.865	—	101,430
Pass-through University of Georgia	RR234-290/S001556	93.865	—	31,258
Pass-through University of Georgia	SUB00000739	93.865	—	18,176
Pass-through University of Massachusetts Medical School	WA00441545-0SP201700	93.865	—	426,865
Pass-through University of Michigan	3,003,518,660	93.865	—	104,618
Pass-through University of Michigan	PO# 3003539487	93.865	—	209,913
Pass-through University of North Carolina Chapel Hill	5,105,608	93.865	—	652,262
Pass-through University of North Carolina Chapel Hill	5,107,706	93.865	—	53,017
Pass-through University of North Carolina Chapel Hill	5,108,801	93.865	—	149,361
Pass-through University of North Carolina Chapel Hill	5,108,806	93.865	—	120,761
Pass-through University of North Carolina Chapel Hill	5,108,966	93.865	—	206,686
Pass-through University of North Carolina Chapel Hill	5,109,011	93.865	—	121,377
Pass-through University of North Carolina Chapel Hill	5,110,647	93.865	—	34,799
Pass-through University of North Carolina Chapel Hill	5,111,111	93.865	—	17,694
Pass-through University of North Carolina Chapel Hill	5,111,133	93.865	—	11,034
Pass-through University of Pennsylvania	569643/ PO #3770643	93.865	—	824
Pass-through University of Washington	BPO 26072	93.865	—	8,369
Pass-through Washington University	WU-17-140	93.865	—	5,411
Pass-through Washington University	WU-18-172	93.865	—	132,028
Total CFDA No. 93.865			1,099,592	13,392,661
Aging Research	1R21AG054903-02	93.866	—	58,981
Aging Research	1RF1AG057471-01	93.866	33,004	231,215
Aging Research	5R01AG056533-02	93.866	38,005	208,930
Aging Research	1R01AG057714-02 REVI	93.866	20,440	353,260
Aging Research	1R01AG058704-01 REVI	93.866	—	21,178
Aging Research	1R21AG058445-01	93.866	21,931	142,957
Aging Research	1RF1AG047667-01	93.866	—	262,781
Aging Research	1RF1AG051538-01A1	93.866	—	941,416
Aging Research	1RF1AG057247-01	93.866	—	417,398
Aging Research	1RF1AG057470-01 REVI	93.866	—	334,180
Aging Research	3RF1AG051514-01S1 RE	93.866	21,738	726,973
Aging Research	3RF1AG051633-01S2	93.866	57,853	1,989,168
Aging Research	3U01AG052460-03S1	93.866	—	852,638
Aging Research	4R01AG019206-15	93.866	—	32,712
Aging Research	5F31AG051310-03REVIS	93.866	—	45,373
Aging Research	5K01AG042498-06	93.866	—	92,572
Aging Research	5K23AG042856-05	93.866	—	95,822
Aging Research	5P50AG025688-14S1	93.866	99,014	1,768,177
Aging Research	5R01AG023695-10	93.866	—	118,914
Aging Research	5R01AG038746-05rev	93.866	—	32,535
Aging Research	5R01AG042127-06 REVI	93.866	—	494,989
Aging Research	5R01AG047408-04	93.866	57,609	433,482
Aging Research	5R01AG049752-03 REVI	93.866	—	770,231
Aging Research	5R01AG054046-03	93.866	—	618,700
Aging Research	5R01AG054079-03S1Rev	93.866	264,443	920,493
Aging Research	5R01AG055634-02 REVI	93.866	—	273,683
Aging Research	5R03AG050930-02 REVI	93.866	—	14,382
Aging Research	5R03AG055810-02	93.866	—	70,767
Aging Research	5R03AG056448-02S1	93.866	—	140,224
Aging Research	5R13AG047064-04 REVI	93.866	—	52,376
Aging Research	5R21AG042730-02	93.866	—	(2,549)
Aging Research	5R21AG050793-03 Rev	93.866	—	122,919
Aging Research	5R21AG054206-02	93.866	—	194,799
Aging Research	5R21AG055995-02 REVI	93.866	—	113,616
Aging Research	5U01AG046161-05	93.866	667,590	1,280,382
Pass-through Baylor College of Medicine	7,000,000,211	93.866	—	376,963
Pass-through Baylor College of Medicine	7,000,000,560	93.866	—	43,684
Pass-through Boston University	4,500,002,111	93.866	—	51,355
Pass-through Georgia Institute of Technology	RJ855-G1	93.866	—	14,504
Pass-through Georgia State University	SP00011514-04	93.866	—	19,756
Pass-through Georgia State University	SP00012468-01	93.866	—	42,044
Pass-through Medical University of South Carolina	MUSC14-075	93.866	—	59,910
Pass-through Northwestern University	60041739EU	93.866	—	26,056

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Northwestern University	60043310 EU	93.866	\$ —	29,084
Pass-through Northwestern University	60048330 EU	93.866	—	32,256
Pass-through Rush University Medical Center	09031002-SUB01 Amend	93.866	—	27,519
Pass-through Rush University Medical Center	17021705-Sub01	93.866	—	256,720
Pass-through University of Alabama Birmingham	000410331-003	93.866	—	26,854
Pass-through University of California San Diego	72,750,918	93.866	—	(8)
Pass-through University of Georgia	RR376-033/S001699	93.866	—	7,844
Pass-through University of Minnesota	N005175201	93.866	—	34,619
Pass-through University of Southern California	79,635,055	93.866	—	46,237
Pass-through University of Washington	UWSC7721	93.866	—	34,003
Pass-through Wake Forest University	WFUHS 115068 Gary MA	93.866	—	10,000
Pass-through Wake Forest University	WFUHS 115068 Neigh	93.866	—	540
Pass-through Wake Forest University	WFUHS 115068 Perkins	93.866	—	7,880
Pass-through Wake Forest University	WFUHS 115238	93.866	—	24,710
Total CFDA No. 93.866			1,281,627	15,398,204
Vision Research	1R01EY028450	93.867	—	68,439
Vision Research	4R01EY021592-04	93.867	—	5,722
Vision Research	5F30EY025154-04 REVI	93.867	—	47,657
Vision Research	5P30EY006360-33	93.867	—	671,373
Vision Research	5R01EY014852-11	93.867	—	(42)
Vision Research	5R01EY017841-08	93.867	—	140,199
Vision Research	5R01EY025978-03 REVI	93.867	78,373	799,915
Vision Research	5R01EY027711-02 REVI	93.867	222,568	400,264
Vision Research	5T32EY007092-32REVIS	93.867	21,605	265,726
Vision Research	5UG1EY013272-14	93.867	—	(4,044)
Vision Research	5UG1EY013287-15	93.867	—	210,887
Vision Research	5UG1EY025553-03 REVI	93.867	93,567	278,252
Vision Research	5P30EY006360-30	93.867	—	(2,709)
Vision Research	5R01EY004864-34S1	93.867	—	266,557
Vision Research	5R01EY014026-10	93.867	—	(12,173)
Vision Research	5R01EY014852-14REVIS	93.867	—	477,111
Pass-through Cambium Medical Technologies	K8501-G1	93.867	—	5,906
Pass-through Georgia Institute of Technology	RG181-G1 AMND3	93.867	—	66,474
Pass-through Jaeb Center for Health Research	RH850-G2 AMD 1	93.867	—	85,409
Pass-through Johns Hopkins University	2,002,484,216	93.867	—	28,185
Pass-through Johns Hopkins University	SA1701/AMND 3	93.867	—	85,775
Pass-through Massachusetts Eye and Ear	3708-01-01-16EU Amd4	93.867	—	27,085
Pass-through University of Pennsylvania	8319sc Amend2	93.867	—	52,107
Pass-through University of Texas Medical Branch	UFDSPO0010865	93.867	—	18,804
Pass-through Vanderbilt University	VUMC 41809	93.867	—	(74,078)
Pass-through Vanderbilt University Medical Center	VUMC 41809	93.867	—	248,567
Pass-through Washington University	WU -16 -110- MOD -3	93.867	—	19,428
Total CFDA No. 93.867			416,113	4,176,796
Medical Library Assistance	1K01LM012924-01	93.879	—	33,549
Medical Library Assistance	5R01LM012372-02	93.879	—	358,586
Total CFDA No. 93.879			—	392,135
Grants for Training in Primary Care Medicine and Dentistry	6 T0BHP28571--04--01	93.884	—	317,793
Total CFDA No. 93.884			—	317,793
HIV Emergency Relief Project Grants:				
Pass-through Fulton County	VS0000014448/PO 1181	93.914	—	12,520
Pass-through Fulton County	VS14448/PO11817S1085	93.914	—	648,024
Total CFDA No. 93.914			—	660,544
HIV Care Formula Grants				
Pass-through University of Washington	UWSC10292 / BPO29452	93.917	—	2,311
Total CFDA No. 93.917			—	2,311
HIV Demonstration, Research, Public and Professional Education Projects	1U01PS005112-03	93.941	13,248	232,131
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS004977-04	93.941	365,054	1,319,116
HIV Demonstration, Research, Public and Professional Education Projects	6U01PS005181-02-01	93.941	122,051	461,528
Total CFDA No. 93.941			500,353	2,012,775
International Research and Research Training	4D43TW009135-05	93.989	—	14,065
International Research and Research Training	4K01TW009664-04	93.989	32,000	119,956
International Research and Research Training	5D43TW007124-14	93.989	—	233,734
International Research and Research Training	5D43TW009127-05 REVI	93.989	—	176,233
International Research and Research Training	5R01TW010664-02	93.989	85,000	229,181
International Research and Research Training	5U2RTW010114-04 REVI	93.989	230,356	335,437
Pass-through Addis Ababa University	1D43TW010143-01	93.989	—	(545)
Pass-through Addis Ababa University	AAU SOM MEPI-JF	93.989	—	113,789
Pass-through Aga Khan University	5D43TW007585-09	93.989	—	(1,214)
Pass-through Vanderbilt University	VUMC 58636	93.989	—	1,486
Pass-through Vanderbilt University	VUMC54581	93.989	—	75,351
Pass-through Vanderbilt University Medical Center	VUMC 63317	93.989	—	17,605
Pass-through Vanderbilt University Medical Center	VUMC 63318	93.989	18,329	18,329
Pass-through Vanderbilt University Medical Center	VUMC63319	93.989	20,315	25,279
Pass-through Vanderbilt University Medical Center	VUMC63320/AMND 1	93.989	16,619	16,619
Total CFDA No. 93.989			402,619	1,375,305



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Contract	200-2011-41278	93.RD	\$ —	493,641
Contract	200-2016-91940	93.RD	—	2,906
Contract	200-2017-92309	93.RD	—	52,558
Contract	200-2017-95890	93.RD	—	289,093
Contract	HHSN26100006 Mod 6	93.RD	155,500	1,739,712
Contract	HHSN2612013000151	93.RD	—	52,582
Contract	HHSN2612018000031	93.RD	—	815,642
Contract	HHNS272201300006C	93.RD	—	2,624,495
Contract	HHNS272200800005C	93.RD	—	1,499
Contract	HHSN272201200031C	93.RD	384,228	937,169
Contract	HHSN272201300018	93.RD	—	380,521
Contract	HHSN2722013000181	93.RD	—	1,485,726
Contract	HHSN2722013000181	93.RD	22,062	4,891,104
Contract	HHSN2722013000181/HH	93.RD	—	1,214,876
Contract	HHSN2722013000181/44	93.RD	—	182,080
Contract	HHSN272201400004C	93.RD	1,311,419	4,500,398
Contract	HHSN272201500008C	93.RD	138,334	941,923
Contract	HHSN2752014000011	93.RD	17,304	619,864
Contract	HHSN275201400017C	93.RD	—	5,745
Contract	HHSN2752015000011	93.RD	28,321	86,940
Contract	HHSN2752015000011	93.RD	—	20,614
Contract	VA268-16-C-0032	93.RD	—	10,556
Pass-through Assoc of Schools & Pgms of Public Health	N1805/AIIMS-EMORY	93.RD	—	63,348
Pass-through Brigham and Womens Hospital	S5033	93.RD	109,364	109,364
Pass-through Brigham and Womens Hospital	S5033	93.RD	—	(2,659)
Pass-through Childrens Healthcare of Atlanta	5 U3REP170552-03-00	93.RD	1,181,821	2,173,522
Pass-through Childrens Healthcare of Atlanta	657004-0218-01	93.RD	—	15,000
Pass-through Childrens Healthcare of Atlanta	1,280,901	93.RD	—	29,710
Pass-through Childrens Healthcare of Atlanta	1R21NS096455	93.RD	—	20,789
Pass-through Childrens Hospital of Los Angeles	40500-032-18182513	93.RD	—	101,413
Pass-through Childrens Mercy Hospital	RH466-S1	93.RD	—	3,853
Pass-through Dana Farber Cancer Institute	GH000258	93.RD	—	108,338
Pass-through Duke University	06-646-9933	93.RD	—	2,094
Pass-through Dystonia Medical Research Foundation	200-2012-53583	93.RD	—	(5,225)
Pass-through Georgia Institute of Technology	14X138	93.RD	160,187	250,316
Pass-through Georgia Institute of Technology	29XS132	93.RD	—	107,675
Pass-through H Lee Moffitt Cancer Center and Res Inst	HHSN250201500009C	93.RD	—	18,659
Pass-through H Lee Moffitt Cancer Center and Res Inst	PUMPIN-PROJECT C-013	93.RD	—	3,943
Pass-through H Lee Moffitt Cancer Center and Res Inst	Quantum dot FRET imm	93.RD	—	3,725
Pass-through H Lee Moffitt Cancer Center and Res Inst	200-2013-5734,1 Task	93.RD	—	30,900
Pass-through Harvard Pilgrim Health Care Institute	200-2013-57341 Order	93.RD	—	49,746
Pass-through Human Sciences Research Council	U01HL112748	93.RD	—	4,817
Pass-through Intl Aids Vaccine Initiative	5-53728	93.RD	—	1,824,733
Pass-through Leidos Biomedical Research	1137965-2-77417	93.RD	—	16,803
Pass-through Leidos Biomedical Research	Tephinet	93.RD	—	(20)
Pass-through Massachusetts General Hospital	000406291-010/AMEND	93.RD	—	705
Pass-through Minneapolis Medical Research Foundation	000500918-T013-005	93.RD	—	8,284
Pass-through Natl Marrow Donor Program	51096- PO#G180120702	93.RD	—	28,799
Pass-through New England Research Institutes	51097 PO G180120701	93.RD	—	20,823
Pass-through Norc At The University of Chicago	A005062101	93.RD	—	124,527
Pass-through Ocean Nanotech	P005639702	93.RD	—	34,697
Pass-through Pennsylvania State University	5,109,872	93.RD	—	37,158
Pass-through Research Support Services Inc	507,258	93.RD	—	80,720
Pass-through Research Support Services Inc	0024031-1	93.RD	—	40,013
Pass-through Research Triangle Institute	75,860,854	93.RD	—	20,231
Pass-through Weill Cornell Medical College	GMO 120703/AMEND #8	93.RD	—	20,016
Total CFDA No. 93.RD			3,508,540	26,696,461
U.S. Department of Health and Human Services Total			53,814,914	393,716,791
U.S. Agency for International Development:				
USAID Foreign Assistance for Programs Overseas	200,008,314	98.001	—	41,874
USAID Foreign Assistance for Programs Overseas	AID-114-A-17-00003/0	98.001	468,159	1,041,972
Pass-through Intl Aids Vaccine Initiative	06-646-9933	98.001	18,071	1,609,622
Pass-through Intl Aids Vaccine Initiative	Annual SOW 2166	98.001	—	76
Total CFDA No. 98.001			486,230	2,693,544
Cooperative Development Program (CDP):				
Pass-through Queensland Institute of Medical Research	AID-OAA-F-16-00094	98.002	—	41,505
Total CFDA No. 98.002			—	41,505
U.S. Agency for International Development Total			486,230	2,735,049
Total Research and Development Cluster			60,538,694	431,344,765
Student Financial Assistance Cluster (notes 2 and 3):				
U.S. Department of Education:				
Federal Work Study Program		84.033	—	1,511,866
Federal Supplemental Education Opportunity Grant Program		84.007	—	1,061,203
Federal Pell Grant Program		84.063	—	7,379,318
Federal Direct Stafford Loan Program		84.268	—	78,705,919
Federal Direct PLUS Loan Program		84.268	—	44,985,529
Federal Perkins Loan Program		84.038	—	11,671,251
Total U.S. Department of Education			—	145,315,086
Total Student Financial Assistance Cluster			—	145,315,086

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
U.S. Department of Agriculture:				
Special Supplemental Nutrition Program for Women, Infants, and Children: Pass-through Georgia Dept of Public Health	40500-041-19161820	10.557	\$ —	66,524
Total CFDA No. 10.557			—	66,524
U.S. Department of Agriculture Total			—	66,524
U.S. Department of Defense:				
Contract:				
Pass-through Cherokee Nation Technology Solutions	0115700-0010	12.CTR	—	(118)
Total CFDA No. 12.CTR			—	(118)
U.S. Department of Defense Total			—	(118)
U.S. Department of State:				
Promotion of the Humanities_ Office of Digital Humanities	HK-230986-15	45.169	—	3,142
Total CFDA No. 45.169			—	3,142
National Endowment for The Arts and Humanities Total			—	3,142
U.S. Department Of Energy				
Office of Science Financial Assistance Program Pass-through Southface Energy Institute	DE-EE0007575	81.049	—	5,806
Total CFDA No. 81.049			—	5,806
National Endowment for The Arts and Humanities Total			—	5,806
U.S. Department of Health and Human Services:				
Global AIDS	5 NU2GGH001443-05-00	93.067	1,420,328	2,663,823
Global AIDS	5NU2GGH001815-03-00	93.067	98,815	98,815
Global AIDS	5NU2GGH001815-03-00	93.067	—	(56,255)
Global AIDS	6NU2GGH001815-02-02	93.067	—	149,871
Total CFDA No. 93.067			1,519,143	2,856,254
Birth Defects and Developmental Disabilities – Prevention and Surveillance	5NU50DD004932-04-00	93.073	—	503,941
Total CFDA No. 93.073			—	503,941
Prevention of Disease, Disability, and Death by Infectious Diseases	6 NU38PS004646-04-02	93.084	596,462	1,261,976
Total CFDA No. 93.084			596,462	1,261,976
Maternal and Child Health Federal Consolidated Programs	4 H46MC24090-05-02	93.110	22,656	585,499
Maternal and Child Health Federal Consolidated Programs	6 H46MC240900301	93.110	—	(24,439)
Maternal and Child Health Federal Consolidated Programs	UH7MC30772-02-00	93.110	58,681	565,291
Total CFDA No. 93.110			81,337	1,126,351
Health Program for Toxic Substances and Disease Registry: Pass-through Amer Academy of Pediatrics	771102-EUSM/AMND3	93.161	—	18,493
Pass-through Amer Academy of Pediatrics	771104_EUSM	93.161	—	149,830
Total CFDA No. 93.161			—	168,323
Disabilities Prevention:				
Pass-through Georgia State University	SP00011716-01 AMEN 3	93.184	—	173,317
Total CFDA No. 93.184			—	173,317
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	200-2016-91959	93.283	36,290	36,290
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	200-2016-91959	93.283	—	(8,087)
Pass-through Assoc of Schools & Pgms of Public Health	U36 OE00002	93.283	—	29,010
Pass-through Association of American Medical Colleges	GT-32001-02-2	93.283	5,851	7,653
Pass-through Atlanta Research and Education Fdtn	AREF MOU M16005	93.283	30,407	46,747
Total CFDA No. 93.283			72,548	111,613
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Syst	NU19GH001583-03-01	93.318	—	140,851
Total CFDA No. 93.318			—	140,851
Child Care and Development Block Grant Pass-through Marcus Autism Center	46900-621-V17MAC001	93.575	—	31,089
Total CFDA No. 93.575			—	31,089
Children's Justice Grants to States:				
Pass-through Georgia Department of Human Services	42700-040-0000056774	93.643	—	1,018
Pass-through Georgia Department of Human Services	42700-040-0000068299	93.643	—	98,564
Total CFDA No. 93.643			—	99,582
Diabetes Prevention – State and Local Public Health Actions to Prevent Obesity, Diabetes, and Heart Pass-through South Carolina Dept of Hlth and Env Ctrl	N. CY-5-626	93.757	—	34,342
Total CFDA No. 93.757			—	34,342

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2018

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Preventive Health and Health Services Block Grant funded solely with Prevention and Public Health Funds (PPHF)				
Pass-through State of New Hampshire	SS-2017-DPHS-14-Life	93.758	\$ —	113
Total CFDA No. 93.758			—	113
Medical Assistance Program				
Pass-through Georgia Department of Behavioral Health	44100-907-000099734	93.778	—	190,000
Pass-through Georgia Department of Behavioral Health	col44100-907-0000087	93.778	—	(15,496)
Total CFDA No. 93.778			—	174,504
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities				
Pass-through Georgia Dept of Public Health	40500-033-16161809	93.817	—	562,568
Total CFDA No. 93.817			—	562,568
HIV Emergency Relief Project Grants				
Pass-through Fulton County	17RW2018A	93.914	—	183,684
Total CFDA No. 93.914			—	183,684
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	6H76HA07848-11-03	93.918	—	287,292
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H76HA07848	93.918	—	402,999
Total CFDA No. 93.918			—	690,291
Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Gr	1 T22HA31187-01-00	93.924	—	1,945
Total CFDA No. 93.924			—	1,945
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiativ	5 U01 DP003894-05	93.946	18,308	347,175
Total CFDA No. 93.946			18,308	347,175
Block Grants for Prevention and Treatment of Substance Abuse				
Pass-through Georgia Dept of Behavioral Health	44100-906-0000086519	93.959	—	46,100
Total CFDA No. 93.959			—	46,100
Contract	1,044,209	93.CTR	—	5,000
Contract	1,044,825	93.CTR	—	5,000
Contract	200-2014-M-58528	93.CTR	—	(61)
Contract	200-2015-87862 00007	93.CTR	—	1,089,700
Contract	200-2016-M-91197	93.CTR	—	75,703
Contract	200-2016-M-92385	93.CTR	—	820
Contract	200-2017-M-95264	93.CTR	—	90,753
Contract	HHSH258201300008C	93.CTR	—	19,924
Pass-through Amer Thrombosis and Hemostasis Netwo	NHPCC-1-01	93.CTR	—	2,862
Pass-through Assoc of State & Territorial Dental Directors	ASTDD072215	93.CTR	—	4,994
Pass-through Georgia Department of Community Health	2,017,001	93.CTR	—	260,425
Pass-through Georgia Dept of Public Health	40500-036-18161798	93.CTR	—	83,926
Pass-through Georgia Dept of Public Health	40500-036-19161798	93.CTR	—	16,634
Pass-through NORC at The University of Chicago	7843.Emory.01	93.CTR	—	300
Pass-through Northwestern University	SP0035018 60041567EU	93.CTR	—	9,386
Pass-through Research Support Services Inc	200-2013-57341ORDER2	93.CTR	—	2,809
Pass-through South Dakota Department of Health	HHSI241201700586P	93.CTR	—	31,312
Pass-through State of New Hampshire	05-95-90-902010-1227	93.CTR	—	7,828
Pass-through Tennessee Department of Health	34347-61317	93.CTR	—	15,526
Pass-through University of Southern California	75,956,840	93.CTR	—	28,436
Total CFDA No. 93.CTR			—	1,751,277
U.S. Department of Health And Human Services Total			2,287,798	10,265,296
U.S. Agency for International Development				
Cooperative Development Program (CDP)				
Pass-through Aspen Institute	AID-00AA-A-15-0038	98.002	—	346,302
Pass-through Aspen Institute	AID-OAA-A-15-0038	98.002	—	20,000
Total CFDA No. 98.002			—	366,302
U.S. Agency for International Development Total			—	366,302
Total Expenditures of Federal Awards			\$ 62,826,492	587,366,803

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND  
EXPENDITURES OF STATE OF GEORGIA AWARDS**

**EMORY UNIVERSITY**

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards  
Year ended August 31, 2018

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
17RW2018A	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	\$ 195,985	183,684
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Program	835,047	260,425
40500-032-18182513	GEORGIA DEPT OF PUBLIC HEALTH	Georgia Department of Public Health Contract for Services 2017	68,123	101,413
40500-033-16161809	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	1,948,714	562,568
40500-036-16161891	GEORGIA DEPT OF PUBLIC HEALTH	Statistical Support for Syndromic Surveillance	7,405	32,300
40500-036-17161798	GEORGIA DEPT OF PUBLIC HEALTH	Georgia Coverdell Acute Stroke Registry	8,620	—
40500-036-18161798	GEORGIA DEPT OF PUBLIC HEALTH	Georgia Coverdell Acute Stroke Registry	65,739	83,926
40500-041-17161820	GEORGIA DEPT OF PUBLIC HEALTH	Medical Foods For WIC Participants With Positive Inborn Errors of Metabolic Disord	10,984	—
40500-041-19161820	GEORGIA DEPT OF PUBLIC HEALTH	Medical Foods For WIC Participants With Positive Inborn Errors of Metabolic Disord	154,260	—
40500-046-17151505	GEORGIA DEPT OF PUBLIC HEALTH	2017 - Contract #40500-046-17151505	34,456	—
40500-051-19161799	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	1,105,290	658,644
42700-040-0000056774	GEORGIA DEPARTMENT OF HUMAN SERVICES	2017 Summer Child Advocacy Program	87,238	1,018
42700-040-0000068299	GEORGIA DEPARTMENT OF HUMAN SERVICES	2018 Summer Child Advocacy Program	39,084	98,564
44100-906-0000086519	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol and Drug Screening project: MASCD	83,323	46,100
44100-907-0000099734	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Emory Neuro Developmental Exposure Clinic (ENEC)	285,000	171,148
44100-907-0000087293	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Neuro Developmental Exposure Clinic (ENEC)	95,000	(15,496)
VS0000014448/PO 1181	FULTON COUNTY	Ryan White Comprehensive AIDS Resources	283,601	12,520
VS14448/PO11817S108584RD	FULTON COUNTY	Ryan White Comprehensive AIDS Resources	886,199	648,024
			<u>\$ 6,194,068</u>	<u>2,844,838</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**EMORY UNIVERSITY**

Notes to Supplementary Schedules of Expenditures of Federal Awards and  
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2018

**(1) Summary of Significant Accounting Policies**

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University (the University) and is presented on the accrual basis of accounting. The Schedule presents all federal assistance received directly from the federal government and awards passed through to the University from non-federal organizations pursuant to federal grants, contracts and similar agreements. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred (i.e., on an accrual basis) by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

**(2) Noncash Federal Assistance**

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the Federal Direct Student Loan Program (FDSLPL) and revolving loan programs, such as the Federal Perkins Loan Program.

The loans advanced and related expenditures are as follows for the various student loan programs:

	CFDA number	Amount
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 8,766,401
Unsubsidized Stafford Loan Program	84.268	69,939,518
Total Direct Stafford Loan Program		78,705,919
Federal Direct PLUS Loan Program		44,985,529
Total Direct Student Loan Programs		\$ 123,691,448
Federal Perkins Loan Program	84.038	\$ 788,827

## EMORY UNIVERSITY

### Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2018

The Federal Perkins Loan Program is administered directly by the University and balances and transactions relating to this program are included in the University's consolidated financial statements. Federal Perkins loans outstanding at August 31, 2018 totaled \$9,473,058.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL loan program. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2018. These loans are not included in the University's consolidated financial statements.

#### **(3) Matching**

Under the Federal Supplemental Educational Opportunity Grant program, the University matched \$353,734 in funds awarded to students for the year ended August 31, 2018 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study program, the University matched \$600,806 in total compensation to students for the year ended August 31, 2018 in addition to the federal share of expenditures included in the Schedule.

#### **(4) Indirect Costs**

For the year ended August 31, 2018, the University did not elect to use the 10% de minimis Indirect Cost Rate permitted by the Uniform Guidance.

## **UNIFORM GUIDANCE REPORTS**





KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

**Independent Auditors' Report on Compliance for Major Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards**

The Board of Trustees  
Emory University:

**Report on Compliance for Major Federal Program**

We have audited Emory University's compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on Emory University's major federal program for the year ended August 31, 2018. Emory University's major federal program is identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

*Management Responsibility*

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

*Auditors' Responsibility*

Our responsibility is to express an opinion on compliance for Emory University's major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Emory University's compliance with those requirements and performing such other procedures as we consider necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for Emory University's major federal program. However, our audit does not provide a legal determination of Emory University's compliance.

*Opinion on Major Federal Program*

In our opinion, Emory University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended August 31, 2018.

*Other Matters*

The results of our auditing procedures disclosed other instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2018-001 and 2018-002. Our opinion on the major federal program is not modified with respect to these matters.



Emory University's responses to the noncompliance findings identified in our audit are described in the accompanying schedule of findings and questioned costs. Emory University's responses were not subjected to the auditing procedures applied in the audit of compliance, and accordingly, we express no opinion on the responses.

### **Report on Internal Control Over Compliance**

Management of Emory University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Emory University's internal control over compliance with the types of requirements that could have a direct and material effect on Emory University's major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for Emory University's major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Emory University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we identified certain deficiencies in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as items 2018-001 and 2018-002, that we consider to be significant deficiencies.

Emory University's responses to the internal control over compliance findings identified in our audit are described in the accompanying schedule of findings and questioned costs. Emory University's responses were not subjected to the auditing procedures applied in the audit of compliance, and accordingly, we express no opinion on the responses.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



**Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards**

We have audited the consolidated financial statements of Emory University and subsidiaries as of and for the year ended August 31, 2018, and have issued our report thereon dated January 31, 2019, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of expenditures of federal awards and supplementary schedule of cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of expenditures of federal awards and supplementary schedule of cash receipts and expenditures of State of Georgia awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

*KPMG LLP*

March 25, 2019

**EMORY UNIVERSITY**

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

**(1) Summary of Auditors' Results**

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
  - Material weaknesses: **No**
  - Significant deficiencies: **None reported**
- (c) Noncompliance which is material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
  - Material weaknesses: **No**
  - Significant deficiencies: **Yes - See findings 2018-001 and 2018-002**
- (e) Type of auditors' report issued on compliance for major program: **Unmodified**
- (f) Audit findings which are required to be reported under 2 CFR 200.516(a): **Yes - See findings 2018-001 and 2018-002**
- (g) Major program: **Student Financial Assistance Cluster (various CFDA numbers)**
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

**(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with Government Auditing Standards**

None.

**EMORY UNIVERSITY**

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

**(3) Findings and Questioned Costs Relating to Federal Awards**

**Finding No. 2018-001**

**Enrollment Reporting**

**Federal Program:**

Student Financial Assistance Cluster

**CFDA Numbers:**

84.033; 84.007; 84.063; 84.268; 84.038

**Federal Agency:**

U.S. Department of Education

**Federal Award Year:**

July 1, 2017 to June 30, 2018

*Criteria or Requirement*

Under the Pell grant and Department of Education (ED) loan programs, institutions must complete and return within 15 days the Enrollment Reporting roster file (FPL, 34 CFR Section 674.19; Pell, 34 CFR Section 690.83(b)(2); FFEL, 34 CFR Section 682.610; Direct Loan, 34 CFR Section 685.309). Once received, the institution must update the file for changes in student status, report the date the enrollment status was effective, enter the new anticipated completion date, and submit the changes electronically through the batch method or the National Student Loan Data System (NSLDS) Web site. Enrollment information must be reported within 30 days whenever attendance changes for students, unless a roster will be submitted within 60 days. Institutions are responsible for timely reporting, whether they report directly or via a third-party servicer.

*Condition Found, Including Facts That Support the Deficiency Identified in the Finding and Information to Provide Proper Perspective for Judging the Prevalence and Consequences of the Finding*

In a sample of 40 students, we identified one student in the fall semester and two students in the spring semester in which the student's status changes were not reported within 60 days, as required. Rather, these two status change instances were reported in 179 and 70 days, respectively. We further identified one instance in the fall and one instance in the spring semester in which the students' status as presented by the University did not agree with the status transmitted to NSLDS.

*Cause and Possible Asserted Effect*

The monitoring control over timely submission of student status changes was not operating effectively during the fall and spring semester because there was a lack of a sufficient control around timely communication of leave of absences from the departments to the Registrar's office. Further, there was a lack of a sufficient control to ensure the student's status properly agreed between the University and NSLDS.

*Questioned Costs*

There were no questioned costs associated with the finding.

**EMORY UNIVERSITY**

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

*Statistically Valid Sample*

The sample was not intended to be, and was not, a statistically valid sample.

*Identification of whether the audit finding was a repeat of a finding in the immediately prior audit*

This is not a repeat finding.

*Recommendation*

We recommend that Emory University strengthen its processes and controls within the Registrar's Office to help ensure that student status changes are communicated timely to the NSLDS and that additional supervisory review procedures be implemented to monitor timely reporting of status changes and required transmissions.

*View of Responsible Officials*

Management concurs with the finding. A sample of 40 students identified one student in the fall semester and two in the spring semester whose enrollment changes were not relayed to the NSC/NSLDS within the prescribed reporting timeframe. These instances were the result of substantial delays in the students' notice of withdrawal/discontinuation. There was also additional lag in processing of those notifications at the department level, which subsequently delayed the relay of information to the Office of the University Registrar. To eliminate similar findings in the future, the Registrar's Office will request a list of all students who are likely unofficial drops due to lack of significant academic activity mid-way through the semester. Department liaisons will prepare information which will include an effective date on applicable students and submit it through the prescribed workflow system on a mandatory deadline, which will be defined as the determining date of status change for reporting this information to the NSC. The Registrar's Office will communicate changes to department liaisons as well as the requirement that departments notify the Registrar's Office within 5 business days. The Registrar's Office will also adjust productions schedules to allow the processing of these updates within 5 business days of department notification.

**EMORY UNIVERSITY**  
Schedule of Findings and Questioned Costs  
Year ended August 31, 2018

**Finding No. 2018-002**

**Reporting – Pell Disbursements**

**Federal Program:**

Student Financial Assistance Cluster

**CFDA Number:**

84.063

**Federal Agency:**

U.S. Department of Education

**Federal Award Year:**

July 1, 2017 to June 30, 2018

*Criteria or Requirement*

Under the Federal Register (82 FR 29061), all schools receiving Pell grants submit Pell payment data to the Department through the Common Origination and Disbursement (COD) System. Institutions must report student payment data within 15 calendar days after the school makes a payment; or becomes aware of the need to make an adjustment to previously reported student payment data or expected student payment data. Schools may do this by reporting once every 15 calendar days, bi-weekly, or weekly, or may set up their own system to ensure that changes are reported in a timely manner.

*Condition Found, Including Facts That Support the Deficiency Identified in the Finding and Information to Provide Proper Perspective For Judging the Prevalence and Consequences of the Finding*

In a sample of 40 students with Pell disbursements, we identified 20 instances from the Fall semester in which the initial Pell disbursement notification to the COD was within 15 days; however, the original record was rejected by the COD and the corrected notifications were made between 29-42 days and not within 15 days as required.

*Cause and Possible Asserted Effect*

The University timely reported initial Pell disbursement notifications; however, due to the high volume of rejections from the COD and the limited resources to correct the rejections, the monitoring control was not operating effectively during the Fall semester, resulting in noncompliance.

*Questioned Costs*

There were no questioned costs associated with the finding.

*Statistically Valid Sample*

The sample was not intended to be, and was not, a statistically valid sample.

## EMORY UNIVERSITY

### Schedule of Findings and Questioned Costs

Year ended August 31, 2018

#### *Identification of whether the audit finding was a repeat of a finding in the immediately prior audit*

This is not a repeat finding.

#### *Recommendation*

We recommend that Emory University strengthen its processes and controls around Pell disbursement reporting to ensure that disbursements outside of normal batch processing are reported timely to the COD. Further, we recommend that Emory University monitor submissions so that any rejections are timely remediated.

#### *View of Responsible Officials*

Management concurs with the finding. The finding noted 20 students who received Pell disbursements which were not reported in a timely manner. Almost all Pell disbursements records during fall 2017 were reported within 15 days of disbursement; however, the original disbursement record rejected at COD due to a Pell cost of attendance (COA) in excess of \$100,000. It was the cleanup and subsequent reporting of these records that fall outside the 15-day requirement.

The annual COA for Emory schools exceeds \$50,000. Delivered logic within PeopleSoft combined with standard operational practices created instances where a student's COA calculated an annual, 2 semester, Pell COA rather than a semester, Pell COA. As a result, subsequent reporting looks to have COA 3 times the allowable amount, and therefore the disbursement record rejects. To resolve this problem, the Office of Financial Aid made two changes. First, a systematic process was created to build fall and spring semester COAs at the same time. Secondly, as part of a system upgrade to Oracle 9.2 security access was removed to prevent advising staff from building a semester COA. These two changes have eliminated the possibility of having an annual Pell COA reject at COD. Further, rather than solely relying on one staff member to monitor Pell reporting several staff members will be reviewing reporting rejects twice a week. This will help ensure that rejected records get the immediate attention they need.